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Intervention of the sophisticated balance between proliferation and 
differentiation process during hematopoiesis leads to an accumulation of immature 
non-functional hematopoietic cells in blood and bone marrow which conduces to 
leukemia. Complications arose from the weakened immune system could be fatal. 
Conventional treatments include chemotherapy, radiotherapy, interferon therapy and 
stem cell transplantation. However, the side effects which are often severe and 
inevitable, spur on the development of novel tactics for treatments. The use of 
Traditional Chinese Medicine has been proposed in the light of discussion as an 
alternative. Tryptanthrin (6,12-dihydro-6,12-dioxoindolo-(2,1 -b)-quinazoline) is a 
weakly basic alkaloid isolated from a number of medicinal indigo plants, including 
Polygonum tinctorium, Isatis tinctoria and Strobilanthes cusia. It has been reported 
to have various biological and pharmacological activities, such as anti-microbial, 
anti-inflammatory, anti-allergic and anti-tumor effects. However, its modulatory 
effects and action mechanisms on myeloid cells remain poorly understood. In this 
study, tryptanthrin was examined for its modulatory effects on the proliferation, 
differentiation and apoptosis of the murine myeloid leukemia WEHI-3B JCS cells. 
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Abstract 
Tryptanthrin was shown to suppress the proliferation of WEHI-3B JCS cells in a ‘ 
t 
！ 
dose- and time-dependent manner with an estimated IC50 value of 1.5 at 48 hours 
of treatment. Interestingly, no significant direct cytotoxicity was exhibited on the 
murine peritoneal macrophages and human hepatocyte-like WRL-68 cells under 
similar conditions. Analysis of the cell cycle profile of WEHI-3B JCS cells after 24 
hours and 48 hours of drug treatment showed an obvious cell cycle arrest at the 
GO/Gl phase. Treatment of WEHI-3B JCS cells with tryptanthrin for 24 hours also 
down-regulated the expression of cyclin D2, D3 genes and cyclin-dependent kinases 
{Cclk2, Cdk 4 and Cdk 6) genes. In addition, the protein expression of Cdk inhibitor 
p i8 and p27 was shown to be up-regulated after treatment with tryptanthrin for 48 
hours. Furthermore, tryptanthrin also reduced the in vivo tumorigenicity of leukemia 
WEHI-3B JCS cells and significantly suppressed the in vivo growth of the WEHI-3B 
JCS cells in BALB/c mice implanted with this tumor. 
Apoptosis was induced in tryptanthrin-treated WEHI-3B JCS cells as DNA 
fragmentation could be observed. It was further supported by the externalization of 
t 
phosphatidylserine in tryptanthrin-treated WEHI-3B JCS cells using Annexin V-GFP 
and PI staining. Mechanistic studies showed that mitochondrial membrane 
depolarization was induced in WEHI-3B JCS after 18 hours of tryptanthrin treatment. 
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Abstract 
Results from real-time PGR indicated that there was an up-regulation of 
pro-apoptotic Box and Bad genes but a down-regulation of anti-apoptotic Bcl-2 and 
BCI-XL genes in WEHI-3B JCS cells at 24 hours of tryptanthrin treatment. In addition, 
a time- and dose-dependent increase in caspase-3 and caspase-9 activities and an 
increase in the expression of cytosolic cytochrome C were detected in 
tryptanthrin-treated WEHI-3B JCS cells. These results strongly indicate the 
possible involvement of the intrinsic pathway in tryptanthrin-induced apoptosis in 
WEHI-3B JCS cells. Apart from that, tryptanthrin also increased the activity of 
caspase-8 and the expression of Fas-ligand in WEHI-3B cells, indicating that the 
extrinsic apoptotic pathway might also be involved. Furthermore, a release of AIF 
from mitochondria to cytoplasm was also observed in tryptanthrin-treated WEHI-3B 
JCS cells and this implies that the caspase-independent pathway might be triggered 
by tryptanthrin to cause apoptosis of the leukemia cells. Lastly, an enhanced 
production of ROS in tryptanthrin-treated WEHI-3B JCS cells was observed, 
suggesting that ROS might play a role in the apoptosis induced by tryptanthrin. 
Morphological studies and flow cytometric analysis revealed that tryptanthrin 
could induce differentiation in WEHI-3B JCS cells, as shown by the increases in 
cytoplasm to nucleus ratio, vacuolation, cell size and granularity as well as NBT-
X 
Abstract 
reducing activity in tryptanthrin-treated cells. 
Collectively, our findings indicate that tryptanthrin might exert its 
anti-proliferative effect on the murine myelomonocytic leukemia WEHI-3B JCS 
cells by causing cell cycle arrest, inducing apoptosis and differentiation of the cells. 
In the future, investigations should be focused on delineating the molecular events 
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Chapter 1 General Introduction 
1.1 Hematopoiesis and Leukemia 
1.1.1 An Overview on Hematopoietic Cell Development 
What makes up a human body? When you have seen tragedy in trauma center, it 
is not hard to believe that a body is just like a bag of blood. A normal individual 
should have 7% by volume of blood which equals to about 5 litres (L) of blood. Out 
of this 5 L, 2.25 L consists of cells, the rest is plasma containing water and proteins. 
Of the 2.25 L cells, most of them are red blood cells, only 0.037 L or 1.6% is 
leukocytes and the platelet volume is only about 0.0065 L. 
What determines the beauty of complexity of our blood circulation? The answer 
is simply hematopoiesis. Hematopoiesis is a highly coordinated and very complex 
process of cell production that involves changes in gene expression in response to 
proliferation, differentiation and apoptotic signals via the close interactions of bone 
marrow microenvironmental elements with precursor cells (Evans, 1997). In humans, 
blood cells are the first differentiated cell types generated in early-stage embryos. 
Hematopoiesis begins early in the stage of embryogenesis. In the first month of 
human gestation, two waves of hematopoietic stem cell generation have already 
begun to take place. The first one occurs in the yolk sac, generating myeloid 
precursor cells devoid of lymphoid potential. The second wave starts from the 27出 
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day of gestation, during which the development of hematopoietic cells takes place on 
the ventral endothelium of the dorsal aorta and vitelline artery. The new forming cells 
are the first multipotent, lympho-myeloid progenitors in human ontogeny (Peault and 
Tavian, 2003). The blood forming activity is attributed to all these hematopoietic 
cells. Then, the site of hematopoiesis is migrated and continued in the liver and 
spleen at mid-gestation. Finally, the red bone marrow gradually becomes the major 
organ for hematopoiesis from the sixth to seventh month of fetal life and thereafter 
(Hoffbrand et a/., 2006). 
Cell maturation is a physiologic continuum from morphologically 
undifferentiated stem cells to cells of a specific lineage that, by convention, are 
arbitrarily subdivided into discrete morphologic maturation stages. The complex 
hematopoietic network begins with pluripotent hematopoietic stem cells (HSC). 
There are only a limited number of stem cells in our body, it is estimated that there is 
only one stem cell out of 100,000 marrow cells (Metcalf，1995). Long term-HSC 
(LT-HSC) are capable of extensive self-renewal and also have a great capacity to 
generate short term-HSC (ST-HSC) which differentiate into progenitor cell progenies 
that are committed to a restricted range of lineages (Kondo et al, 2003). Stem cells 
can be stimulated to proliferate by combinations of hematopoietic regulators. 
- 2 -
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Cytokines, interleukins (IL), chemokines and colony stimulating factors (CSF) 
produced by the microenvironmental cells are the key effectors which monitor this 
sophisticated differentiation of HSC. These regulators are also able to activate stem 
cells to become responsive to other regulators. First of all, two major types of 
progenitors arose from HSC by the stimulation of 
granulocyte-macrophage-colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3), 
they are the common myeloid progenitors (CMP) and common lymphoid progenitors 
(CLP) respectively. CMP then differentiate into myeloid cells while CLP have their 
unique lineage specificity to lymphoid cells. The common myeloid progenitor is the 
precursor of erythro-megakaryocytic and granulo-monocytic lineages. For the 
erythro-megakaryocytic lineage, it branches out into erythrocytes and blood platelets; 
while for the granulo-monocytic lineage, the precursors give rise to neutrophils, in 
response to granulocyte-colony-stimulating factor (G-CSF), or monocytes, if 
stimulated by macrophage-colony-stimulating factor (M-CSF) (Zhu and Emerson, 
2002). The monocytes, which are located in the circulation, when migrate to tissue 
will carry out their function as macrophages. Apart from that, CMP also give rise to 
eosinophil progenitor and basophil progenitor, which differentiate into eosinophils 
and basophils in response to IL-5 and IL-4 respectively. For the lymphoid progenitor 
arose by the stimulation of IL-3, it is subdivided into two different pathways for the 
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generation of B and T lymphocytes. Interleukins such as IL-7 and IL-2 are involved 
in the process of mature T cells and B cells generation and development. The 
hematopoietic process is depicted in Fig. 1.1. 
In conclusion, hematopoiesis is a complex and highly regulated process, 
abnormalities or diseases like leukemia, aplastic anemia, lymphoma, myelodysplasia, 
myeloproliferative disorders, inborn errors of metabolism and a number of 
hematologic malignancies may arise when there is a disorder of hematopoiesis. 
Among them, leukemia will be discussed in detail in the next section. 
- 4 -
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Fig. 1.1 Hematopoiesis. Different types of mature blood cells are developed from 
pluripotent hematopoietic stem cells. Generally speaking, throughout the whole 
developmental process, the proliferative capacity of the cells decreases with 
increasing degree of differentiation in their functions and number. (Howard and 
Hamilton, 2002) 
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1.1.2 Leukemia 
Leukemia represents a large proportion of hematological malignancies that 
occur as acute or chronic disease (Tsiftsoglou et al., 2003). The HSC present in the 
human bone marrow are able to self-renew themselves and also differentiate into 
different blood cell types (Metcalf, 1998; Orkin, 2000; Tsiftsoglou et al； 2003). 
Commitment of HSC into differentiation pathways is accompanied by irreversible 
maturation, cell cycle arrest, or apoptosis initiated by the stimulation of the external 
growth factors and/or cytokines (Enver et al, 1998; Fisher 2002). Leukemia cells are 
defined as the early hematopoietic progenitors which are irresponsive to the external 
stimuli within the bone marrow microenvironment and hence differentiate into 
discrete blood lineage (Fialkow et al, 1981; Tsiftsoglou et al., 2003). These cells 
acquire immortality, self-perpetuate, proliferate in high numbers in the bone marrow 
at the expense of other cells and finally spill into the peripheral blood, eventually 
reach the lymph nodes, the spleen, the liver, the central nervous system and other 
organs such as testicles, ovaries, kidneys, gum, skin, etc. (Tsiftsoglou et al., 2003; 
Hoffbrand et al” 2006; American Cancer Society, 2007). Leukemic disorders are so 
attributed to these cells resulting from uncoupling of cell proliferation, apoptosis and 
differentiation processes (Domen, 2001). Apart from the leukocytes leukemia, there 
are also leukemias involving erythrocytes and megakaryocytes though they are quite 
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rare. General symptoms of leukemia are discussed in the following section. 
1.1.2.1 General Symptoms of Leukemia 
Symptoms in leukemia patients vary, depending on the type of leukemia, the 
organ involved as well as the condition of the patient. However, leukemia patients do 
have some generalized symptoms as follows. 
1) Fatigue, weakness, weight loss and lose of appetite 
Leukemia cells proliferate at the expense of other cells which leads to a shortage 
of normal and functional blood cells like erythrocytes. Lower level of 
erythrocytes results in insufficient oxygen intake which might lead to anemia and 
weakness. 
2) Easy bruising and profuse bleeding 
Low blood platelets count which causes difficulty in blood clotting is always 
seen in leukemia patients and this is the reason for the bruises and bleedings. 
3) Bone and back pain 
Continuous proliferation of leukemia cells in bone marrow exerts pressure on the 
nerves and causes a sensation of pain. 
4) Frequent infections 
Weakened immune response caused by the lack of functional white blood cell 
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explains for the frequent infections. 
5) Swelling of lymph nodes 
It is caused by the accumulation of the leukemia cells in the lymph nodes. 
1.1.2.2 Classification of Leukemia 
There are two basic criteria in classifying leukemias. First is the degree of 
maturity of the leukemia cells together with their onset rate. They are classified as 
acute or chronic. In acute leukemia, the affected cells stop to differentiate in an 
earlier stage of hematopoiesis and thus appeared to be immature (Hoffbrand et al., 
2006; Leung et al., 2005). This type of leukemia has a sudden onset and progresses 
very rapidly which causes an accumulation of immature functionless cells in the 
marrow and blood. It could be fatal within a few months if the patient is not well 
treated. In chronic leukemia, however, the affected cells appear to be more mature 
but malfunctional. The disease usually progresses slower than the acute one and with 
a prolonged clinical course (HofFbrand et al., 2006; Leung et al.，2005). 
Another factor considered in classifying leukemias is the developmental lineage 
of the leukemia cells. Lymphocytic leukemia develops in bone marrow from 
precursor cells of the lymphocytic lineage while the myeloid leukemia develops from 
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the precursor cells of the granulocytic, monocytic, erythrocytic or megakaryocytic 
lineage (Leung et al,, 2005). Therefore, by using the above two classifications, most 
cases of leukemia can be briefly sorted into one of the four major types: acute 
myelocytic leukemia (AML), acute lymphocytic leukemia (ALL), chronic 
myelocytic leukemia (CML), and chronic lymphocytic leukemia (CLL). 
I Acute Myelocytic Leukemia (AML) 
AML is more common in elderly. Although the cause of AML is not known, 
there are several factors which might increase the risk of having AML. About 20 % 
of adult AML cases are linked to smoking (Brownson et al, 1993). Chromosomal 
translocations, deletions and inversions which turn on oncogenesis, shut down 
tumor-suppressor genes or genes for differentiation which might lead to development 
of AML. AML was found to occur more frequently in people with inherited disorders 
such as Down syndrome, ataxia telangiectasia, Bloom's syndrome and several other 
genetic diseases (Sandler and Ross, 1997). People who have been exposed to high 
dose of radiation, industrial solvents (Rinsky et al, 1987) or products containing 
benzene and patients having chemotherapy treatment for other cancers tend to be 
more susceptible to AML (Sandler and Ross, 1997). In order to have a better 
prognosis and design for the cancer therapy, cancers are given stages of I’ II，III and 
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IV according to the tumor size and the degree of metastasis. However, since 
leukemia is not a solid tumor, this approach is not applicable. A more comprehensive 
morphologic-histochemical classification system for AML was developed by the 
French-American-British (FAB) Cooperative Group to help with the prognosis. This 
classification system (Table 1.1) categorizes AML into 8 subtypes, designated as MO 
to M7, and is based on the microscopic appearance of the cells such as ultrastructural 
morphology, cytogenetics, immunophenotyping and immunohistochemical markers 
(Hoffbrand et al, 2006). 
II Acute Lymphocytic Leukemia (ALL) 
An estimation of 52,000 people in the United States are expected to be 
diagnosed to have ALL in 2007 (American Cancer Society, 2007). It is the most 
common type of leukemia in children aged under 15, however, it also happens in 
adults especially for those who are older than age 45. The reason leading to ALL is 
still under investigation. Scientists believe that genetic changes, life style and 
environmental factors are the main concerns. A causal relationship between the 
Human T-Lymphotropic Virus type I (HTLV-I) and adult T-cell leukemia and 
lymphoma is suspected but not proved (The American Cancer Society, 2007). ALL 
can also be sub-classified on the basis of both morphologic and immunologic studies 
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into 3 subtypes: LI to L3 (Harr i sesa l , 1999; Pui and Evans, 1998) (Table 1.1). ALL 
may spread to brain and spinal cord. Age is the most important factor affecting the 
prognosis (outlook for chances of survival) — children do well, adults usually don't. 
I l l Chronic Myelocytic Leukemia (CML) 
Philadelphia chromosome abnormality is usually found to be the cause of CML. 
The translocation of chromosome 22 to chromosome 9 forms a new hybrid BCR-ABL 
oncogene and a 210-kD BCR-ABL protein is expressed. This fusion protein has 
increased protein tyrosine kinase activity compared to the normal gene and this 
increase in the activity is essential for the BCR-ABL protein to transform normal 
cells to CML (Ososki, 2001). In addition to the presence of the Philadelphia 
chromosome in 95% of CML patients, the marrow is extremely hypercellular and 
may be devoid of fat, myeloid elements are increased, and megakaryocytes may be 
excessive (Ososki, 2001). About 21,501 people in the United States are living with 
CML and about 4,570 people in the United States will be diagnosed to have CML in 
2007 (SEER, National Cancer Institute, 2007). Both children and adults can get CML 
but most patients are adults. 
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IV Chronic Lymphocytic Leukemia (CLL) 
The development of CLL is more a result of genetic predisposition than 
environmental influences. A strong correlation exists between CLL and autoimmune 
diseases such as autoimmune hemolytic anemia and immune thrombocytopenia 
purpura (Ososki, 2001). A defect in apoptosis rather than a change in cell cycle 
regulation causes CLL. Most cells are Go quiescent cells that gradually accumulate 
because they survive too long (Reed, 1998). About 95,579 people in the United 
States are living with CLL and 15,340 new cases was diagnosed in 2007 (SEER, 
National Cancer Institute, 2007). More people are living with CLL than any other 
types of leukemia. Most people with CLL are at least 50 years old. 
An estimated 44,240 new cases of leukemia was diagnosed in the United States 
in 2007. The incidents are more in adults than in children (About 40,440 adults 
compared to 3,800 in children aged from 0 - 19). The most common types of 
leukemia in adults are AML and CLL while ALL is more common in children. Most 
of the CML occurs in adults, there are only 2.4% of children leukemia patients who 
are suffering from CML. Among all types of leukemia, AML is the one causing the 
highest death rate as well as the lowest five-year relative survival rate which is only 
20.7%. 
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Table 1.1: Classification of leukemia 
Type Subclass Variant 
Acute Acute Myeloid MO: minimal differentiation 
Leukemia (AML) M1: myeloblastic (>90% myeloblasts) 
M2: myeloblastic with granulocytic maturation (>10% 
promyelocytes or later granulocytes) 
M3: promyelocytic (coarsely granular or microgranular 
promyelocytes) 




M6: erythroblastic (>50% erythroblasts) 
M7: megakaryoblastic (>50% megakaryoblasts) 
Acute Lymphoblastic LI: homogeneous small blasts with little cytoplasm 
Leukemia (ALL) L2: heterogeneous larger blasts with variable amounts of 
cytoplasm 
L3: homogeneous large blasts with vacuolated basophilic 
cytoplasm 
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Chronic Chronic Myeloid Philadelphia-positive chronic myeloid leukemia 
Leukemia (CML) Philadelphia-negative chronic myeloid leukemia 
Juvenile chronic myeloid leukemia 
Chronic neutrophilic leukemia 
Eosinophilic leukemia 
Chronic myelomonocytic leukemia 
Chronic Lymphocytic B-chronic lymphocytic leukemia 
Leukemia (CLL) B-prolymphocytic leukemia 
Hairy cell leukemia 
Plasma cell leukemia 
T-chronic lymphocytic leukemia 
T-prolymphocytic leukemia 
Adult T-cell leukemia / lymphoma 
(Modified from Hoffbrand et al, 2006) 
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1.1.2.3 Conventional Treatments against Leukemia 
Conventional treatments for leukemia include chemotherapy, radiotherapy and 
hematopoietic stem cell transplantation. 
I Chemotherapy 
Chemotherapy is the most common treatment used to treat leukemia. It makes 
use of different kinds of drugs to kill the leukemia cells. The drugs can be delivered 
orally, by intravenous injection, intramuscular injection or through cerebrospinal 
fluid. The dosage, the route of administration and the type of drug used depend on 
the type and the progression of leukemia. In general, chemotherapy treatment for 
leukemia can be divided into 3 stages: 1) Induction: high dosage of drug is used in 
order to rapidly kill and reduce the cancer cells in bone marrow and blood. 2) 
Intensification: more drugs and higher dosages are used in order to further reduce the 
hidden cancer cells in other organs, and the duration varies in different patients. 3) 
Maintenance: low dosage of drug is used so as to keep the cancer cells under control 
and to prevent the relapse of leukemia. In any case, if there is no relapse within 5 
years, the patient is regarded to be completely cured. Though chemotherapy has an 
advantage of direct and rapid delivery of drugs to exert the killing effect on the 
cancer cells, this has accompanied with many side effects due to the cytotoxicity of 
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drugs on a variety of normal cells. For examples, rapidly dividing cells like the hair 
follicular cells and gastrointestinal epithelial cells are harmed or might be killed by 
the drugs administered which eventually cause loss of hair, diarrhea and vomiting 
respectively. There are also other side effects like mouth sores, weakened immunity, 
easy bruising, bleeding and fatigue. A more devastating side effect is tumor lysis 
syndrome caused by rapid breakdown of large amount of leukemia cells, resulting in 
the release of cellular contents like cell fragments, metabolic products and minerals 
into the blood circulation. These substances can damage the kidneys, heart and 
nervous system, often lead to a higher rate of morbidity and mortality. Currently, 
there is still a lot of ongoing research working on developing more chemotherapeutic 
regimens with more potent anti-leukemia activities with fewer side effects. 
II Radiotherapy 
Radiotherapy is often used with chemotherapy and is sometimes given as 
conditioning treatment to prepare a patient for a blood or marrow stem cell transplant. 
Radiotherapy works by distorting the genetic materials inside the cells, hence 
preventing the cells from growing and proliferating. Patients need to first undergo 
simulation in which the most effective way of treatment is determined. The dosage 
and the radiation used during the treatment depend on various factors of the patient, 
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like the type of leukemia, the progression of the disease and the aim of treatment. 
Though the radiation is directed to cancer cells, healthy cells surrounding the cancer 
cells may be damaged which causes fatigue, diarrhea, nausea, loss of appetite, skin 
irritation and hair loss on the body part being radiated (American Cancer Society, 
2007). Children who receive radiation to the brain may develop problems with 
learning and coordination, and radiation to the testicles is likely to affect both fertility 
and hormone production. Therefore, children are proceeded to have radiotherapy 
only when chemotherapy is not working (Leung et al, 2005). 
I l l Hematopoietic Stem Cell Transplantation 
Patients with any kind of leukemia which is poorly responsive to standard 
therapy or shows biological features which are known to predict a poor response to 
chemotherapy, may be treated with very intensive chemotherapy and/or radiotherapy 
followed by complementary stem cell transplantation. There are two major types of 
stem cell transplantations, namely allogeneic transplantation and autologous stem 
cell infusion. Allogeneic transplantation uses the stem cells from a donor, usually a 
brother or sister with same tissue type as the patient; whereas autologous 
transplantation uses patients' healthy HSC which were frozen previously. Sources of 
the stem cells could be from bone marrow, peripheral blood or cord blood. After 
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several decades of development, stem cell transplantation has been used to treat 
immune deficiency, inherited severe blood cell diseases, marrow failure and other 
inherited disorders. Allogeneic stem cell transplantation is the only treatment that can 
cure CML at this time. Trials of autologous marrow transplantation have also begun 
in CLL patients. Despite the fact that it is used successfully to cure leukemia patients 
with high risk of relapse and low responsiveness to treatment, there are many 
limitations. Firstly, there are a lot of factors needed to be seriously considered before 
making the decision of using the stem cell treatments which complicated the process. 
For example, the patient's age, general health, medical condition, the probability that 
the disease respond to the conditioning treatment and the availability of an human 
leukocyte antigen (HLA) matched donor or the ability to use patient's own stem cells. 
Secondly, the cytotoxic effects of the Intensive intake of the conditioning regimen 
cause a lot of adverse impacts to the patients. It also markedly decreases blood 
counts, like the blood platelets and red blood cells, which leads to anemia. The 
decrease in number of functional white blood cells increases the risk of infection like 
interstitial pneumonia. The allogeneic transplantation faces another hindrance called 
graft versus host disease (GVHD) which is a condition that the transplanted donor 
stem cells attack the patient's body. GVHD is not a side effect of autologous stem 
cell infusion because patient's own stem cells are used. Though drugs are available to 
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suppress the immune system and prevent GVHD, the patients need to take them 
continuously for months after transplantation which hence increases the risk of 
getting infection. 
IV Immunotherapy 
Immunotherapy involves the use of immune cells or antibodies to fight against 
the disease or simply to suppress the progression of leukemia. This treatment is of 
high specificity and hence minimizes the toxic effect on the normal tissues. Three 
types of therapy are being investigated: antibody treatment, vaccine development and 
immune cell administration. Campath®-1 H is a monoclonal antibody directed 
against the antigen cluster of differentiation 52 (CD52) found on T and B 
lymphocytes and is very active against the lymphocytes in CLL patients (Byrd et al., 
2004). Another drug name Mylotarg® is an antibody which had been approved by 
the Food and Drug Administration (FDA) to treat patients with AML (Waldmann et 
«/•，2000). Scientists are working on the vaccines which could make use of the 
immune system of the patients to inhibit the growth of cancer cells. 
1.1.2.4 Novel approaches 
Remarkable progress has been achieved in the treatment of leukemia over the 
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last few decades, nevertheless, problems like the multidrug resistance, cellular 
heterogeneity, heterogeneous molecular abnormalities, karyotypic instability and lack 
of selective action of anti-neoplastic agents still remain unsolved (Tsiftsoglou et al, 
2003). Scientists are therefore looking for other novel ways to tackle the disease 
especially on the mechanism which allows the cancer cells to escape from the 
chemotherapy and eventually develop the resistance. The tactic is to suppress the cell 
to develop resistance against chemotherapeutic drug used in treating leukemia and 
hence increase the efficacy of the chemotherapy. There are some agents being tested 
in AML patients. 
I Gene Therapy 
Gene therapy is another novel approach. Proposed agents act on either the 
(deoxyribonucleic acid DNA) or ribonucleic acid (RNA) level to prevent the 
formation of particular gene products which transform norma丨 cells into malignant 
cancer cells. In studies of CML, scientists try to modify BCR-ABL that produces a 
protein which stimulates malignant cell growth (The Leukemia and Lymphoma 
Society, 2007). As mentioned previously, HSC are normally programmed to 
differentiate into cell lineage restricted pathways of blood cell development by 
external growth factors that keep balancing cell growth, differentiation and 
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programmed cell death in the bone marrow (Fisher, 2002; Tsiftsoglou et al, 2003). 
However, in leukemias, early hematopoietic progenitors fail to respond to the 
microenvironment in the bone marrow to differentiate themselves into terminate 
functional blood cells (Fialkow et al, 1981; Tsiftsoglou et al, 2003). These cells are 
often unable to undergo both differentiation and apoptosis; they proliferate in a large 
number at the expense of other cells, and eventually spill into the peripheral blood. 
The degree of differentiation is inversely related to the malignancy which basically 
suggests that differentiation is uncoupled from the cell growth control in leukemia 
(Sachs, 1980). Therefore, the induction of both apoptosis and differentiation should 
be able to minimize or abrogate the malignancy of the leukemia cells. 
n Apoptosis 
The study of apoptosis is relevant to many aspects of tumor biology which 
include tumorigenesis, tumor homeostasis, angiogenesis, metastasis and clinical 
treatment. Malignant cells often harbor mutations in critical components of the 
apoptosis pathway which lead to poor prognosis. Tumors must circumvent the 
apoptotic pathway in order to metastasize and establish secondary tumor sites 
(Mcgill et al, 1997). Accumulated data show that many of the anti-cancer drugs fight 
against the tumor cells through the induction of apoptosis (Robertson et al” 2000; 
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Tong et al, 2004). 
The apoptotic cell is characterized by cell shrinkage, blebbing of the plasma 
membrane and chromatin condensation that are consistent with DNA cleavage in 
ladders which actively destroys itself without causing harm to the neighboring cells 
or inducing any inflammatory response. It is different from necrosis which occurs 
after severe cell injury and results in swelling and lysis of a cell. It is therefore of 
prime importance for this new approach to be developed to full. Numerous drugs 
have been designed to target at the abnormal molecules which inhibit apoptosis, for 
instance, death receptors, caspases and Bcl-2 family proteins as well as other 
transcription factors such as nuclear factor kappa B (NF-KB) involving in apoptosis 
regulation (Fisher and Schulze-Osthoff, 2005; Reed and Pellecchia, 2005). 
Mitochondrion is another candidate being targeted to induce apoptosis. 
I l l Differentiation 
All-trans retinoic acid (ATRA) and arsenic trioxide (AS2O3) have been shown to 
be effective in treating acute promyelocytic leukemia (APL). One of the causes of 
APL is the chromosome translocation of t(15;17)(q22;q21) which generates a fusion 
gene and results in the formation of fusion protein PML-RARa. This protein blocks 
differentiation of myeloid cells and inhibits apoptosis of the cells. Administration of 
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ATRA degrades the fusion protein and restores the normal differentiation of the 
promyeloid cells (Wang, 2003) and inhibits their replicative capacity, eventually 
exhausting the malignant clone. In ALL, low doses of 6-mercaptopurine and 
methotrexate used in the maintenance therapy were found to be potential inducers of 
differentiation. These two drugs inhibited the clonogenic growth of the ALL cell 
lines without inducing immediate apoptosis, and were associated with induction of 
phenotypic differentiation. They up-regulated lymphoid antigen expression, while 
decreased CD 34 expression on patients' ALL blasts (Lin et al, 2007). A lot of 
experiments are being carried out to elucidate the mechanisms leading to 
differentiation and to search for more effective agents in treating leukemia by 
induction of leukemic cell differentiation. 
Apart from ATRA, dozens of differentiation-inducing agents have been studied, 
these include vitamin analogs, cytokines like tumor necrosis factor-alpha (TNF-a) 
and interferon-gamma (IFN-y), polar-aplanar compounds, inhibitors of DNA 
methylation, chemotherapeutic agents and plant growth regulators derived from 
medicinal plants. In the last two decades, the development of natural products from 
either Chinese herbs or plants as a potential anti-cancer drug had caught the sight of 
scientists. Several natural products including isoflavonoid，green tea catechin, red 
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wine resveratrol and extract from Sophora flavescens were reported to have potent 
differentiation-inducing effect on leukemia cells (Miller and Waxman 2002; Tan et 
aL, 2000). The above mentioned arsenic trioxide is also one of the traditional 
Chinese medicines which has been used for thousands of years and it was found to 
exert both apoptotic and differentiation-inducing effects on leukemia (Wang, 2003). 
Natural products with insignificant adverse effects will definitely be the trend and 
direction for drug development in the future. 
1.2 The Chinese Medicinal Herb-Banlangen (板藍根） 
1.2.1 An Overview on Natural Indigo Compounds Derived from Banlangen 
In 2003, when there was an outbreak of Severe Acute Respiratory Syndrome 
(SARS), it was believed that continuous intake of a Chinese medicinal herb called 
Banlangen could boost up the immune system and help preventing SARS, though 
there was no medical evidence proving its applicability. This even led to a sold out of 
stock in the market. It is not since then does Banlangen attract the attention of 
scientists, but started from centuries ago, Banlangen was already on the list of hot 
discussion. 
According to the Pharmacopoeia of People's Republic of China, there are 4 
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types of Banian, namely Isatis indigotica fort (粒藍)，Baphicacanthus cusia bremek 
G馬藍)，Polygonum tinctorium lour (蓼藍 )and Indigofera tinctoria (木藍 ) .Their 
leaves and roots are known as Daqingye (大青葉） a n d Banlangen (板藍根） 
respectively and they have been used as traditional medicine for hundreds of years as 
anti-pyretic, anti-viral, anti-inflammatory, anti-influenza and detoxifying agents in 
China, Korea and Japan (Liau et al, 2007; Takei et al., 2003). Indigofera tinctoria 
was also employed in Europe for the treatment of wounds, ulcers, snake bites, 
hemorrhoids and various inflammatory ailments (Lee et al, 2007). A number of 
chemical constituents have been identified in Daqingye and Banlangen including 
alkaloids (indigoid alkaloids such as indirubin and indigo; quinazolinone alkaloids 
like tryptanthrin), sucrose, organic acids and glycosides. Many compounds have been 
isolated from Polygonum tinctorium and their biological activities have been 
investigated (Honda et al., 1980). Among them, three alkaloids are suspected to have 
various pharmaceutical activities. They are indigo (Fig. 1.2), indirubin (Fig. 1.3) and 
tryptanthrin (Fig. 1.4) 
Indirubin is one of the active compounds in Polygonum tinctorium, it exerts an 
inhibitory effect on the production of IFN-y by human myelomonocytic HBL-38 
cells. It can inhibit the production of IFN-y and IL-6 in murine splenocytes with no 
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influence on the proliferation of normal cells (Kunikata et al.’ 2000). Moreover, by 
using 2,4,6-trinitro-l-chlorobenzene (TNCB)-induced delayed-type hypersensitivity 
mice as a representative inflammatory reaction model, indirubin was shown to be 
able to inhibit the ear swelling. The amount of IFN-y in the culture supernatants of 
elicited mouse lymphocytes was inhibited by indirubin treatment. These suggested 
that indirubin is a compound with anti-inflammatory effects (Kunikata et al., 2000). 
The effect of indirubin on the expression of the chemokine CCL5 or Regulated upon 
Activation, Normal T cell Expressed and Secreted (RANTES) by the influenza 
virus-infected H292 human epithelial cell line was also examined. It was reported to 
reduce the expression and production of RANTES in influenza A/NWS/33-infected 
H292 cells. Inhibition was also observed in influenza virus B/Lee-infected cells. 
These suggest that indirubin is one of the components in the Chinese medicinal herb 
(Banlangen) with immunomodulatory activity (Mak et al, 2004). Apart from its 
anti-inflammatory, anti-viral and immunomodulatory effects, indirubin has been 
proven to exhibit anti-cancer effect. Indirubin underwent extensive preclinical 
development in China as an anti-cancer drug (Tang and Eisenbrand, 1992). It showed 
good inhibitory effect and low toxicity in animal leukemia and lung carcinoma 
models (Hoessel et al, 1999). Mechanistic studies showed that indirubin binds to the 
ATP binding site of cyclin dependent kinase (Cdk) in an ATP-competitive manner 
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and acts as a potent inhibitor. Inhibition of Cdk by indirubin leads to cell cycle arrest, 
preferentially in Gi and/or Gi/M-phase, and in most cases followed by induction of 
apoptosis (Eisenbrand et al., 2004). Based on this mechanism, a number of indirubin 
derivatives were made to improve the bioavailability. 
Indirubin-3'-oxime (Fig 1.5), one of the modified indirubin derivatives with 
kinase inhibitory activity, also mediates a potent inhibitory effect on the expression 
of RANTES. The influenza virus infection-induced phosphorylation of the nuclear 
transcription NF-KB regulatory molecules inhibitor of kappa B alpha (IICB-a) and the 
p38 mitogen-activated protein kinase (MAPK) were also found to be inhibited by 
indirubin-3'-oxime (Mak et al, 2004). 
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Fig. 1.5 Chemical Structure of Indirubin-3'-Oxime 
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1.2.2 Tryptanthrin 
Quinazoline alkaloids constitute a moderately sized group of natural products. 
Tryptanthrin, chemically named as indolo[2,1 -b]quinazoline-6,12-dione, is one of the 
representatives of quinazoline alkaloids. The beautiful yellow tryptanthrin had been 
isolated from Isatis tinctoria as an anti-fungal and an anti-dermatophytic agent 
(Honda et al., 1980) since 1980 and was later investigated by several other groups 
(Tang and Eisenbrand, 1992; Seifert and linger, 1994; Mitscher and Baker, 1998). 
Tryptanthrin was found to possess a wide spectrum of activities. It is anti-bacterial 
(Mitscher and Baker, 1998), anti-tumor (Romano and Claria, 2003; Kataoka et al, 
2001) and anti-inflammatory (Takei et al, 2003; Hamburger, 2003). 
1.2.2.1 Anti-bacterial Activity of Tryptanthrin 
Staphylococcus aureus produces various toxins including staphylococcal 
enterotoxins and toxic shock syndrome toxin-1. These toxins will be absorbed 
through the intestinal epithelium in an immunologically intact form and trigger a 
series of reactions which lead to polyclonal activation of T cells and results in the 
overproduction of cytokines, including IFN-y, IL-2 and TNF-a which are tightly 
associated with the toxin-elicited symptoms like food poisoning and toxic shock 
syndrome. Tryptanthrin can inhibit cytokine production by lymphocytes stimulated 
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with the staphylococcal enterotoxin B (SEB) (Takei et al., 2003). It suppresses 
SEB-induced IFN-y and IL-2 production by mouse spleen cells and Peyer's patches 
(PP) lymphocytes in vitro. The elevated IFN-y produced by PP lymphocytes induced 
by SEB was significantly inhibited by oral tryptanthrin administration in vivo. These 
suggest that tryptanthrin may be employed in treating intestinal disorders such as 
food poisoning (Takei et al., 2003). 
At the beginning of century, tuberculosis (TB) was a devastating infectious 
disease known as the "White Plague". Mankind had no effective treatment and so the 
morbidity and mortality were very high. However, with a more thorough research 
done on TB, a succession of effective anti-tubercular chemotherapeutic agents was 
discovered. Tryptanthrin was proven to be more potent against MTB H37Rv (1 mg/L) 
and M. avium (4 mg/L) than against M Smegatis (6 mg/L) by BACTEC technology 
(Mitscher and Baker, 1998). Its potency is more or less the same as that of well 
known anti-tubercular agents such as streptomycin, isoniazid and ethambutol. More 
surprisingly, tryptanthrin works equally active on the multiple drug resistant (MDR) 
M. tuberculosis strain 10038, while the former drugs mentioned are less potent. This 
may imply that tryptanthrin works with a different mechanism from the one used by 
most of the anti-tubercular drugs. In case if the existing agents are not functioning, 
- 3 0 -
Chapter 1 General Introduction 
tryptanthrin may be able to take up the job (Mitscher and Baker, 1998). 
The in vitro effect of tryptanthrin on H. pylori colony formation was 
investigated too. It was found to inhibit the colony formation of H, pylori in a 
dose-dependent manner (Kataoka et al, 2000). H. pylori infected Mongolian gerbils 
were prepared to determine the anti-bacterial effect of tryptanthrin in vivo. The 
administration of tryptanthrin at 5 mg/gerbil significantly decreased the number of H, 
pylori colonies in the stomach of the gerbils. Neither acute toxicity nor marked loss 
of body weight was observed. Macroscopic observation did not show any marked 
changes in internal organs resulting from the administration of tryptanthrin. 
Complete bacterial clearance was expected with a prolong administration of it. All 
these indicate that tryptanthrin would be applicable for anti-//. pylori therapy 
(Kataoka et al, 2000). 
1.2.2.2 Anti-tumor Activity of Tryptanthrin 
Hepatocyte growth factor (HGF) has been shown to be involved in malignant 
cell transformation and in growth, invasion and metastasis in cancer cells (Comoglio 
et al, 2002; Danilkovitch-Miagkova and Zbar, 2002). Tryptanthrin was found to be 
able to inhibit the production of HGF stimulated by various HGF inducers like 
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phorbol 12-myristate 13-acetate (PMA) in human dermal fibroblast, and this may 
have the potential to interfere with malignant cell transformation and progression of 
tumors and cause no appreciable cytotoxic effect. It further inhibits the proliferation 
of the fibroblast induced by epidermal growth factor and platelet-derived growth 
factor to the level of proliferation of unstimulated fibroblast. There is no inhibitory 
effect of tryptanthrin on MAPK phosphorylation upregulated by PMA, suggesting 
that tryptanthrin inhibits HGF induction through the events down-stream of MAPK 
activation (Motoki et al, 2005). 
Multidrug resistance is always the major problem found in chemotherapy. 
Inhibition of MDRl gene function, either by blocking the P-glycoprotein (P-gp) by 
inhibiting MDRl gene expression, has been one of the most extensive studies. 
However, until now only a few chemicals have been reported to down-regulate 
MDRL Tryptanthrin was found to depress the over-expression of M D R l as well as 
the P-gp in the breast cancer cell line MCF-7. It works by enhancing interaction of 
the nuclear proteins with the negatively regulatory CAAT region of MDRl gene 
promoter in MCF-7 cells and hence suppresses the activity of MDRl gene promoter. 
Furthermore, tryptanthrin was proven to decrease the amount of mutant p53 protein 
which enhances MDRl gene expression by decreasing mutant p53 protein stability. It 
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might contribute to a negative regulation of MDRl gene. In conclusion, tryptanthrin 
exhibits MDR reversing effect by down-regulation of MDRl gene and might be a 
new adjuvant agent for chemotherapy (Yu et al, 2007). 
1.2.2.3 Anti-inflammatory Activity of Tryptanthrin 
Production of nitric oxide (NO) and prostaglandins by macrophages have been 
implicated in the pathogenesis of several inflammatory diseases. The effect of 
tryptanthrin on NO and prostaglandin E2 production by IFN-y and 
lipopolysaccharide-stimulated murine macrophage-like RAW 264.7 cells was 
investigated. It was found that tryptanthrin was able to effectively inhibit both NO 
and prostaglandin E2 production in a dose-dependent manner. Mechanistic studies 
showed that the decrease in the amount of NO production was due to the inhibition 
of NO synthase expression. While for prostaglandin, tryptanthrin inhibits the 
cyclooxygenase (COX) enzyme activity instead of exerting its effect through 
suppressing the expression of the enzyme (Ishihara et al, 2000). 
Tryptanthrin strongly inhibited COX-2 catalyzed eicosanoid synthesis in 
LPS-stimulated Mono Mac 6 cells (Danz et al, 2001). It gave a comparable IC50 
value (0.037 |LIM) when compared to those common COX-2 inhibitors like 
- 3 3 -
Chapter 1 General Introduction 
nimesulide (0.027 \xM). The potency of tryptanthrin was found to be hundred times 
lower in inhibiting the COX-1 catalysed thromboxane B2 formation in HEL cells 
when compared to 2 other non-selective COX inhibitors dicolfenac and 
indomethacin. The effect of tryptanthrin on the 5-lipoxygenase activity was also 
tested indirectly by measuring the release of leukotriene B4 (Danz et al., 2002). 
Tryptanthrin can inhibit the production of leukotriene B4 with comparatively low 
IC50 when compared to clinically used 5-lipoxygenase inhibitor like zileuton. It 
inhibits the formation of three major groups of pro-inflammatory substances in a 
cell-based assay at nM to [iM concentrations (Hamburger, 2002). All these suggest 
that tryptanthrin possesses anti-inflammatory properties and may be a potential drug 
that can be used for the treatment of inflammatory disease. 
In addition, tryptanthrin was shown to be weakly insecticidal (Seifert and linger, 
1994). Cyto-inhibitory activity was also reported for tryptanthrin (Kimoto et al, 
1999). 
1.2.2.4 Cutting Edges of Tryptanthrin as a Drug 
The advantage of tryptanthrin is that it exhibits a unique spectrum of activities 
and considerable potency in vitro with structural features that are considered as 
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typical of orally available drugs in terms of molecular mass, lipophilicity，number of 
proton acceptor and donor sites (Lipinski et al., 1997). The compound is easy to be 
synthesized and structural modification is allowed for lead optimization. In addition, 
tryptanthrin was only slightly affected by serum protein binding (Mitscher and Baker, 
1998). 
1.2.2.5 Metabolism of Tryptanthrin 
Indigo, indirubin and indirubin-3，-oxime have been suggested to be the 
physiological ligands of the aryl hydrocarbon receptors (Adaci et al” 2001) and they 
can induce biological responses in mammalian cell culture and whole animal. Among 
them, indirubin was found to be 50 times more potent than 
2,3,7,8-tetrachlorodibenzo[p]dioxin (TCDD) as a receptor agonist using a 
yeast-based system. When rats were treated with these indigoids in the range of 
1.5-50 mg/kg, induction of hepatic cytochrome P450 l A l was detected. A stronger 
response was observed with inclirubin-3'-oxime. The metabolism of these indigoids 
was also investigated by incubating the chemicals with the rat liver microsomes and 
the HPLC profiles were analyzed. The metabolites have not been identified. However, 
it was found that among the three indigoids, incubation of indirubin-3'-oxime with 
rat liver microsomes led to the loss of the parent compound. The oxidation of the 
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oxime was nicotinamide adenine dinucleotide phosphate (NADPH) dependent (Peter 
Guengerich et al., 2004). 
A very crucial process in drug development is the understanding of the 
metabolic profile of the potential candidate, but so far, there was only one report 
studying the metabolic profile of tryptanthrin. Tryptanthrin was incubated with rat 
liver microsomes in the presence of NADPH-generating system. It was then 
metabolized by cytochrome P450 lAl in rat liver microsomes. The metabolites were 
identified by liquid chromatography/electrospray ionization-tandem mass 
spectrometry. One metabolite was proposed to be 8-hydroxytryptanthrin. It was also 
suggested that this metabolite will further be converted into another compound in 
acetone-induced microsomes. This hypothesis is still under investigation both in vivo 
and in vitro (Lee et al, 2007). 
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1.3 Aim and Scope of This Project 
Although a number of investigations have been conducted on the biological and 
pharmacological activities of tryptanthrin, however, its modulatory effects and action 
mechanisms on leukemia cells remain poorly understood. In my study, tryptanthrin 
was examined for its modulatory effects on the proliferation, differentiation and 
apoptosis of the murine myeloid leukemia WEHI-3B JCS cells. 
In this project, the anti-proliferative effect of tryptanthrin was studied using a 
we 11-characterized and subcloned murine myelomonocytic leukemia WEHI-3B JCS 
cell model. Its effects on other myeloid leukemia cell lines of human (EoL-1, HL-60, 
K-562) and murine (Ml) origin was also compared. These were done using the 
tritiated thymidine incorporation assay. Its cytotoxicity was studied using the 
colorimetric MTT assay and trypan blue exclusion assay. The kinetics as well as the 
reversibility of the anti-proliferative effect of tryptanthrin were also tested. Cell cycle 
profile of JCS cells after tryptanthrin treatment was analyzed by flow cytometry. 
Apoptosis-inducing ability of tryptanthrin was measured by various techniques 
including the DNA fragmentation assay, and Annexin V-GFP and propidium iodide 
(PI) double staining assay. The underlying mechanism was investigated by 
measuring the apoptosis-related protein expression and gene expression using both 
Western blotting and the real time PGR. Apart from that, the induction of caspases 
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activities and mitochondrial membrane depolarization were measured. In addition, 
the in vivo tumorigenicity and anti-tumor effect were also studied in BALB/c mice. 
Finally, preliminary studies on the differentiation of WEHI-3B JCS cells induced by 
tryptanthrin were carried out. These include analyzing the morphological and 
functional changes in WEHI-3B JCS cells induced by tryptanthrin by Hemacolor 
staining on cytospin preparation, flow cytometry and the NBT-reduction colorimetric 
assay respectively. 




Chapter 2 Materials & Methods 
2.1 Materials 
2.1.1 Animals 
Inbred female BALB/c (H-2'') mice aged 6-8 weeks old were bred at the 
University Laboratory Animal Services Centre of The Chinese University of Hong 
Kong under specific pathogen-free condition. Animal diet (Chow 5001，Rodent 
Laboratory) and tap water were given as main food to the mice. 
2.1.2 Cell Lines 
1) WEHI-3B 
WEHI-3B (D') is a myelomonocytic leukemia cell line induced by mineral oil 
from BALB/c mice. It was originally acquired from Dr. D. Metcalf (Walter and Eliza 
Hall Institute for Medical Research, Melbourne, Australia) and subsequently 
subcloned at the John Curtin School of Medical Research, Australian National 
University, Canberra, Australia. One of the subclones named WEHI-3B JCS (Leung 
et al, 1984) was used in this study. 
2) M l 
Ml is a murine myeloblastic leukemia cell line established in vitro from a 
spontaneous myeloid leukemia of SL strain mice by Y. Ichikawa in the Kyoto 
University of Japan in 1969 (Ichikawa, 1969). The cell line was purchased from the 
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American Type Culture Collection (ATCC), U.S.A. 
3) HL-60 
HL-60 is a human promyelocytic leukemia cell line derived by leukopheresis 
from a 36-year-old Caucasian female with acute promyelocytic leukemia (Collins et 
al, 1977). It was purchased from the ATCC, U.S.A. 
4) K-562 
K-562 is a human chronic myelogenous leukemia (CML) cell line established 
from the pleural effusion of a 53-year-old female with CML in terminal blast crises 
(Lozzio and Lozzio, 1975). It was purchased from the ATCC, U.S.A. 
5) EoL-1 
EoL-1 is a human acute eosinophilic leukemia cell line established from the 
peripheral blood of a 33-year-old male with acute eosinophilic leukemia 
(Philadelphia chromosome-negative eosinophilic leukemia) and hyper-eosinophilic 
syndrome (Saito et al., 1985). The cell line was kindly provided by Prof. C.K. Wong. 
Department of Chemical Pathology, The Chinese University of Hong Kong, Hong 
Kong, China. 
6) WRL 68 
WRL 68 is a human hepatocyte-like cell line with functional characteristics of 
normal human hepatocytes (Apostolov, 1976). The cell line was kindly provided by 
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Prof. K.P. Fung, Department of Biochemistry, The Chinese University of Hong Kong, 
Hong Kong, China. 
2.1.3 Cell Culture Medium, Buffers and Other Reagents 
1) Cell Culture Medium 
For the preparation of the culture medium, the powdered form of RPMI 1640 
medium (GIBCO BRL Life Technologies Inc.), supplemented with 25 mM 
N-2-hydroxy-ethy 1-piperazine-N -1 -ethane-sulfonic acid (HEPES) and 2 mM 
L-glutamine was used. After dissolving the powdered medium in the deionized water, 
the solution was buffered with 2 g sodium bicarbonate (NaHCOa) (Sigma Chemical 
Co.) per litre. The mixture was then adjusted to pH 7.14 by 1 M hydrochloric acid 
(HCl) or sodium hydroxide (NaOH) (Sigma Chemical Co.) Then, it was sterilized by 
membrane filtration through a 0.22 |am Millipore filter and stored at 4�C until use. 
“Plain Medium" (PM) which is the RPMI medium supplemented with 1% 
antibiotics was usually used for washing cells while complete RPMI medium (CM) 
prepared by supplementing PM with 10% or 20% fetal bovine serum (FBS) was used 
for culturing cells. Most of the human and murine cell lines were cultured with 10% 
FBS-supplemented CM while HL-60 was cultured with 20% FBS-supplemented CM. 
Culture medium used for assays was prepared by supplementing PM with 10% or 
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20% heat-inactivated fetal bovine serum (HI-FBS). 
2) Serum Supplements 
Fetal Bovine Serum (FBS) (GIBCO BRL Life Technologies Inc.) was used. To 
make the HI-FBS, FBS was heated at 56�C for 30 minutes. Both of them were stored 
at - 20�C as 20 and 50 ml aliquots until use. 
3) Antibiotic Solutions 
Two types of antibiotics solution were used in alternative periods: antibiotics 
PSF [10,000 units/ml penicillin G (sodium salt), 10,000 |Lig/ml streptomycin sulfate 
and 25 昭/ml amphotericin B as Fungizone in 0.85% saline] and antibiotics PSN 
[10,000 units/ml penicillin G (sodium salt), 10,000 |ag/ml streptomycin sulfate and 
5,000 |j.g/ml neomycin sulfate in 0.85% saline]. The lOOX stock solutions were 
purchased from GIBCO CRL Life Technologies Inc. They were kept at - 20�C as 5 ml 
aliquots. 
4) Dulbecco's Phosphate-Buffered Saline (PBS) 
PBS (Sigma Chemical Co.) was prepared by dissolving 8 g sodium chloride, 0.2 
g potassium chloride, 0,2 g monobasic potassium phosphate and 1.15 g dibasic 
sodium phosphate in one litre of deionized water. The pH of the solution was 
adjusted to 7.4 by either adding 1 M HCl or NaOH and then it was sterilized by 
autoclaving at 121°C for 20 minutes before use. 
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5) Thioglycollate (TG) Broth 
TG broth (3% w/v) was prepared by suspending 3 g of dehydrated 
thioglycollate powder (Difco Lab) in 100 ml deionized water. It was then heated for 
complete solvation and then sterilized by autoclave at 121°C for 20 minutes. It was 
kept in dark at room temperature for at least one month before use. 
6) Methylthiazoletetrazolium (MTT) 
MTT was purchased from Sigma Chemical Co. in powdered form. It was 
dissolved in deionized water to prepare the stock solution at 5 mg/ml concentration. 
The stock was stored at 4°C until used. 
7) Dye Solutions 
a) Hemacolor Staining Solutions 
Three distinct hemacolor staining solutions (Diagnostica Merck), including 
Solution 1, containing methanol for cell fixation; Solution 2, a buffered color reagent 
red; and Solution 3，a buffered color reagent blue, were used for staining cell in glass 
microscopic slides after cytocentrifugation. The buffer solutions were freshly 
prepared by dissolving 1 buffer tablet in 1 litre of deionized water. They were 
light-protected, stored in a tightly closed brown glass bottle at room temperature. 
b) Trypan Blue Solution 
Trypan blue solution was purchased from Gibco BRL Life Technologies Inc. It 
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contains 0.4% (w/v) trypan blue dissolved in 0.85% saline. 
c) 0.5% Crystal Violet solution 
Crystal violet powder composed of crystal violet and methyl violet was 
purchased from Sigma-Aldrich Co. The dye was prepared by dissolving 0.5 g of 
crystal violet powder, 0.9 g NaCl, 2% (v/v) formaldehyde in 50 ml ethanol and then 
added up the volume to 100 ml with deionized water. The solution was kept in dark 
and stored at room temperature. 
d) Nitro Blue Tetrazolium (NBT) 
Nitro Blue tetrazolium powder was purchased from Sigma-Aldrich Co. The dye 
was prepared by dissolving 0.02 g NBT powder in 10 ml RPMI containing 1 |ig/ml 
PMA. 
e) Safranin 
Safranin powder was purchased from South East Chemicals and Instruments 
Ltd. The dye was prepared by dissolving 0.1 g of safranin in 10 ml of distilled water. 
f) Tryptanthrin 
Tryptanthrin used in this study was purchased from Wako Pure Chemical 
Industries, Ltd. The powdered compound (with molecular weight of 248.24 and ^ 
97% purity as determined by TLC) was dissolved in 100 % DMSO to give 10 mM 
stock solutions. The stocks were stored at -20°C. 
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g) Indirubin-3'-oxime 
Indirubin-3'-oxime used in this study was purchased from Sigma Aldrich Co. 
The powdered compound (with molecular weight of 277.28 and purity ^ 98% as 
determined HPLC) was dissolved in 100% DMSO to give 10 mM stock solution. 
The stocks were stored at -20°C until use. 
2.1.4 Reagent for ^H-Thymidine Incorporation Assay 
1) [Methyl-3H� Thymidine (^H-TdR) 
The ^H-TdR stock solution (Amersham Life Science Ltd.) with specific activity 
of 2 Ci/mmol was kept as 500 jul aliquots at 4°C. It was freshly diluted to 25 jiCi/ml 
working solution by using 10% FBS-supplemented complete RPMI medium (10% 
CM) for DNA labeling. Twenty microlitres working solution was added into each 
well of the 96-well flat-bottomed microtiter plate when performing the proliferation 
assay. 
2) Liquid Scintillation Cocktail 
The ready-to-use optiPhase "High" safe-2 liquid scintillation cocktail, obtained 
from Perkin-Elmer Co., is based on biodegradable solvents with dioctyl 
sulfonsuccinate, sodium salts and poIy(ethyleneglycol)mono(4-nonylphenyl)-ether. 
It was stored in dark at room temperature. 
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2.1.5 Reagents and Buffers for Flow Cytometry 
1) Propidium Iodide (PI) DNA Staining Buffer 
The PI DNA staining buffer, freshly prepared in PBS, contains 400 |ig/ml 
ribonuclease A (RNase A) (Boehringer Mannheim), 50 )Lig/ml propidium iodide 
(Boehringer Mannheim), 10 mM EDTA (pH 7.4) (Sigma Chemical Co.), 0.1% 
trisodium citric acid (Sigma Chemical Co.) and 0.1% Triton X-100 (Sigma Chemical 
Co.). All these reagents were stored at 4°C until use. 
2) Green Fluorescence protein (GFP)-conjugated Annexin V 
Annexin V-GFP was kindly supplied by Prof. S.K. Kong, Department of 
Biochemistry, The Chinese University of Hong Kong, Hong Kong, China. Annexin V 
is a 35kDa phospholipid-binding protein that has high affinity for phosphatidylserine 
which is externalized out of the cells during the early phase of apoptosis. The SOX 
reagent was stored in dark at - 2 0 � C and was diluted with Annexin V binding buffer 
before use. 
3) Annexin V Binding Buffer 
It was made up of 10 mM HEPES at pH 7.4，140 mM NaCl and 2.5 mM CaCb. 
The chemicals were ordered from USB Corporation. The buffer was filtered and 
stored at -4°C until use. 
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4) JC-1 Staining Solution 
5,5',6,6'-tetrachloro-l,r,3,3'-tetraethylbenzimidazolyl-carbocyanine iodide, in 
short (JC-1), was purchased from Molecular Probes Inc. (U.S.A). It is a cationic dye 
capable of illustrating a fluorescence emission shift from green (-525 nm) to red 
( -595 nm) when there is a potential-dependent accumulation in mitochondria. It was 
dissolved as a stock solution at a concentration of 5 mg/ml in DMSO and was kept at 
-20�C. The dye was diluted to 0.13% in warm PBS when performing assays. 
5) 2，，7'-Dichlorodihydrofluorescein Diacetate (DCFDA) 
DCFDA (Calbiochem) is a cell-permeable fluorogenic probe for detecting 
reactive oxygen species (ROS) and NO and it is commonly used for assessing the 
degree of the oxidative stress. The stock solution (20 mg/ml) was prepared by 
dissolving 20 mg powder in 1 ml DMSO and was stored at -20°C in dark. The 
light-sensitive working solution was freshly prepared by diluting the stock solution 
with warm culture medium to a concentration of 200 |ig/ml. 
6) Superoxide Dismutase (SOD) 
SOD (Sigma Chemical Co.) catalyzes the dismutation of superoxide radicals 
into hydrogen peroxide and molecular oxygen. It has been reported to suppress 
apoptosis in cultured rat ovarian follicles, neural cell lines and transgenic mice (Tilly 
and Tilly, 1995; Keller et al., 1998). The 200 units/ml SOD working solution was 
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prepared by dissolving 30,000 units/ml powder in 150 ml RPMI medium 
supplemented with 10% HI-FBS. It was kept at -20°C until use. 
7) 1% Paraformaldehyde 
Paraformaldehyde was purchased from Sigma Chemical Co. in powdered form. 
One gram of paraformaldehyde was dissolved in 50 ml of deionized water by heating 
to 60°C and stirring in fume hood for 1 hour. To dissolve better, a few drops of 
NaOH were added. After cooling down, 1% paraformaldehyde in IX PBS was 
obtained by adding 50 ml of 2X PBS. The solution was then stored at 4°C until use. 
8) FACS Medium 
The FACS Medium was made up of 2% HI-FBS and 0.05% sodium azide in 
PBS. It was used for washing and resuspension of cells in FACS analysis and was 
kept at 4°C. The azide added was to avoid patching, capping and the internalization 
of cell-bound antibodies. 
9) FACS Flow Sheath Fluid 
The sheath fluid comprises of sodium chloride, potassium chloride, disodium 
EDTA, sodium fluoride and an anti-microbial agent. It is a ready-to-use solution 
purchased from Becton Dickinson International and was kept at room temperature. 
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2.1.6 Reagent for DNA Extraction 
1) IGEPAL CA-630 Lysis Buffer 
This lysis buffer was purchased from Sigma Chemical Co and "IGEPAL" is a 
registered trademark of Phone-Poulenc, Inc. It was prepared in 50 mM Tris 
[hydroxylmethyl] amino methane (Tris)-HCl, pH 7.5 with 3% non-ionic detergent 
IGEPAL CA-630 ((Octylphenoxy) polyethoxyethanol) and 20 mM EDTA. It was 
kept at room temperature. 
2) Proteinase K 
The Proteinase K used is a highly active subtilisin type of protease purified from 
the mold Tritirachium album Limber. It was purchased from Boehringer Mannheim 
in powdered form. The stock solution was prepared at a concentration of 20 mg/ml 
by using antoclaved deionized water and stored as 500 aliquots at -20°C until use. 
3) RNase A 
RNase A is a pancreatic RNase powder purchased from Boehringer Mannheim. 
The stock was prepared at a concentration of 10 mg/ml by dissolving 10 mg RNase A 
in 10 mM Tris-HCl (pH 7.5) and 15 mM NaCl. It was then stored as 500 |il aliquots 
at -20°C until use. 
4) Sodium Acetate Solution (NaOAc) 
The NaOAc acetate solution was purchased from Sigma Chemical Co in 
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powdered form. The stock solution was prepared at a concentration of 3 M by 
dissolving 24.61 g sodium acetate in 100 ml deionized water. It was sterilized by 
antoclaving at 121°C for 20 minutes and then kept at room temperature. 
5) TioEo.1 Buffer 
The TioEo.i buffer contains 10 mM Tris-HCl (pH 7.5) and 0.1 mM EDTA in 
deionized water. The solution was kept at room temperature. 
2.1.7 Reagents for Measuring Caspase Activity 
1) Cell Lysis Buffer 
This lysis buffer was made up of 1% (v/v) IGEPAL-CA 630 (Sigma Chemical 
Co.), 150 mM NaCl, 50 mM Tris-HCl (pH 7.5) and a tablet of protease inhibitor 
cocktail. The tablet was purchased from Roche Molecular Biochemicals, after 
dissolved in 50 ml deionized water, it gives a mixture of several protease inhibitors 
with a broad spectrum of activity on serine-, cysteine-metalloproteases and calpains. 
The buffer was stored at 4�C until use. 
2) Reaction Buffer 
The reaction buffer was made up of 10 mM HEPES-KOH (pH 7.0), 40 mM 
P-glycerophosphate, 50 mM NaCl, 2 mM MgCb, 5 mM EGTA, 0.1% CHAPS, 100 
^ig/ml BSA, 10 mM DTT. The solution was kept at 4°C. 
- 5 0 -
Chapter 2 Materials & Methods 
3) Dithiothreitol (DTT) 
DTT was purchased from Invitrogen Life Technologies Inc. It was dissolved in 
deionized water as 1 M stock and stored at -20°C. It was added to the reaction buffer 
to make up a final concentration of 10 mM and was used to stabilize the enzymes 
with free sulfhydryl groups to give full activity of the enzymes. 
4) Caspase-3 Substrate, Ac-DEVD-AMC 
Ac-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC), a 
specific fluorogenic caspase-3 substrate, was purchased from Sigma Chemical Co. 
The stock was prepared at 2 mM by dissolving the Ac-DEVD-AMC in DMSO and 
stored at -20�C. 
5) Caspase-3 Inhibitor, Ac-DEVD-CHO 
Ac-Asp-Glu-Val-Asp-CHO (Ac-DEVD-CHO), a specific caspase-3 inhibitor, 
was purchased from ALEXIS Biochemicals. The stock was prepared at 10 mM by 
dissolving the Ac-DEVD-CHO in DMSO and stored at -20�C. 
6) Caspase-8 Substrate, Ac-DEVD-AMC 
Ac-Ile-Glu-Thr-Asp-7-amido-4-methylcoumarin (Ac-IETD-AMC), a specific 
fluorogenic caspase-8 and granzyme B substrate, was purchased from ALEXIS 
Biochemicals. The stock was prepared at 1 mM by dissolving the Ac-IETD-AMC in 
DMSO and stored at -20°C. 
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7) Caspase-8 Inhibitor, Ac-IETD-CHO 
Ac-Ile-Glu-Thr-Asp-CHO (Ac-IETD-CHO), a caspase-8 and granzyme B 
inhibitor, was purchased from ALEXIS Biochemicals. The stock was prepared at 10 
mM by dissolving the Ac-IETD-CHO in DMSO and stored at -20°C. 
8) Caspase-9 Substrate, Ac-LEHD-AFC 
Ac-Leu-Glu-His-Asp-7-amido-4-trifluoromethylcoumarin (Ac-IETD-AFC), a 
specific fluorogenic caspase-9 substrate, was purchased from ALEXIS Biochemicals. 
The stock was prepared at 5 mM by dissolving the Ac-IETD-AFC in DMSO and 
stored at -20�C. 
9) Caspase-9 Inhibitor, Ac-LEHD-CHO 
Ac-Leu-Glu-His-Asp-CHO (Ac-LEHD-CHO), a caspase-9 inhibitor, was 
purchased from ALEXIS Biochemicals. The stock was prepared at 10 mM by 
dissolving the Ac-LEHD-CHO in DMSO and stored at -20°C. 
10) 7-Amido-4-MethyI Coumarin (AMC) 
To quantify the activities of caspase-3 and caspase-8, AMC was used as a 
standard marker. It was dissolved in DMSO and made up a stock solution of 0.05 M. 
It was further diluted to 100 \iM with lysis buffer. Both solutions were stored at 4 � C . 
11) 7-Ainido-4-Trifluoromethyl Coumarin (AFC) 
To quantify the activities of caspase-9, AMC was used as a standard marker. It 
- 5 2 -
Chapter 2 Materials & Methods 
was dissolved in methanol and made up a stock solution of 0.02 M. It was further 
diluted to 80 \iM with lysis buffer. Both of the solutions were stored at 4°C. 
2.1.8 Reagents for Total RNA Isolation 
1) DEPC-treated Deionized Water 
0.1% of diethyl pyrocarbonate (DEPC) purchased from Sigma Chemical Co. 
was added into deionized water and allowed to stand overnight. The DEPC remained 
in the solution was removed by autoclaving it at 121°C for 20 minutes. 
2) Trizol Reagent 
Trizol reagent, a mono-phasic solution of phenol and guanidine isothiocyanate, 
was purchased from Invitrogen Life Technologies Inc. and stored in dark at 4 � C until 
use. This ready-to-use solution was used to disrupt and dissolve cell components 
while maintaining the integrity of RNA. 
3) Chloroform 
Chloroform with 99.0 to 99.4% purity was purchased from BDH Laboratory 
Supplies. It was used together with Trizol reagent to isolate RNA. 
4) Isopropanol 
Isopropanol with 99.7% purity was purchased from BDH Laboratory Supplies. 
It was used to precipitate RNA. 
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2.1.9 Reagents and Buffers for Reverse Transcription PCR 
1) Moloney Murine Leukemia Virus Reverse Transcriptase 
The enzyme was purchased from Invitrogen Life Technologies Inc. It was 
isolated from Escherichia coli (E.coli) expressing a portion of the pol gene of 
M-MLV on a plasmid. This enzyme was stored in a buffer of 20 mM Tris-HCl 
(pH 7.5)，1 mM DTT, 0.01% (v/v) NP-40, 0.1 mM disodium EDTA, 0.1 M 
sodium chloride and 50% (v/v) glycerol at -20°C. One unit of its activity was 
defined as the amount of enzyme that would incorporate 1 mole of 
deoxythymidine triphosphate (dTTP) into acid-precipitable material in 10 
minutes at 37°C using poly (A) and oligo-dTi2-i8 as template and primer 
respectively. 
2) First Strand Buffer (5X) 
The first strand buffer in a form of 5X solution containing 250 mM Tris-HCl 
(pH 8.3)，375 mM KCl and 15 mM MgCb was purchased from Invitrogen Life 
Technologies Inc. It was stored at -20°C until use. 
3) Oligo-dTi2-i8, Sodium Salt (pd(T)i2-i8, sodium salt) 
It was purchased from Promega Corporation. The stock was prepared at 1 fag/ml 
in TioEo.i buffer and stored at -20°C until use. 
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4) TioEi Buffer 
The TioEi buffer consists of 10 mM Tris-HCl (pH 8) and 1 mM EDTA in 
DEPC-treated deionized water. All these chemicals were purchased from Sigma 
Chemical Co. 
5) R N a s e O U T T M Recombinant Ribonuclease Inhibitor 
It was affinity purified from a recombinant strain of E. coli expressing a cloned 
porcine liver gene and purchased from Invitrogen Life Technologies Inc. It has a 
concentration of 40 units/|al and 1 mM DTT is required to maintain its activity. This 
inhibitor shows a very high binding affinity for pancreatic-type ribonuclease such as 
RNase A and is active against RNase A, RNase B and RNase C. It was stored at 
-20°C in a buffer containing 20 mM Tris-HCl (pH 8)，50 mM KCl, 0.5 mM EDTA, 8 
mM DTT and 50% (v/v) glycerol. One unit was defined as the amount of the 
inhibitor required to inhibit by 50% the activity of 5 ng of RNase A as determined by 
the inhibition of hydrolysis of cytidine 2' , 3，-cyclic monophosphate by RNase A. 
6) Thermoprime — ' DNA Polymerase 
This is a thermostable DNA polymerase isolated from thermophile bacteria and 
was purchased from Advanced Biotechnologies Ltd. It is a 94 kDa single polypeptide 
which has 5' to 3' polymerization-dependent exonuclease replacement activity, but 
without 3' to 5' exonuclease activity. One unit of the enzyme was defined as the 
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amount that would incorporate 10 nmoles of dNTPs into acid insoluble material in 30 
minutes at 47°C. It was stored at -20°C until use. 
7) Reaction Buffer IV (lOX) 
The reaction buffer in a form of lOX solution of 200 mM (NH4)2S04，750 mM 
Tris-HCl (pH 9) and 0.1% (w/v) Tween was purchased from Advanced 
Biotechnologies Ltd. It was stored at -20°C until use. 
8) MgCh Solution 
Magnesium chloride was purchased from Advanced Biotechnologies Ltd. with 
concentration of 25 mM and was stored at -20°C until use. 
9) Ultrapure dNTP Set, 2'-Deoxyribonucleoside 5'-Triphosphate, Sodium Salt 
It was purchased from Pharmacia Biotech and each nucleotide was in form of 
100 mM solution in deionized water (pH 7.5). Ten microtitres of each nucleotide 
stock solution was mixed with 60 ml TioEi buffer to make a working solution. The 
working solution was stored at -20°C. 
10) Primer Pairs 
Based on the published sequence of cloned cDNA, specific pairs of 
oligonucleotide primers will be designed and they were synthesized by Invitrogen 
Life Technologies Inc. The lyophilized primer pairs were then dissolved in 
DEPC-treated deionized water to a concentration of 2.5 |JM and were stored as 500 
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)aL aliquots at -20�C. The annealing temperatures were set to be 56°C to 61°C. The 
primers used in real time PCR and the predicted sizes of the PCR products were 
shown in Table 2.1. 
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Table 2.1: Primers used in real-time PCR and the predicted sizes of the PCR 
products 
Predicted size of the 
cDNA 
Strand Sequence (5，to 3') amplified PCR 
amplified 
product (bp) 
Sense TGA AGGTCG GAG TCA ACG GAT TTG GT 
GAPDH 226 
Antisense CAT GTG GGC CAT GAG GTC CAC CAC 
Sense AGC TGC ACC TGA CGC CCT T 
Bcl-2 293 
Antisense CAG CCA GGA GAA ATC AAA CAG AGG 
Sense TGC AGA GGA TGA TTG CTG A 
Bax 173 
Antisense GAT CAG CTC GGG CAC TTT A 
Sense ACA GGT TTG TGG ATG C 
Bid 240 
Antisense CTG GGG GAC AAG ATA C 
Sense TGG CAA CCC ATC CTG GCA CCT 
BCI-XL 583 
Antisense ACT GAA GAG TGA GCC CAG AAC 
Sense AAG GAG AAG CTG TCC CTG ATC 
Cyclin D2 273 
Antisense GAA CTG CTG CAG GCT GTT CAG 
Sense CCG TGA TTG CGC ACG ACT TC 
Cyclin D3 397 
Antisense TCT GTG GGA GTG CTG GTC TG 
Sense CAC AGC CGT GGA TAT CTG GAG 
Cdk 2 253 
Antisense TTG CGA TAA CAA GCT CCG TC 
Sense ACG CCT GTG GTG GTT ACG CT 
Cdk 4 280 
Antisense CCA TCT CTG GCA CCA CTG AC 
Sense ATG GAG AAG GAC AGC CTG AGT CGC 
Cdk 6 313 
Antisense AGT CTT GAT CAA CAT GCT CAA ACA 
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2.1.10 Reagents and Buffers for Real Time- PCR (RT-PCR) 
1) Brilliant SYBR® Green QPCR Master Mix 
Brilliant SYBR® Green QPCR Master Mix was purchased from Stratagene. The 
master mix solution was stored at 4°C until use. 
2) TaqMan® 2X PCR Master Mix 
TaqMan® 2X PCR Master Mix was purchased from Applied Biosystems. The 
master mix solution was stored at 4°C until use. 
2.1.11 Reagents and Buffers for Gel Electrophoresis of Nucleic Acids 
1) Tris-Borate-EDTA (TBE) Electrophoresis Buffer (5X) 
The 5X buffer stock with pH 8 was prepared by dissolving 54 g Tris, 27.5 g 
boric acid and 20 ml 0.5 M EDTA in 1 litre deionized water. The stock was then 
diluted to 0.5X working concentration by using deionized water. Both of the working 
and the stock solutions were stored at 4°C. 
2) Gel Loading Dye (5X) 
The 5X gel loading dye solution contains 0.05% (w/v) bromophenol blue, 40% 
(w/v) sucrose, 0.1 M EDTA (pH 8.0) and 0.5% sodium dodecyl sulfate (SDS). The 
solution was used for non-denaturing agarose gel electrophoresis of nucleic acids. 
3) 100 bp DNA Marker 
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The 100 bp DNA marker was purchased from Invitrogen Life Technologies Inc. 
The 1 fj-g/ml stock was diluted to working solution of 0.1 fag/ml by TioEi buffer. 
4) Agarose Gel 
The agarose gel was purchased from Sigma Chemical Co. 1% and 2% agarose 
gels (w/v) were prepared for RNA gel electrophoresis and DNA, PGR product gel 
electrophoresis respectively. The 1% agarose gel was prepared by dissolving 10 g 
agarose in 1 litre 0.5X TBE buffer, while 2% agarose gel contained 20 g agarose in 1 
litre of 0.5x TBE buffer. To achieve better solvation, the solutions were heated to 
70°C with constant stirring until it became clear. 
5) Ethidium Bromide (EtBr) 
It was purchased from Sigma Chemical Co. The 10 mg/ml stock was prepared 
by dissolving EtBr in deionized water. It was then diluted by 10,000 fold to form the 
working solution. Both stock and working solutions were kept in dark at room 
temperature. 
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2.1.12 Reagents, Buffers and Materials for Western Blot Analysis 
1) Cell Lysis Buffer 
This lysis buffer was made up of 1% (v/v) IGEPAL-CA 630 (Sigma Chemical 
Co.), 150 mM NaCl, 50 mM Tris-HCl (pH 7.5) and a tablet of protease inhibitor 
cocktail. The tablet was purchased from Roche Molecular Biochemicals, after 
dissolved in 50 ml deionized water, it gives a mixture of several protease inhibitors 
with a broad spectrum of activity on serine-, cysteine- metalloproteases and calpains. 
The buffer was stored at 4 � C until use. 
2) Bradford Solution 
The ready-to-use Bradford colution was purchased from Bio-Rad Laboratories. 
It was stored at 4°C until use. 
3) 30% (w/v) Acrylamide 1 Bis Solution 37.5:1 
The ready-to-use acrylaminde solution containing 30% (w/v) of acrylamide 
(146.1 g) and N’N，-methylene-bis-acrylamide (3.9 g) for a total monomer to 
crosslinker ratio of 37.5:1 was purchased from Bio-Rad Laboratories. It was stored at 
4°C until use. 
4) Lower Buffer for Separating Gel 
The lower buffer is a 1,5 M Tris-HCl buffer with pH 8.8. It was purchased from 
Sigma Chemical Co. and was stored at 4 � C until use. 
- 6 1 -
Chapter 2 Materials & Methods 
5) 10% Sodium Dodecyl Solution (SDS) 
SDS was purchased from Sigma Chemical Co. in powdered form. 10% SDS 
solution (w/v) was prepared by dissolving 10 g SDS in 100 ml deionized water. It 
was then stored at room temperature. 
6) 10% Ammonium Persulfate (APS) 
It was purchased from Bio-Rad Laboratories in powdered form. 10% APS 
solution was prepared by dissolving 0.5 g APS in 5 ml deionized water. The solution 
was kept in 500 jjJ aliquots at -20°C until use. 
7) N,N,N',N'-Tetra-Methylethylenediamine (TEMED) 
It was purchased from Bio-Rad Laboratories and was stored at 4°C until use. 
8) Upper Buffer for Stacking Gel 
The upper buffer is a 0.5 M Tris-HCl buffer with pH adjusted to 6.8. It was 
purchased from Sigma Chemical Co. and stored at 4°C until use. 
9) 4X SDS Sample Loading Buffer 
This loading buffer was prepared by mixing 0.4 ml 0.05% (w/v) bromophenol 
blue, 2 ml upper buffer, 2 ml glycerol, 2 ml 10% SDS, 1.4 ml deionized water and 
0.2 ml 2-mercaptoethanol. It was then stored at 4°C until use. All reagents were 
purchased from Sigma Chemical Co. 
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10) Kaleidoscope Prestained Standards 
These prestained standards consist of seven colored proteins including myosin 
(199,000 Da), p-galactosidase (128,000 Da), bovine serum albumin (85,000 Da), 
carbonic anhydrase (41,000 Da), soybean trypsin inhibitor (32,100 Da), lysosome 
(18,300 Da) and aprotinin (7,500 Da). They were purchased from Bio-Rad 
Laboratories and prepared in 33% (v/v) glycerol, 3% SDS, 10 mM Tris (pH 7)，10 
mM DTT, 2 mM EDTA, 0.01% NaNs. They were stored at -20°C until use. 
11) Tris-Glycine-SDS Electrophoresis Buffer (lOX) 
The lOX buffer was prepared by mixing 0.25 M Tris-HCl (pH 8.6), 1.92 M 
glycine and 1% SDS in deionized water, the mixture was then proceeded to filtration 
through a 0.2 |am Millipore filter and was stored at 4 � C . The lOX buffer was freshly 
diluted to IX working buffer for SDS-PAGE. 
12) Tris-Glycine Buffer (lOX) 
This lOX buffer was prepared by mixing 0.25 M Tris-HCl (pH 7.5) with 1.92 M 
glycine in deionized water. The mixture was then filtered by 0.22 |iM Millipore filter 
and the filtrate was stored at 4°C. 
13) Tris-Glycine-Methanol Transfer Buffer (IX) 
This IX transfer buffer was prepared by mixing 100 ml methanol with 50 ml 
lOX Tris-glycine buffer in 350 ml deionized water. It was kept at 4°C. 
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14) Polyvinylidene Difluoride (PVDF) Western Blotting Membranes 
This membrane with a pore size of 0.45 jum was purchased from Roche Applied 
Science. It was stored at room temperature. 
15) TBS-Tween Washing Buffer (lOX) 
The washing buffer consists of 100 mM Tris-HCl (pH 7.5), 1 M NaCl and 1% 
(v/v) Tween 10 in deionized water. The stock was diluted 10 fold to working solution 
by using deionized water. Both stock and the working solutions were stored at 4°C. 
All the constituent reagents were purchased from Sigma Chemical Co. 
16) 5% Skimmed Milk Solution (Blocking Solution) 
It was prepared by dissolving Nestle's skimmed milk powder in 1 washing 
buffer at a concentration of 5% (w/v). 
17) Primary Antibodies 
a) Rabbit Anti-FasL Polyclonal Antibody 
This anti-FasL antibody is a rabbit polyclonal antibody raised against a 
recombinant protein corresponding to amino acids 100-278 mapping at the carboxyl 
terminus of FasL of rat origin. It was purchased from Santa Cruz Biotechnology, Inc. 
Each vial contained 100 |ag IgG in 1 ml PBS, 0.1% sodium azide and 0.2 % gelatin. 
It reacts with FasL of mouse, rat and human origin. The antibody was stored at 4°C. 
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b) Rabbit Anti-Fas Polyclonal Antibody 
This anti-FasL antibody is a rabbit polyclonal antibody raised against a 
recombinant protein corresponding to amino acids 1-335 mapping at the full-length 
of Fas of human origin. It was purchased from Santa Cruz Biotechnology, Inc. Each 
vial contained 100 jug IgG in 1 ml PBS, 0.1% sodium azide and 0.2% gelatin. It 
reacts with FasL of mouse, rat and human origin. The antibody was stored at 4°C. 
c) Mouse Anti-Bax Monoclonal Antibody 
This anti-Bax antibody is a mouse monoclonal antibody raised against amino 
acids 1-171 of Bax a of mouse origin. It was purchased from Santa Cruz 
Biotechnology, Inc. Each vial contained 200 jig IgG2b in 1 ml PBS, 0.1% sodium 
azide and 0.1% gelatin. It reacts with Bax of mouse, rat and human origin. The 
antibody was stored at 4 � C . 
d) Rabbit Anti-Bid Polyclonal Antibody 
This anti-Bid antibody is a rabbit polyclonal antibody raised against a 
recombinant protein corresponding to amino acids 1-195 mapping at the full length 
of Bid of human origin. It was purchased from Santa Cruz Biotechnology, Inc. Each 
vial contained 200 \xg IgG in 1 ml PBS, 0.1% sodium azide and 0.2% gelatin. It 
reacts with Bid of mouse, rat and human origin. The antibody was stored at 4°C. 
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e) Rabbit Anti-Bcl-XL Polyclonal Antibody 
This anti-Bcl-XL antibody is a rabbit polyclonal antibody raised against a 
peptide mapping at the carboxy terminus of BC1-XL of human origin. It was purchased 
from Santa Cruz Biotechnology, Inc. Each vial contained 200 }ig IgG in 1 ml PBS, 
0 . 1 % sodium azide and 0.2% gelatin. It reacts with BC1-XL of mouse, rat and human 
origin. The antibody was stored at 4 � C . 
f) Mouse Anti-Bcl-2 Monoclonal Antibody 
This anti-Bcl-2 antibody is a mouse monoclonal antibody raised against a 
recombinant protein corresponding to amino acids 1-205 of Bcl-2 of human origin. It 
was purchased from Santa Cruz Biotechnology, Inc. Each vial contained 200 |j.g IgG 
in 1 ml PBS, 0.1% sodium azide and 0.2% gelatin. It reacts with Bcl-2 of mouse, rat 
and human origin. The antibody was stored at 4°C. 
g) Mouse Anti-Cytochrome C Monoclonal Antibody 
This anti-cytochrome C antibody is a mouse monoclonal antibody derived from 
the clone 7H8.2C12. It recognizes an epitope within amino acids 93-104 of pigeon 
cytochrome C. Synthetic peptides corresponding to amino acids 1-80，81-104 and 
66-104 of pigeon cytochrome C were used as immunogens. The IgG was dissolved 
in 0.1 ml of aqueous buffered solution with less than 0.09% sodium azide. The 
antibody reacts with cytochrome C of mouse, rat and human origin. The product was 
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Stored at 4°C. 
h) Mouse Anti-AIF Monoclonal Antibody 
This anti-AIF antibody is a mouse monoclonal antibody raised against amino 
acids 1-300 of AIF of human origin. It was purchased from Santa Cruz 
Biotechnology, Inc. Each vial contained 200 fig IgG2b in 1 ml PBS, 0.1% sodium 
azide and 0.1% gelatin. It reacts with AIF of mouse, rat and human origin. The 
antibody was stored at 4°C. 
i) Rabbit Anti-P15/P16 Polyclonal Antibody 
This an t i -p l5 /p l6 antibody is a rabbit polyclonal antibody raised against amino 
acids 96-138 mapping at the C-terminus of p l 5 of human origin. It was purchased 
from Santa Cruz Biotechnology, Inc. Each via丨 contained 200 jig IgG in 1 ml PBS, 
0.1% sodium azide and 0.1% gelatin. It reacts with p i 5 and p i 6 of mouse, rat and 
human origin. The antibody was stored at 4°C. 
j) Rabbit Anti-P18 Polyclonal Antibody 
This ant i -pl8 antibody is a rabbit polyclonal antibody raised against a peptide 
mapping at the C-terminus of pi 8 of mouse origin. It was purchased from Santa Cruz 
Biotechnology, Inc. Each vial contained 200 fig IgG in 1 ml PBS, 0.1% sodium azide 
and 0.1% gelatin. It reacts with p i 8 of mouse, rat and human origin. The antibody 
was stored at 4°C. 
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k) Mouse Anti-P27 Monoclonal Antibody 
This anti-p27 antibody is a mouse monoclonal antibody raised against amino 
acids 1-197 representing full length of p27 of mouse origin. It was purchased from 
Santa Cruz Biotechnology, Inc. Each vial contained 200 )ig IgGi in 1 ml PBS, 0.1% 
sodium azide and 0.1% gelatin. It reacts with p27 of mouse, rat and human origin. 
The antibody was stored at 4°C. 
1) Mouse Anti-p Actin Monoclonal Antibody 
This antibody is a monoclonal antibody (mouse IgG2a isotype) derived from the 
AC-74 hybridoma as a result of the fusion of mouse myeloma cells and splenocytes 
from an immunized mouse. It binds to the epitope located on the N-terminal end of 
the p-isoform of actin (42 kDa) in a wide variety of tissues and species using 
immunoblotting. The product was purchased from Sigma Chemical Co. and provided 
as ascites fluid containing 0.1% sodium azide as a preservative. It was stored at 
-20°C. 
18) Secondary Antibodies 
Two types of secondary antibodies were used in this study, they were sheep 
anti-mouse IgG, peroxidase-linked species-specific whole antibody and donkey 
anti-rabbit IgG, peroxidase-linked species-specific whole antibody. Both of them 
were supplied at a concentration of 1 mg/ml and were used in 1:1000 dilution. They 
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were purchased from Amersham Pharmacia Biotech and stored at 4°C. 
19) Western Blotting Luminol Reagents 
The Western blotting luminal reagents consist of solution A (125 ml) and 
solution B (125 ml). They were purchased from Santa Cruz Biotechnology Inc. and 
were kept at 4°C. Solution A and solution B were freshly mixed in 1:1 ratio before 
use. 
20) X-ray Films (Fuji, Japan) 
The Fuji X-ray films were stored in dark at 4°C. 
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2.2 Methods 
2.2.1 Culture of Tumor Cell Lines 
The murine and human leukemia cell lines (WEHI-3B JCS, Ml , EoL-1, K-562,) 
were cultured using RPMI medium supplemented with 10% FBS, 1% PSF or PSN. 
For the human promyelocytic leukemia HL-60 cells, they were maintained in the 
same medium but with 20% FBS. All cells were cultured in 25 or 75 cm^ tissue 
culture flasks and incubated at 37�C in a humidified incubator supplied with 5% 
carbon dioxide (CO2). Depending on the doubling time, cells were usually 
sub-cultured every 2 or 3 days. Cells in the exponential growth phase were used for 
all the experiments. Long term storage of cell lines was done by cryo-preservation in 
liquid nitrogen. 
2.2.2 Isolation, Preparation and Culture of Mouse Peritoneal Macrophages 
BALB/c mice were injected intraperitoneally (i.p) with 1 ml sterile 3% 
thioglycollate broth to stimulate the recruitment of macrophages into the peritoneal 
cavity. After three days, the mice were sacrificed by cervical dislocation and placed 
ventral side up on a clean surface. First, the abdominal skin of the mouse was 
cleaned with 70% ethanol, a small cut was made and the skin was torn apart until the 
abdominal wall was seen. Plain medium (3 ml) and an equal volume of air were 
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injected into the peritoneal cavity in order to wash out the cells and to inflate the 
cavity respectively. The procedures were repeated twice in order to collect as much 
peritoneal exudate cells as possible. These were done by using 5 ml syringe equipped 
with a 20-gauge needle. The collected thioglycollate-elicited peritoneal macrophages 
were then washed with plain medium supplemented with 10% HI-FBS and seeded 
into 96-well microtiter plates at a concentration of 10^ cells/ml and then incubated at 
37°C for 2 hour s for the adhesion of the macrophages to the bottom of the wells. The 
non-adherent peritoneal cells were then removed and different concentrations of 
tryptanthrin were added to test for its cytotoxicity on the peritoneal macrophages. 
2.2.3 Determination of Cell Viability 
1) Trypan Blue Exclusion Assay 
Trypan blue exclusion assay was based on the integrity of plasma membrane 
and the ability of the viable cells to exclude the trypan blue dye. Viable cells with 
intact membrane were visible as clear cell bodies while the dead cells were stained 
blue. It was employed to determine the number of viable cells in cultures. The cells 
were incubated with different concentrations of tryptanthrin at 37�C. The viability of 
the cells was then determined at the designated time interval. Viable cells were 
counted and cell viability was obtained using the Vi-cellTM XR cell viability 
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analyzer (Beckman Coulter). The results were expressed as the mean percentage of 
cell viability 士 S.E. of triplicate cultures. 
2) MTT Colorimetric Assay 
The thioglycollate-elicited murine peritoneal macrophages (10^ cells/ml) and 
WRL 68 normal hepatocyte-like cells (10^ cells/ml) were either treated with solvent 
control (0.05% DMSO) or different concentrations of tryptanthrin in 96-well 
flat-bottomed microtiter plates at 37°C for different time intervals (24, 48 and 72 
hours) inside a humidified 5 % CO2 incubator. MTT (30 |il) at a concentration of 5 
mg/ml in PBS was then added to the wells and incubated for 4 hours. Then the 
medium was removed and 100 i^l DMSO was added in order to dissolve the crystal 
formed inside the cells. The absorbance was measured at 540 nm, using a Benchmark 
microtiter plate reader (BioRad Laboratories), the viability of cells was calculated as 
follows: 
0/0 viable cells = (OD540 of test sample / OD540 of control) x 100% 
2.2.4 Determination of Cell Proliferation by [^H]-TdR Incorporation Assay 
Leukemia (lOMo^ cells/ml) were seeded either treated with solvent control 
(0.05% DMSO) or different concentrations of tryptanthrin in 96-well flat-bottomed 
microtiter plates at 37°C for different time intervals (24, 48 and 72 hours) inside a 
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humidified 5% CO2 incubator. The cells were then pulsed with 0.5 mCi [^H]-TdR in 
20 |Lil complete medium for 6 hours. Cells were undergone a freeze and thaw cycle 
before being harvested onto a glass microfiber filter. The radioactivity was measured 
by the liquid scintillation analyzer Packard Topcount. The results were expressed as 
the percentage inhibition of [^H]-TdR incorporation, using solvent-treated cells as a 
control (Leung et al., 1994). The percentage inhibition of [^H]-TdR incorporation 
was calculated as follows: 
0/0 inhibition = (cpm of control - cpm of test sample) / cpm of control x 1 0 0 % 
2.2.5 Determination of Anti-leukemia Activity In Vivo 
1) In Vivo Tumorigenicity Study 
WEHI-3B JCS cells (10^ cells/ml) were incubated with tryptanthrin for 16 hours 
at 37°C inside a humidified 5% CO2 incubator. The cells were then harvested and 
washed with plain medium for three times. Syngeneic WEHI-3B JCS cells (10^) 
resuspended in 1 ml of RPMI medium were then injected i.p. into each BALB/c 
mouse in groups of five. The body weight of the mice was measured every 
alternative day for checking of their health status. On day-12 post-tumor inoculation, 
WEHI-3B JCS cells were recovered from the peritoneal cavity of mice and the 
number of viable tumor cells were counted by using Vi-cellTM XR cell viability 
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analyzer (Beckman Coulter). 
2) In 1P7v6> Anti-tumor Assay 
WEHI-3B JCS cells (10^ cells) in 1 ml RPMI medium were inoculated i.p. into 
each BALB/c mouse in groups of five on day 0. Starting from day 6 after inoculation 
of JCS cells, mice were divided into four groups with five mice in each group and 
injected i.p. either with solvent control or different doses of tryptanthrin (0.04 mg/kg, 
0.08 mg/kg and 0.16 mg/kg) for 5 consecutive days. At day-12 post-tumor cell 
inoculation, viable WEHI-3B JCS cells recovered from the peritoneal cavity were 
counted using Vi-cellTM XR cell viability analyzer (Beckman Coulter). 
2.2.6 Analysis of Cell Cycle Profile / DNA Content by Flow Cytometry 
WEHI-3B JCS cells (10"^  cells/ml) were first synchronized by culturing in plain 
RPMI medium for 24 hours. After that, they were cultured in RPMI + 10% HI-FBS 
with different concentrations of tryptanthrin at 37°C for different time intervals (24 
and 48 hours) inside a humidified 5% CO2 incubator. Then cells were harvested and 
washed with PBS by spinning at 430 g for 5 minutes. Next, cells were fixed with 1 
ml 70% ethanol at 4°C for 30 minutes. Afterwards, ethanol was removed and the 
cells were washed with PBS. One millilitre of freshly prepared propidium iodide 
DNA staining solution (50 mg/ml PI) was used to resuspend the cells. The cells were 
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kept in dark at room temperature for 30 minutes. Stained cells were analyzed by flow 
cytometric analysis. By using the fluorescence-activated cell sorter (Becton 
Dickinson FACSCanto) equipped with an argon laser emitting at 488 nm and the 
CellQuest software, the fluorescence intensity of the stained cells can be measured. 
At least 104 cells were analyzed for each determination. The percentages of cells in 
Go/Gi, S and G2/M cell cycle phases were calculated by the Modfit 3.0 program 
(Verity Software House). 
2.2.7 Measurement of Apoptosis 
1) DNA Fragmentation Analysis 
DNA fragmentation is known to be the hallmark of apoptosis. That is why 
DNA laddering is commonly used as an indicator of cells undergoing apoptosis. 
WEHI-3B JCS cells (10^ cells/ml) were cultured in RPMI + 10% HI-FBS with either 
solvent control (0.05% DMSO) or different concentrations of tryptanthrin at 37°C for 
different time intervals (48 and 72 hours) inside a humidified 5% CO2 incubator. 
WEHI-3B JCS cells (3x10^ cells) were harvested and washed with cold PBS. After 
centrifugation at 430 g for 5 minutes, the cell pellets were then treated with 200 ml 
IGEPAL CA-630 lysis buffer for 10 minutes at 37°C. The samples were then 
centrifuged at 6000 g for 5 minutes. Supernatant containing DNA fragments were 
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collected and 50 i^l 5% SDS was added. Ten micro litres RNase A (10 mg/ml) was 
added to the samples and incubated at 56°C for 1.5 hours in order to remove cellular 
RNA. Then, 20 |j.l proteinase K was added and incubated at 56°C for 1.5 hours in 
order to remove the proteins. Next, the DNA was precipitated with 0.1 volume of 3 
M sodium acetate and 2.5 volumes of absolute ethanol. The samples were 
centrifuged at 20,800 g for 30 minutes, the DNA pellets were washed with 70% 
ethanol and then absolute ethanol. After washing, they were air dried for 10 minutes. 
The dried pellets were resuspended in 20 )il TioEo.i buffer and incubated at 37�C for 
30 minutes. After heated to 65°C for 5 minutes, 5 jul of loading dye was added into 
each sample which was then loaded into the wells of 2% agarose gel for 
electrophoresis at 100 volts. After electrophoresis, the gels were stained with 
ethidium bromide (1 |Lig/ml) for 3 minutes and destained with deionized water for 15 
minutes. The DNA bands were visualized with UV illumination and the images were 
captured by Bio-Rad Gel Doc 2000. 
2) Detection of Early Apoptosis by Annexin V-GFP/PI Double Staining 
WEHI-3B JCS cells (lO* cells/ml) were incubated with either solvent control 
(0.05% DMSO) or different concentrations of tryptanthrin for different time intervals. 
Cells (10^) were harvested and washed with PBS. Reaction buffer was prepared by 
mixing 5 |al Annexin V-GFP and 2 PI (50 |ag/ml) with 496 …Annexin V binding 
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buffer. The washed cells were then resuspened with 500 fil of the reaction buffer and 
kept on ice in dark for 15 minutes. After incubation, the fluorescence of samples was 
recorded by the BD FACSCanto flow cytometer. The data were then analyzed by 
FACS Diva Software (Becton Dickson). 
2.2.8 Determination of the Mitochondrial Membrane Potential 
WEHI-3B JCS cells cells/ml) were cultured in RPMI + 10% HI-FBS 
with either solvent control (0.05% DMSO) or different concentrations of tryptanthrin 
at 3 7 � C for 18 hours inside a humidified 5 % CO2 incubator. After treating the 
WEHI-3B JCS cells with tryptanthrin, the mitochondrial membrane potential of the 
cells was measured by using the JC-1 staining method (Dorrie et al., 2001). 
WEHI-3B JCS cells were harvested and centrifuged, the pellet was resuspended in 1 
ml JC-1 working solution obtained by mixing 1.3 |LI1 JC-1 stock solution (5 mg/ml in 
DMSO) with 1 ml of warm PBS. The mixtures were incubated for 15 minutes at 
37�C. After incubation, the samples were subjected to flow cytometric analysis. 
Excitation was made at 488 nm and the emission of red ( -590 nm) and green (-525 
nm) fluorescence were measured simultaneously. 
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2.2.9 Measurement of Caspase Activity 
Two steps were involved in measuring the caspase activity: 
1) Treatment of Cells and Protein Extraction 
WEHI-3B JCS cells (⑴彳 cells/ml) were cultured in RPMI + 10% HI-FBS with 
either solvent control (0,05% DMSO) or different concentrations of tryptanthrin at 
37°C for different time intervals (24 and 48 hours) inside a humidified 5% CO2 
incubator. The cells were then harvested and washed twice with cold PBS by 
centrifuging at 430 g for 5 minutes at 4 � C . Cells were counted by trypan blue 
exclusion test and the pellet was resuspended in 150 lysis buffer (50 fil / 1 c e l l s ) 
and vortexed vigorously. The cell lysates were then kept on ice for 10 minutes and 
centrifuged at 18,000 g for 3 minutes at 4°C. The supernatants were collected for 
future use. 
2) Fluorometric Measurement of Caspase Activity 
To assure the signal detected was due to the caspase activity, special control was 
set up with the presence of the specific inhibitor. The control was set up by 
incubating 50 fjJ cell lysate and 50 |j.l reaction buffer with 1 of caspase inhibitor in 
a 96-well flat-bottomed microtiter plate at 3 7 � C for 30 minutes. On the other hand, 
50 |j.l of cell lysate was incubated with the same amount of reaction buffer but 
without inhibitor. One microlitre of specific caspase substrate was added to all the 
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wells. All the samples including the control were then incubated at 37°C for 1 hour. 
The fluorescence emitted was measured by the fluorescence plate reader, TECAN 
polarion. Caspase activity was then converted from the fluorescence reading by using 
standard curve. The standard curve was made by diluting the AMC or AFC solution 
to 0.5 mM, 1 mM, 2 mM and 4 mM with lysis buffer. 
2.2.10 Study of Intracellular Accumulation of Reactive Oxygen Species (ROS) 
1) Effect of Tryptanthrin on ROS Production in Murine Myelomonocytic 
Leukemia WEHI-3B JCS Cells 
WEHI-3B JCS cells (10"^  cells/ml) were either incubated with solvent control 
(0.05% DMSO) or treated with different concentrations of tryptanthrin at 37°C for 48 
hours. The medium was removed and the induced cells were then washed with PBS 
for once and cultured with dichlorodihydrofluorescein diacetate (DCFDA) for one 
hour, the fluorescence was measured by fluorospectrometer with a 485 nm excitation 
filter and a 535 nm emission filter set at a gain of 60. 
2) Effect of Superoxide Dismutase on Tryptanthrin-treated Murine 
Myelomonocytic Leukemia WEHI-3B JCS Cells 
WEHI-3B JCS cells (10"^  cells/ml) were preincubated with/without 200 units/ml 
SOD for 6 hours and then cultured with solvent control (0.05% DMSO), or 
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tryptanthrin for 48 hours and then stained with the GFP-conjugated Annexin V and 
propidium iodide (PI) dye. Cells (10^) were then harvested and washed with PBS. 
Reaction buffer was prepared by mixing 5 |il Annexin V-GFP and 2 |j.l PI (50 |ig/ml) 
with 496 |j,l Annexin V binding buffer. The washed cells were then resuspended with 
500 |jJ of the reaction buffer and kept on ice in dark for 15 minutes. After incubation, 
the sample fluorescence was recorded by the BD FACSCanto flow cytometer. The 
data were then analyzed by ModFit 3.0 program (Verity Software House). 
2.2.11 Gene Expression Study 
Four steps were involved in the study of the gene expression 
1) Isolation of Total Cellular RNA 
WEHI-3B JCS cells (10^ cells/ml) were cultured in RPMI + 10% HI-FBS with 
either solvent control (0.05% DMSO) or different concentrations of tryptanthrin at 
37°C for different time intervals inside a humidified 5% CO2 incubator. Cells were 
then harvested by centrifugation at 430 g for 5 minutes at 4°C. TRIZOL reagent (1 ml 
TRIZOL for 5 x 10^ cells) was added accompanied by vigorous shaking in order to 
lyse the cells. The lysates were stood at room temperature for 5 minutes to allow 
complete dissociation of nucleoprotein complexes. Followed by the addition of 
chloroform (200 |LI1 per ml of TRIZOL reagent) and the robust shaking of the cells, 
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the samples were allowed to stand at room temperature for 3 minutes without 
disruption. After centrifugation at 12,000 g for 15 minutes at 4°C, the upper aqueous 
phase which contained RNA (-400 was collected. Isopropanol (500 fil) was 
added and the samples were allowed to stand at room temperature for 10 minutes in 
order to precipitate the RNA. Next, centrifugation was carried out at 12,000 g at 4°C 
for another 10 minutes, RNA pellet obtained was washed with 1 ml 75% ethanol, 
followed by centrifugation at 7,500 g at 4°C for 5 minutes and the supernatant was 
removed and the RNA pellet was air-dried for about 5 minutes. Finally, the RNA was 
dissolved in 30 |LX1 DEPC-treated water and stored at -70°C until use. 
The RNA content was calculated by measuring the absorbance at 260 nm using 
a spectrophotometer. After measurement, small aliquots of RNA with a working 
concentration of 0.5 |j.g/ml were prepared according to the result of calculation. 
Samples were then kept at -70�C until use. The purity of the RNA was assessed by 
the ratio of A260/A280’ samples with a range between 1.0 to 2.0 would be considered 
as pure. The integrity was tested by running 1 \x\ of RNA sample with a total amount 
of 5 |Lig on 1% agarose gel which would then be stained with ethidium bromide. 
2) Reverse Transcription (RT) 
The RNA sample was converted to its complementary DNA (cDNA) before it 
could be used for the PCR amplification of the target gene. Reaction mixture 
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containing 40 units of RNASEOUT™ recombinant ribonuclease inhibitor, IX M-MLV 
first strand buffer, 0.5 mM of each dNTP, 10 mM DTT, 0.1 |ag oligo (dT)i2-i8 and 200 
units of M-MLV reverse transcriptase was prepared, and 2 )xg RNA sample was 
added into 20 reaction mixture. A negative control using DEPC- treated water 
instead of RNA sample was used to check if there was any contamination. The 
thermocycler, GeneAmp PCR System 9700 (Perkin-Elmer Co.) was used for the 
reverse transcription. The mixtures were first incubated at 3 7 � C for 1 hour, then at 
99°C for 5 minutes to inactivate the reverse transcriptase and to denature the template. 
Finally the samples were cooled down to 4 � C . The cDNA samples were then kept at 
-20�C until use. 
3) Real Time PCR for SYBR® Green 
Real time PCR was performed with 20 i^l reaction mixture which contained an 
amount equivalent to 0.1 fig of cDNA, 2X Brilliant SYBR® Green Master Mix 
solution, 0.2 jiM of both sense and antisense oligonucleotide primers and deionized 
water with the use of Applied Biosystems 7500 Fast Real Time PCR System. Cycling 
procedure consisted of initial denaturation for 5 minutes at 94�C，followed by 20-40 
thermal cycles with denaturation at 9 4 � C for 30 seconds, annealing at 6 r C for 1 
minute to 1 minute and 15 second and elongation at 7 2 � C for 1 minute. A final 
extension of 5 minutes at 7 2 � C was needed to complete the reaction. The annealing 
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temperature and the number of cycle were varied and optimized for different primer 
pairs to allow the detection of the amplified products. The threshold cycle (CT), 
which represents the PGR cycles at which an increase in reporter fluorescence above 
a baseline signal, was detected by 7000 SDS 1.1 RQ software. The relative gene 
expression was then analyzed by the Method as described by Livak et al, 
(2001). 
2.2.12 Protein Expression Study 
1) Cell Treatment and Protein Extraction 
WEHI-3B JCS cells (lO'^  cells/ml) were cultured in RPMI + 10% HI-FBS with 
either solvent control (0.05% DMSO) or different concentrations of tryptanthrin at 
37°C for different time intervals (24 and 48 hours) inside a humidified 5% CO2 
incubator. The cells were then harvested and washed twice with cold PBS by 
centrifuging at 430 g for 5 minutes at 4°C. Cells were counted by the trypan blue 
exclusion test and the pellet was resuspended in lysis buffer (50 |j,l / 10^ cells) and 
vortexed vigorously. The cell lysates were then kept on ice for 10 minutes and 
centrifuged at 20,000 g for 5 minutes at 4 � C . The supernatants were collected for 
future use. 
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2) Quantification of Proteins 
The protein concentrations of the cell lysate were measured using the Bradford 
protein assay. Known concentrations of bovine serum albumin were prepared using 2 
mg/ml BSA and deionized water. Protein samples (3 fjJ) were diluted with 2400 |LI1 
deionized water. The diluted samples and the standards (800 jil) were mixed with 
200 p-l Bradford reagent in cuvettes. After thorough mixing, they were allowed to 
stand at the room temperature for 5 minutes and the absorbance was measured at 595 
nm by Biophotometer (Eppendorf) using Bradford reagent as a blank. The 
concentrations of the standards and the samples were determined by the machine 
automatically. Adjustment by diluting the sample with lysis buffer was needed in 
order to obtain samples with 20 )Lig of proteins in a similar volume ( � 2 0 jil). Protein 
samples were then subjected to SDS-polyacrylamide gel electrophoresis (PAGE). 
3) Western Blotting Analysis 
Twenty microlitres of protein samples were mixed with 5 |LI1 4X protein loading 
buffer to make up a total volume of 25 fil. The mixed samples were boiled for 5 
minutes and loaded into the SDS-polyacrylamide gel with 5% stacking gel. 
Kaleidoscope prestained protein standards (8 |al) were loaded and the gel was run 
under constant voltage of 100 volts for about 2 hours. Gels with different 
compositions were used according to the molecular weight of the target protein. A 
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protein with higher molecular weight needs a lower percentage of acrylamide gel and 
vice versa. 
Following electrophoresis, the stacking gel was cut with spacer and discarded. 
The gel was washed with deionized water for 5 minutes to remove SDS which might 
affect the protein transfer onto the membrane. After that, it was washed twice in the 
transfer buffer for 5 minutes. Before the electroblotting, the PVDF membrane was 
activated with 100% methanol while filter papers were soaked in IX transfer buffer 
for 10 minutes. Three pieces of filter paper were then placed on the semi-dry 
electroblotter (Bio-Rad Laboratories), and on top of it, the activated PVDF 
membrane was placed, followed by the gel and finally another 3 pieces of filter paper 
were put on top of the gel. Air bubbles were excluded by rolling a glass tube on the 
surface of the filter paper and the surrounding water should be dried before 
electroblotting. Electroblotting was carried out with a voltage of 16 volts for a 
duration of 45 minutes. After electroblotting, the membrane was washed with IX 
washing buffer for 10 minutes and then incubated with 5% skimmed milk at room 
temperature for at least 1 hour with rotation to block the non-specific sites for 
probing. Primary antibody binding to the target protein was added into the milk 
solution at a ratio of 1:1,000. After incubating with the primary antibody at 4 � C with 
rotation for a whole night, the membrane was washed with IX washing buffer for 
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5-10 minutes for three times the next day, then incubated with the corresponding 
horseradish peroxidase-1 inked secondary antibody at 1:1,000 dilution in washing 
buffer for 1 hour at room temperature with rotation. After the incubation, the 
membrane was washed three times with IX washing buffer and subjected to ECL 
assay. 
4) ECL Assay 
Two detection reagents (reagent A and reagent B, 0.5 ml each) were mixed and 
spread over the membrane which was then placed in a transparent plastic bag and the 
ECL film was placed on top of it in the dark room. The film cassette was closed for 
different exposure times (from 15 seconds to 5 minutes). Finally, the film was 
developed and the protein bands were visualized on the X-ray film. The intensity of 
the bands was quantified by the ImageQuant software (Molecular Dynamics). After 
normalization with respect to the house-keeping protein p-actin, the relative intensity 
of each protein band was compared to that of the solvent control. 
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2.2.13 Measurement of Cell Differentiation 
1) Morphological Detection of Cell Differentiation 
a) Morphological Examination on Cytospin Preparation 
The effect of tryptanthrin on the differentiation of WEHI-3B JCS cells was 
assessed by preparing cytospin smear. WEHI-3B JCS cells (2500 cells/ml) were 
cultured in RPMI + 10% HI-FBS with either solvent control (0.05% DMSO) or 
different concentrations of tryptanthrin at 37�C for 48 hours inside a humidified 5% 
CO2 incubator. Treated cells (5 x l O ) were fixed onto a microscopic glass slide by 
cytocentrifugation at 500 rpm for 5 minutes using the Shandon Cytospin 3 centrifuge 
(Shadon Scientific Ltd., U.K.). The cells were air-dried and subsequently stained 
with Hemacolor staining solutions for 15 seconds and destained with deionized water. 
Finally, the slides were mounted with neutral mounting medium, Canada Balsam 
(Sigma Chemical Co.) and the cell morphology was examined under the light 
microscope. The stained cells were further scored as the immature blast cells, 
intermediate stage cells or mature macrophage-like cells as described by Chan et al, 
(1997). 
- 8 7 -
Chapter 2 Materials & Methods 
b) Detection of the Changes in Cell Size and Granularity by 
FlowCytometry 
WEHI-3B JCS cells (lO^ cells/ml) were incubated with either solvent 
control (0.05% DMSO) or different concentrations of tryptanthrin for 48 hours. Cells 
(10^) were harvested and washed with PBS, then fixed with paraformaldehyde and 
were analyzed for FSC and SSC by using the BD FACSCanto flow cytometer. The 
data were then analyzed by FACS Diva Software. 
2) Detection of Differentiated Cells by Nitroblue Tetrazolium Reduction Assay 
WEHI-3B JCS cells (2500 cells/ml) were either incubated with solvent control 
(0.05% DMSO) or tryptanthrin for 48 hours. Then, 100 \i\ NBT-PMA mix was added 
and incubated at 37°C in dark for 4 hours. The cells were then harvested and washed 
twice with cold plain RPMI with vigorous shaking. After that, the cells were 
resuspended in RPMI + 10% HI-FBS. Treated cells (5 x 10^ cells) were 
cytocentrifuged onto microscopic glass slides and stained with safranin for 30 
seconds and washed with running water. The differentiated cells, which had 
intracellular black-blue formazan deposit, were examined by counting at least 200 
cells in triplicate for each determination. 
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2.2.14 Statistical Analysis 
Each experiment was performed at least two to three times and the results of 
only one representative experiment were presented. The data were expressed as 
arithmetic mean 土 standard error. The student's t-test was used for statistical analysis. 
Normally, p < 0.05 was regarded as significantly different. 
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Chapter 3 Anti-Proliferation 
3.1 Introduction 
Banlangen is a common name referring to the dried roots of indigo plants which 
include Polygonum tinctorium, Isatic indigoticum and Strobilanthes cusia. Indigo 
plants have been an important source of dyes for Asian countries since ancient time 
and they are also commonly used as therapeutics in traditional Chinese medicine. 
These medicinal herbs are known to have anti-viral, anti-bacterial and 
anti-inflammatory activities. In China, water extracts of Banlangen are frequently 
used as anti-inflammatory and anti-viral medicine for the treatment of hepatitis, 
influenza, and various kinds of inflammation. A number of biologically active 
ingredients have been identified in Banlangen, which include indigoid alkaloids (e.g. 
indigo and indirubin) and quinazolinone alkaloids (e.g. tryptanthrin). In fact, indigo 
indirubin and tryptanthrin are known to be three marker compounds found in 
Banlengen (Liau et al,’ 2007). 
A well known traditional Chinese Medicine prescription which composed of 11 
herbal constituents called Danggui Longhui Wan (當歸育•薈九）has been shown to 
be clinically active in treating chronic myelogenous leukemia (Han, 1994). It was 
once believed that the blue dye indigo could be the active principle (Chan and Xie, 
1984)，but finally it turned out to be the minute amount of indirubin that present in 
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the medicinal preparation (Wu et al., 1979; Zheng et al, 1979). In clinical trials with 
patients suffering from chronic myelocytic and chronic granulocytic leukemia, 
indirubin was reported to induce complete remission in 26% and partial remission in 
33% of the 314 cases, showing only low toxicity and limited side effects (Marko et 
al.’ 2001). In view of the fact that conventional treatments of leukemia have various 
shortcoming and limitations, it is of great interest to find out more potential natural 
products like indirubin to treat leukemia. In this study, two natural products derived 
from Banlangen (indirubin-3'-oxime and tryptanthrin) had been screened for their 
growth-inhibitory effects on various myeloid leukemia cell lines of both human and 
murine origins. 
Indirubin, a 3,2'-bisindole isomer of indigo, is a traditional Chinese medicine 
commonly used for the treatment of myelocytic leukemia in humans. Both indirubin 
and its derivatives have been shown to function as potent inhibitors of 
cyclin-dependent kinases (Cdk), and exhibit growth-inhibitory effects on human 
tumor cells (Marko et al,’ 2001). Indirubin-3'-oxime, a cell permeable derivative of 
indirubin, was also found to be a selective and potent inhibitor of Cdk. 
Indirubin-3'-oxime triggers Gi and G2/M phase cell cycle arrest in the hematopoietic 
Jurkat cells and SV40-transformed human breast epithelial HBL-100 cells (Hoessel 
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et al, 1999). Further mechanistic studies showed that indirubin-3'-oxime induces 
G2/M phase arrest by inhibiting Cdkl and glycogen synthase kinase-3p (GSK-3p) in 
HBL-100 cells, and induces G2/M and Gi phase arrest in MCF-7 cells (Damiens et 
al., 2001). More recently, indirubin-3'-oxime was shown to induce cell cycle arrest at 
Gi phase and induced apoptosis in Hep-2 human laryngeal carcinoma cells. The 
growth inhibition was found to be associated with induction of Cdk inhibitor p21, 
inhibition of cyclin D1 and activation of caspase-3 (Kameswaran and Ramanibai, 
2008). 
Tryptanthrin, 6,12-dihydro-6,12-dioxoindolo-(2,1 -b)-quinazoline, is also an 
active ingredient isolated from Banlangen. It was first isolated from Stwbilanthes 
cusia as an anti-fungal agent against dermatophytes (Honda et al, 1979). 
Tryptanthrin is a weakly basic alkaloid and has been reported to have various 
biological activities, such as anti-microbial activities against a variety of 
microorganisms which include bacteria, yeasts, dermatophytes and phytopathogens 
(Honda et al, 1979; Ksataoke et al,，2001; Ishihara et al, 2000; Takei et al, 2003)， 
anti-inflammatory activities (Danz et al., 2001; Ishihara et al., 2000; Takei et al., 
2003) and anti-tumor activities towards a variety of human leukemia cells and cancer 
cells (Kimoto et al., 1999; Ishihara et al” 2000; Takei et al., 2003). Moreover, crude 
- 9 2 -
Chapter 3 Anti-Proliferation 
ethyl acetate extract and tryptanthrin extracted from the Indigo plant Polygonum 
tinctorium have cancer chemopreventive activity by prevention of 
azoxymethane-induced intestinal tumor formation in F344 rats (Koya-Miyata et al., 
2001). 
Uncoupling of the proliferation and differentiation processes resulting in the 
formation of undifferentiated, non-functional blood cells is the cause of leukemia. So 
the basic concept of targeting against leukemia is to specifically suppress this out-of-
control proliferation process without causing much toxicity of the normal cells. 
Therefore, in this chapter, the anti-proliferative of two Banlangen-derived 
compounds (indirubin-3，-oxime and tryptanthrin) on different myeloid leukemia cell 
lines would be examined. The cytotoxic effect of tryptanthrin was tested using a 
human normal hepatocyte-like cell line and primary culture of murine macrophages. 
The kinetic study and the reversibility of the anti-proliferative activity exerted by 
tryptanthrin on the murine myelomonocytic leukemia WEHI-3B JCS cells were also 
performed. Mechanistic studies on the anti-proliferative effect of tryptanthrin on 
WEHI-3B JCS cells were investigated by observing the cell cycle profile as analyzed 
by flow cytometry, and by examining the expression of several cell 
growth-regulatory genes at both mRNA and protein levels using real-time 
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polymerase chain reaction (RT-PCR) and Western blotting respectively. Apart from 
all these in vitro experiments, the effects of tryptanthrin on the growth and 
tumorigenicity of leukemia WEHI-3B JCS cells were also studied in vivo using 
syngeneic BALB/c mice. 
3.2 Results 
3.2.1 Effects of Indirubin-S'-Oxime and Tryptanthrin on the Proliferation of 
Myeloid Leukemia Cell Lines of Human and Murine Origins 
The suppressive effect of tryptanthrin and indirubin-3'-oxime on the 
proliferation of myeloid leukemia cells was studied using the tritiated thymidine 
incorporation assay as described in Chapter 2. In this assay, the extent of cell 
proliferation is directly proportional to the amount of [^H]-TdR incorporated into the 
DNA of the cells. As shown in Fig 3.1 to 3.10, both tryptanthrin and 
indirubin-3'-oxime were found to be very potent in inhibiting the growth of various 
myeloid leukemia cell lines including EoL-1, K-562, HL-60, JCS and Ml cells with 
IC50 ranging from 0.2 |aM to 8 |aM. The estimated IC50 values of tryptanthrin and 
indirubin-3'-oxime on different cell lines were summarized in Table 3.1. 
The results showed that both tryptanthrin and indirubin-3'-oxime inhibited the 
proliferation of various myeloid leukemia cells lines in a dose-dependent manner. 
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Among the cell lines tested, the K-562 cells seem to be the least responsive to both 
drugs as shown by the highest IC50 values while EoL-1 cells being the most sensitive 
cell line. For both EoL-1 and HL-60 cells, a high percentage of inhibition was hard to 
achieve (< 60%) even tryptanthrin was present at relatively high concentration 
though they appeared to have a very low IC50 value (Fig. 3.2 and 3.3). The reason 
behind this phenomenon was unknown. The murine myelomonocytic leukemia 
WEHI-3B JCS cells responded well to both indirubin-3'-oxime and tryptanthrin in a 
dose-dependent manner with an estimated IC50 value of ~ 1.5 - 2 |iM. This cell line 
has a very short doubling time of around 16 hours, and it is also well characterized 
and sub-cloned by our group. In addition, another advantage of using this cell line is 
that it can be easily transplanted into syngeneic BALB/c mice without causing any 
rejection from the mice and is therefore a good model for studying the anti-tumor 
activity in vivo. Therefore, in this project, the murine myelomonocytic leukemia 
WEHI-3B JCS cells were mainly used as an experimental cell model for our 
mechanistic studies of tryptanthrin on myeloid leukemia cells. When compared to a 
common anti-leukemia drug doxorubicin, tryptanthrin was found to have a 
comparable IC50 on the WEHI-3B JCS cells (Table 3.1 & 3.2). Moreover, the solvent 
control, DMSO, had consistently found to have no significant inhibitory effect on the 
proliferation of the WEHI-3B JCS cells (Fig. 3.11). 
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Fig. 3.1: Anti-proliferative effect of tryptanthrin on the EoL-1 cells after 48 hour 
treatment. EoL-1 cells (10^ cells/ml) were incubated with different concentrations 
(0-5 jiM) of tryptanthrin at 37°C for 48 hours. Cultures were pulsed with 0.5 fiCi of 
^H-TdR for 6 hours before harvest. Radioactivity, expressed as counts per minute 
( cpm ) � was determined using a liquid scintillation counter. Results were expressed as 
% inhibition of ^H-TdR incorporation with respect to the solvent-treated cells. Each 
point represents the mean 土 S.E. of quadruplicate cultures. 
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Fig. 3.2: Anti-proliferative effect of indirubin-3'-oxime on the EoL-1 cells after 
48 hour treatment. EoL-1 cells (10^ cells/ml) were incubated with different 
concentrations (0-3 )iM) of indirubin-3'-oxime at 3 7 � C for 48 hours. Cultures were 
pulsed with 0.5 fj-Ci of ^H-TdR for 6 hours before harvest. Radioactivity, expressed 
as counts per minute (cpm), was determined using a liquid scintillation counter. 
Results were expressed as % inhibition of ^H-TdR incorporation with respect to the 
solvent-treated cells. Each point represents the mean 土 S.E. of quadruplicate 
cultures. 
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Fig. 3.3: Anti-proliferative effect of tryptanthrin on the HL-60 cells after 48 
hour treatment. HL-60 cells (10^ cells/ml) were incubated with different 
concentrations (0-5 |j.M) of tryptanthrin at 37°C for 48 hours. Cultures were pulsed 
with 0.5 \iCi of ^H-TdR for 6 hours before harvest. Radioactivity, expressed as 
counts per minute (cpm), was determined using a liquid scintillation counter. Results 
were expressed as % inhibition of ^H-TdR incorporation with respect to the 
solvent-treated cells. Each point represents the mean 土 S.E. of quadruplicate 
cultures. 
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Fig. 3.4: Anti-proliferative effect of indirubin-3，-oxiine on the HL-60 cells after 
48 hour treatment. HL-60 cells (10^ cells/ml) were incubated with different 
concentrations (0-20 )JM) of indirubin-3'-oxime at 37°C for 48 hours. Cultures were 
pulsed with 0.5 p-Ci of ^H-TdR for 6 hours before harvest. Radioactivity, expressed 
as counts per minute (cpm), was determined using a liquid scintillation counter. 
Results were expressed as % inhibition of ^H-TdR incorporation with respect to the 
solvent-treated cells. Each point represents the mean 土 S.E. of quadruplicate 
cultures. 
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Fig. 3.5: Anti-proliferative effect of tryptanthrin on the K-562 cells after 48 hour 
treatment. K-562 cells (10^ cells/ml) were incubated with different concentrations 
(0-15 i^M) of tryptanthrin at 37°C for 48 hours. Cultures were pulsed with 0.5 ^Ci of 
H-TdR for 6 hours before harvest. Radioactivity, expressed as counts per minute 
(cpm), was determined using a liquid scintillation counter. Results were expressed as 
% inhibition of ^H-TdR incorporation with respect to the solvent-treated cells. Each 
point represents the mean 土 S.E. of quadruplicate cultures. 
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Fig. 3.6: Anti-proliferative effect of indirubin-3'-oxime on the K-562 cells after 
48 hour treatment. K-562 cells (10^ cells/ml) were incubated with different 
concentrations (0-30 juM) of indirubin-3'-oxime at 37�C for 48 hours. Cultures were 
pulsed with 0.5 |aCi of ^H-TdR for 6 hours before harvest. Radioactivity, expressed 
as counts per minute (cpm), was determined using a liquid scintillation counter. 
Results were expressed as % inhibition of ^H-TdR incorporation with respect to the 
solvent-treated cells. Each point represents the mean 土 S.E. of quadruplicate 
cultures. 
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Fig. 3.7: Anti-proliferative effect of tryptanthrin on the murine myelomonocytic 
leukemia WEHI-3B JCS cells after 48 hour treatment. The leukemia WEHI-3B 
JCS cells (104 cells/ml) were incubated with different concentrations (0-5 |iM) of 
tryptanthrin at 37°C for 48 hours. Cultures were pulsed with 0.5 ^iCi of^H-TdR for 6 
hours before harvest. Radioactivity, expressed as counts per minute (cpm), was 
determined using a liquid scintillation counter. Results were expressed as % 
inhibition of ^H-TdR incorporation with respect to the solvent-treated cells. Each 
point represents the mean 士 S.E. of quadruplicate cultures. 
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Fig. 3.8: Anti-proliferative effect of indirubin-3，-oxinie on the murine 
myelomonocytic leukemia WEHI-3B JCS cells after 48 hour treatment. The 
leukemia WEHI-3B JCS cells (10'* cells/ml) were incubated with different 
concentrations (0-3 |LXM) of indirubin-3'-oxime at 37°C for 48 hours. Cultures were 
pulsed with 0.5 ^iCi of ^H-TdR for 6 hours before harvest. Radioactivity, expressed 
as counts per minute (cpm), was determined using a liquid scintillation counter. 
Results were expressed as % inhibition of ^H-TdR incorporation with respect to the 
solvent-treated cells. Each point represents the mean 土 S.E. of quadruplicate 
cultures. 
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Fig. 3.9: Anti-proliferative effect of tryptanthrin on the murine myelomonocytic 
leukemia M l cells after 48 hour treatment. Ml cells (10^  cells/ml) were incubated 
with different concentrations (0-20 |iM) of tryptanthrin at 3 7 � C for 48 hours. 
Cultures were pulsed with 0.5 )aCi of ^H-TdR for 6 hours before harvest. 
Radioactivity, expressed as counts per minute (cpm), was determined using a liquid 
scintillation counter. Results were expressed as % inhibition of^H-TdR incorporation 
with respect to the solvent-treated cells. Each point represents the mean 士 S.E. of 
quadruplicate cultures. 
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Fig. 3.10: Anti-proliferative effect of doxorubicin on the murine 
myelomonocytic leukemia WEHI-3B JCS cells after 48 hour treatment. The 
leukemia WEHI-3B JCS cells cells/ml) were incubated with different 
concentrations (0-10 |a,M) of doxorubicin at 37°C for 48 hours. Cultures were pulsed 
with 0.5 faCi of ^H-TdR for 6 hours before harvest. Radioactivity, expressed as 
counts per minute (cpm), was determined using a liquid scintillation counter. Results 
were expressed as % inhibition of ^H-TdR incorporation with respect to the 
solvent-treated cells. Each point represents the mean 土 S.E. of quadruplicate 
cultures. 
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Fig. 3.11: Effect of D M S O on the proliferation of the murine myelomonocytic 
leukemia WEHI - 3 B JCS cells after 48 hour treatment. The leukemia WEHI-3B 
JCS cells (104 cells/ml) were incubated with different concentrations (0-0.2%) of 
DMSO at 3 7 � C for 48 hours. Cultures were pulsed with 0.5 fiCi of ^H-TdR for 6 
hours before harvest. Radioactivity, expressed as counts per minute (cpm), was 
determined using a liquid scintillation counter. Results were expressed as % 
inhibition of ^H-TdR incorporation with respect to the untreated control cells. Each 
point represents the mean 士 S.E. of quadruplicate cultures. 
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Table 3.1: The estimated IC50 values of indirubin-3'-oxime and tryptanthrin on 
the proliferation of different myeloid leukemia cell lines as 
determined by the [^H]-TdR incorporation assay. 
X Estimated ICsn value (uM) for different cell lines as 
determined by [^H1-TdR incorporation assay 
WEHI-3B 
EoL-1 K562 HL-60 M-1 
JCS 
Indirubin-3'-oxime i .3 3 5 2 N.D. 
Tryptanthrin 1 8 0.2 L5 4 
Doxorubicin N.D. N.D. N.D. 0.8 N.D. 
I C 5 0 value is the estimated concentration of the drug which causes 50 % inhibition on 
the in vitro proliferation of that particular cell line. 
N.D. = Not determined 
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3.2.2 Kinetic and Reversibility Studies of the Anti-proliferative Effect of 
Tryptanthrin on Murine Myelomonocytic Leukemia WEHI-3B JCS 
Cells In Vitro 
Kinetic studies of the anti-proliferative effect of tryptanthrin on WEHI-3B JCS 
cells were done by incubating WEHI-3B JCS cells with different concentrations of 
tryptanthrin at 37°C for different time intervals (24, 48，72 hours), and cell 
proliferation was then measured by the [^H]-TdR incorporation assay. Results 
showed that tryptanthrin inhibited the proliferation of WEHI-3B JCS cells in a dose-
and time-dependent manner (Fig. 3.12). 
Similarly, the growth-inhibitory activity of tryptanthrin on WEHI-3B JCS cells 
was also examined using the trypan blue exclusion assay. The leukemia WEHI-3B 
JCS cells were first treated with tryptanthrin for 24, 48 and 72 hours and then further 
proceeded to viable cell counting. The number of viable cells was recorded. As 
shown in Fig. 3.13, tryptanthrin inhibited the in vitro growth of WEHI-3B JCS cells 
very effectively at all the concentrations tested (1-5 |iM). Significant suppression of 
WEHI-3B JCS cell growth was detected at 48 and 72 hours of treatment with 
tryptanthrin and complete suppression of WEHI-3B JCS cell growth was observed 
when the concentration of tryptanthrin was > 2.5 | iM. 
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The reversibility of the anti-proliferative effect of tryptanthrin on WEHI-3B JCS 
cells was also studied. The cells were incubated with different concentrations of 
tryptanthrin for 8，18 and 48 hours, after that, the cells were washed to remove the 
tryptanthrin and then re-incubated with fresh medium for up to 48 hours. As shown 
in Fig 3.14，tryptanthrin (1.25 |uM, 2.5 |aM and 5 j^M) inhibited the [^H]-TdR 
incorporation of WEHI-3B JCS cells after 24 hours of incubation to 10%, 40% and 
80% respectively while 60%, 90% and 100% inhibition were seen in WEHI-3B JCS 
cells incubated with tryptanthrin for 48 hours. The results indicate that the 
growth-inhibitory effect of tryptanthrin could be partially reversed during the early 
period of incubation. The longer the exposure time to tryptanthrin, the less reversible 
the anti-proliferative effect was. In order to achieve a more potent anti-proliferative 
effect of tryptanthrin on WEHI-3B JCS cells, a longer incubation time is needed for 
the tryptanthrin to exert its effect. 
- 1 0 9 -
Chapter 3 Anti-Proliferation 
1 /S RT 
1 ^  u 
I 
^ ： r f ^ ^ ^ I 
1 '' f / f - / / 
20 7/ .. |-#-24hr 
II -£s-48hr 
丨 -•-72hrl 
Q • — 1 1 L J I_I 1 
0 1 2 3 4 5 6 
Tryptanthrin concentration ( | iM) 
Fig. 3.12: Kinetic study of anti-proliferative effect of tryptanthrin on the murine 
myelomonocytic leukemia WEHI-3B JCS cells. The leukemia WEHI-3B JCS cells 
(104 cells/ml) were incubated with different concentrations of tryptanthrin at 37�C for 
24, 48 and 72 hours. Cultures were pulsed with 0.5 juCi of ^H-TdR for 6 hours before 
harvest. Radioactivity, expressed as counts per minute (cpm), was determined using a 
liquid scintillation counter. Results were expressed as % inhibition of ^H-TdR 
incorporation with respect to the solvent-treated cells. Each point represents the 
mean 士 S.E. of quadruplicate cultures. 
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Fig. 3.13: Effect of tryptanthrin on the in vitro growth of murine 
myelomonocytic leukemia WEHI-3B JCS cells. The leukemia WEHI-3B JCS cells 
(104 cells/ml) were incubated with either solvent control (0.05%DMSO) or different 
concentrations of tryptanthrin (1，2.5 and 5 juM) or at 37°C for 1, 2, 3 days. The 
number of viable cells was counted using Vi-cellTM XR cell viability analyzer 
(Beckman Coulter). Results were expressed as the number of viable cells 士 S.E. of 
triplicate cultures. 
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Fig. 3.14: Reversibility study on the anti-proliferative effect of tryptanthrin on 
the murine myelomonocytic leukemia WEHI-3B JCS cells. The leukemia 
WEHI-3B JCS cells (lO* cells/ml) were treated with different concentrations of 
tryptanthrin for 8，18 and 48 hours. Tryptanthrin were washed away and replaced by 
complete medium at particular time and all cultures were incubated up to 48 hours. 
Cultures were pulsed with 0.5 |j.Ci of ^H-TdR for 6 hours before harvest. 
Radioactivity, expressed as counts per minute (cpm), was determined using a liquid 
scintillation counter. Results were expressed as % inhibition of ^H-TdR incorporation 
with respect to the solvent-treated cells. Each point represents the mean 士 S.E. of 
quadruplicate cultures. 
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3.2.3 Cytotoxic Effect of Tryptanthrin on Murine Myelomonocytic Leukemia 
WEHI-3B JCS Cells In Vitro 
The cytotoxicity of tryptanthrin on WEHI-3B JCS cells was investigated using 
the trypan blue exclusion assay. The leukemia WEHI-3B JCS cells were first treated 
with tryptanthrin for 24, 48 and 72 hours and then further proceeded to viable cell 
counting. Results showed that 1 |j,M tryptanthrin was virtually non-cytotoxic to 
WEHI-3B JCS cells (Fig. 3.15). The viability of WEHI-3B JCS cells remained fairly 
high (> 85% viable at 72 hours of incubation) when the concentration of tryptanthrin 
was increased to 2.5 fj,M. However, about 30% dead cells were observed at 72 hours 
of incubation when tryptanthrin was present at 5 |iM. These data suggest that 
tryptanthrin has no direct cytotoxicity on WEHI-3B JCS cells at the concentration 
which inhibits 50% of the JCS cell proliferation. 
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Fig. 3.15 Effect of tryptanthrin on the viability of murine myelomonocytic 
leukemia W E H I - 3 B J C S cells. The leukemia WEHI-3B JCS cells (lO^ cells/ml) 
were incubated with different concentrations of tryptanthrin ( 0 - 5 fiM) or solvent 
control (0.05% DMSO) at 37°C for 1, 2, 3 days. The number of viable cells was 
counted using Vi-cellTM XR cell viability analyzer (Beckman Coulter). Results were 
expressed as mean percentage of viable cells 土 S.E. of triplicate cultures. 
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3.2.4 Cytotoxicity of Tryptanthrin on Non-Cancer Cell Line and Primary 
Myeloid Cells In Vitro 
All the data so far obtained suggest that tryptanthrin is a potent compound 
exerting its anti-proliferative activity on different myeloid leukemia cell lines. 
However, it is rather crucial to know whether it also exerts cytotoxicity on normal 
cells in vitro. In this study, human hepatocyte-like WRL 68 cells and 
thioglycollate-elicited murine peritoneal macrophages were cultured in vitro and 
treated with different concentrations of tryptanthrin for 24 and 48 hours. The 
viability was then measured by the MTT assay. For thioglycollate-elicited murine 
peritonea丨 macrophages, the cell viability remained around 100% and only slight 
cytotoxicity was seen at a higher concentration after 48 hours of treatment (Fig. 3.16). 
On the other hand, tryptanthrin showed no cytotoxicity at all for human 
hepatocyte-like WRL 68 cells even at a high concentration of tryptanthrin (15 |JM) 
which was about 10-fold of the I C 5 0 for WEHI-3B JCS cells (Fig. 3.17). 
- 1 1 5 -
Chapter 3 Anti-Proliferation 
120 • • • ^ —— —] 
100 丨 













2 0 - ！ 
j- - • - 2 4 hr 
！ - • - 4 8 hr 
0 5 10 15 
Tryptanthrin concentration ()iM) 
Fig. 3.16: Effect of tryptanthrin on the growth and survival of murine 
peritoneal macrophages in vitro. Thioglycollate-elicited BALB/c peritoneal 
macrophages (10^ cells/ml) were cultured with different concentrations of 
tryptanthrin for 24 and 48 hours at 37°C. Cell growth and survival was determined by 
the MTT assay. Results were expressed as percentage of cells, use solvent treated 
cells as control. Each point represents the mean 土 S.E. of quadruplicate cultures. 
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Fig. 3.17: Effect of tryptanthrin on the growth and survival of human 
hepatocyte-like W R L 68 cells. WRL 68 cells (10^ cells/ml) were incubated with 
different concentrations of tryptanthrin at 37°C for 24 and 48 hours. Cell growth and 
survival was determined by the MTT assay. Results were expressed as percentage of 
cells, use solvent treated cells as control. Each point represents the mean 土 S.E. of 
quadruplicate cultures. 
- 1 1 7 -
Chapter 3 Anti-Proliferation 
3.2.5 Effects of Tryptanthrin on the Cell Cycle Profile of Murine 
Myelomonocytic Leukemia WEHI-3B JCS Cells In Vitro 
One of the possible mechanisms of tryptanthrin leading to its potent 
anti-proliferative effect is its ability to interrupt with the normal cell cycle 
progression. To address this issue, the leukemia WEHI-3B JCS cells were first 
treated with tryptanthrin for designated time intervals of 24 and 48 hours, and then 
stained with propidium iodide and followed by flow cytometric analysis for the cell 
cycle profile. As shown in Fig. 3.18，there was a very obvious increase in proportion 
of cells in Go/Gi phase of the cell cycle, accompanied by a significant decrease in the 
percentage of cells in S phase. There were little, if any, changes in the percentage of 
cells in the G2/M phase after 24 hours of treatment (Fig. 3.18). Similar changes in the 
cell cycle distribution were observed at 48 hour treatment of WEHI-3B JCS cells 
with tryptanthrin (Fig. 3.19). 
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Fig. 3.18a: Histograms (raw data) showing the effect of tryptanthrin on the cell 
cycle profile of murine myelomonocytic leukemia WEHI-3B JCS cells after 24 
h o u r t rea tment . The leukemia WEHI-3B JCS cells (lO^ cells/ml) were either 
incubated with (A) solvent control (0.05% DMSO) or tryptanthrin at various 
concentrations (B) 1 |LIM, (C) 1.5 |aM, (D) 2.5 ^M and (E) 2.5 ^M for 24 hours. 
Treated cells (10^ cells) were fixed with ethanol and stained with PI under hypotonic 
condition. The fluorescence intensity of the stained cells was measured by using the 
FACSCanto flow cytometer. Cell cycle distribution was analyzed by using RFIT 
analysis model of MODFIT program. 
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Fig. 3.18b: The effect of tryptanthrin on the cell cycle profile of murine 
myelomonocytic leukemia WEHI-3B JCS cells after 24 hour treatment. The 
leukemia WEHI-3B JCS cells (10"^  cells/ml) were either incubated with solvent 
control (0.05% DMSO) or tryptanthrin at various concentrations for 24 hours. 
Treated cells (10^ cells) were fixed with ethanol and stained with PI under hypotonic 
condition. The fluorescence intensity of the stained cells was measured by using the 
FACSCanto flow cytometer. Cell cycle distribution was analyzed by using RFIT 
analysis model of MODFIT program. 
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Fig. 3.19a: Histograms (raw data) showing the effect of tryptanthrin on the cell 
cycle profile of murine myelomonocytic leukemia WEHI-3B JCS cells after 48 
h o u r t r ea tmen t . The leukemia WEHI-3B JCS cells (lO* cells/ml) were either 
incubated with (A) solvent control (0.05% DMSO) or tryptanthrin at various 
concentrations (B) 1 |aM, (C) 1.5 | iM, (D) 2.5 |aM and (E) 2.5 [iM for 48 hours. 
Treated cells (10^ cells) were fixed with ethanol and stained with PI under hypotonic 
condition. The fluorescence intensity of the stained cells was measured by using the 
FACSCanto flow cytometer. Cell cycle distribution was analyzed by using RFIT 
analysis model of MODFIT program. 
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Fig. 3.19b: The effect of tryptanthrin on the cell cycle profile of murine 
myelomonocytic leukemia WEHI-3B JCS cells after 48 hour treatment. The 
leukemia WEHI-3B JCS cells (lO^ cells/ml) were either incubated with solvent 
control (0.05% DMSO) or tryptanthrin at various concentrations for 48 hours. 
Treated cells (10^ cells) were fixed with ethanol and stained with PI under hypotonic 
condition. The fluorescence intensity of the stained cells was measured by using the 
FACSCanto flow cytometer. Cell cycle distribution was analyzed by using RFIT 
analysis model o f M O D F I T program. 
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3.2.6 Effects of Tryptanthrin on the Expression of Cell Cycle Related Genes in 
Murine Myelomonocytic Leukemia WEHI-3B JCS cells In vitro 
Cell division can be divided into two stages: mitosis (M) and interphase. 
Interphase includes Gi, S and G2 phases (Norbury and Nurse 1992). G! is a phase in 
which the cell prepares for DNA synthesis followed by S phase during which 
replication of DNA occurs. It is the G2 phase that comes after for the cell to prepare 
for mitosis. Gi, S, G2 and M phases are the traditional subdivisions of the standard 
cell cycle. The transition from one cell cycle phase to another occurs in an orderly 
fashion and is sophistically regulated by different cellular proteins. Key regulatory 
proteins are the cycl in-dependent kinases (Cdk), a family of serine / threonine protein 
kinases that are activated at specific points of the cell cycle by binding to different 
cyclins that are required at different phases of the cell cycle (Vermeulen et al., 2003). 
Since it was shown that tryptanthrin arrested the WEHI-3B JCS cells at GQ/GI 
phase, the gene expressions of cyclins and Cdk which are involved in the transition 
of Go/Gi to S phase were examined. They included cyclin D2, D3 and Cdk 2, 4，6. 
Using the technique of real time polymerase chain reaction (RT-PCR), it was shown 
that the mRNA level of Cdk 2, 4, 6 decreased in a time-dependent manner after 
treatment with 2.5 juM of tryptanthrin, whereas optimal suppression of cyclin D2 and 
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D3 gene expression was seen as early as 4 hours after treatment with tryptanthrin 
(Fig. 3.20). 
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Fig. 3.20: Effect of tryptanthrin on the m R N A expression of cell cycle related 
genes in the murine myelomonocytic leukemia WEHI-3B JCS cells after 24 hour 
t r ea tment . The leukemia WEHI-3B JCS cells (10"^  cells /ml) were either incubated 
with solvent control (0.025% DMSO), or 2.5 ^iM tryptanthrin at 37°C for 4，12 and 
24 hours. After treatment, total mRNA was isolated by TRIZOL method, followed by 
reverse transcription to produce cDNA. Brilliant SYBR® Green QPCR analysis for 
cyclin D2, D3, Cdk 2, 4，and 6 were then performed according to the manufacturer's 
instruction. The data were analyzed by the method as described by Livak et al. 
(2001). 
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3.2.7 Expression of Cdk Inhibitors in Tryptanthrin-treated Murine 
Myelomonocytic Leukemia WEHI-3B JCS Cells 
The cell cycle, apart from the cyclins and the Cdk, is indeed also regulated by 
different Cdk inhibitors. There are two families of Cdk inhibitors: the INK4 family 
and Cip/Kip family (Sherr and Roberts, 1995). The INK4 family includes p i5 
(INK4b), p l 6 (INK4a), p l 8 (INK4c), p l 9 (INK4d), which specifically inactivate G, 
Cdk (Cdk4 and Cdk6). The second family of inhibitors, the Cip/Kip family, includes 
p21 (Waf l , Cipl) , p27 (Cip2), p57 (Kip2). These inhibitors inactivate Cdk-cyclin 
complexes (Polyak et al, 1994; Harper et al, 1995; Lee et al, 1995). They inhibit 
the G] Cdk-cyclin complexes, and to a lesser extent, Cdkl-cyclin B complexes 
(Hengst and Reed, 1998). 
In our study, the protein expressions of pi 5，p27 and p i 8 were studied after the 
WEHI-3B JCS cells were treated with different concentrations of tryptanthrin for 48 
hours. As shown in Fig. 3.21，an increase of 48% and 46% in the expression of pi 8 
and p27 proteins was observed when the WEHI-3B JCS cells were treated with 2.5 
[iM and 1 ^iM tryptanthrin respectively while the expression of pi 5 protein remained 
more or less the same as the solvent control. 
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Fig. 3.21: Effect of tryptanthrin on the expression of Cdk inhibitors in the 
murine myelomonocytic leukemia WEHI-3B JCS cells after 48 hour treatment. 
The leukemia W E H I - 3 B JCS cells (lO* cells /ml) were either incubated with solvent 
control (0.05% DMSO) or with different concentrations (1 }iM, 2.5 |iM, 5 i^M) of 
tryptanthrin at 3 7 � C for 48 hours. The proteins of each sample were extracted and 
analyzed by Western blotting as described in Chapter 2. The extracted protein (20 fig 
per sample) were electrophoresed on a polyacrylamide gel and then transferred onto 
PVDF membrane for probing with specific primary antibodies followed by 
horseradish peroxidase-conjugated secondary antibody. Then ECL detection assay 
was carried out in order to generate visible signal by exposing the membrane to 
X-ray films. The relative intensity of each protein band was normalized with respect 
to P-actin and compared with the corresponding solvent control. The results shown 
are representative of two independent experiments with similar results. 
• Arrow indicating the described protein band 
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3.2.8 Effects of Tryptanthrin on the In Vitro Tumorigenicity of Murine 
Myelomonocytic Leukemia WEHI-3B JCS cells 
Previous work has demonstrated the anti-proliferative effect of tryptanthrin on 
the leukemia WEHI-3B JCS cells in vitro. It is equally important to show its 
growth-inhibitory effect on the WEHI-3B JCS cells in vivo. In the present study, the 
leukemia WEHI-3B JCS cells were pretreated with different concentrations of 
tryptanthrin for 16 hours, then washed with PBS and then injected i.p. into BALB/c 
mice. Twelve days after inoculation, the leukemia cells were then harvested from the 
peritoneal cavity and the viable cells were counted. Our results showed that the 
tumorigenicity of the pretreated WEHI-3B JCS cells was reduced in a 
dose-dependent manner, and 83% suppression of leukemia cell growth in vivo was 
seen when the WEHI-3B JCS cells were pretreated with 7.5 fiM tryptanthrin in vitro 
(Fig. 3.22). 
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Fig. 3.22: Effect of in vitro pre-treatment of murine myelomonocytic leukemia 
WEHI-3B JCS cells with tryptanthrin on their tumorigenicity in syngeneic 
BALB/c mice. The leukemia WEHI-3B JCS JCS cells (lO* cells /ml) were either 
incubated with solvent control (0.075% DMSO) or with three different 
concentrations of tryptanthrin (2.5 |iM, 5 juM and 7.5 )j,M) at 37°C for 16 hours. The 
cells were then washed four times with PBS. Viable WEHI-3B JCS cells ( Ix 10^ in 1 
ml plain RPMI) were injected i.p. into each BALB/c mouse in groups of five. At 12 
post-tumor inoculation, leukemia cells recovered from the peritoneal cavity were 
counted using Vi-cellTM XR cell viability analyzer (Beckman Coulter). Results were 
expressed as number of viable cells per mouse. Each bar represents the mean 土 S.E. 
for groups of five mice. (*p<0.05, **p<0.005, significant different from solvent 
control) 
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3.2.9 In Vivo Anti-tumor Effect of Tryptanthrin on Murine Myelomonocytic 
Leukemia WEHI-3B JCS Cells 
In view of the observation that tryptanthrin can reduce the tumorigenicity of 
WEHI-3B JCS cells, it is therefore of interest to investigate its anti-tumor activity in 
vivo. The leukemia WEHI-3B JCS cells were (10^ cells/mouse) first injected i.p. into 
syngeneic BALB/c mice for 5 days to allow the cells to grow inside the peritoneal 
cavity. On day 6，mice were injected i.p. either with solvent control or with 
tryptanthrin at three different dosages (0.04 mg/kg, 0.08 mg/kg and 0.16 mg/kg) for 5 
consecutive days. At day-12 post-tumor cell inoculation, viable WEHI-3B JCS cells 
recovered from the peritoneal cavity were counted. As shown in Fig. 3.23, 
tryptanthrin administered in vivo was able to suppress the cell growth of WEHI-3B 
JCS cells in BALB/c mice and significant suppression was seen at the dosages of 
0.08 mg/kg and 0.16 mg/kg. 
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Fig. 3.23: Effect of tryptanthrin on the in vivo growth of murine 
myelomonocytic leukemia WEHI-3B JCS cells with in syngeneic BALB/c mice. 
The leukemia WEHI-3B JCS cells (10^ cells /mouse) in RPMI were injected i.p. into 
BALB/c mice at day 0. Starting from day 6 after inoculation of WEHI-3B JCS cells, 
mice were divided into 3 groups with five mice in each group. They were injected i.p. 
either with solvent control or with tryptanthrin at three different dosages (0.04 mg/kg, 
0.08 mg/kg and 0.16 mg/kg) for 5 consecutive days. At day 12 post-tumor cell 
inoculation, viable WEHI-3B JCS cells recovered from the peritoneal cavity were 
counted using Vi-cellTM XR cell viability analyzer (Beckman Coulter). Results were 
expressed as number of viable cells per mouse. Each bar represents the mean 士 S.E. 
for groups of five mice. (*p<0.05, **p<0.005, significant different from solvent 
control) 
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3.3 Discussion 
In this chapter, the anti-proliferative effect of tryptanthrin on the murine 
myelomonocytic leukemia WEHI-3B JCS cells was studied. Tryptanthrin was found 
to inhibit the growth of WEHI-3B JCS cells in a dose-dependent manner with an 
estimated I C 5 0 value of 1.5 [xM after 48 hours of incubation. In order to show that the 
observed anti-proliferative effect of tryptanthrin is not tumor cell line specific, it was 
also tested on several other myeloid leukemia cell lines of murine (Ml) and human 
(EoL-1, K-562, HL-60) origins. For Ml cells, tryptanthrin also showed an inhibitory 
effect on the leukemic cell growth however with an I C 5 0 value of 10 |iM. For other 
human leukemia cell lines, relatively potent inhibitory effect of tryptanthrin was 
observed. However, the I C 5 0 for K-562 cells was relatively higher when compared to 
the WEHI-3B JCS cells. Interestingly, for both EoL-1 and HL-60, although 
tryptanthrin was found to have much lower I C 5 0 values for these cell lines, however, 
the inhibitory effect flattened out at a very low concentration and the maximum 
suppression of cell proliferation was found to be - 6 0 % even though a very high 
concentration of tryptanthrin was used. The reason for this phenomenon remains 
unclear. The potency of tryptanthrin was comparable with a very common 
anti-leukemia drug doxorubicin which showed an ICsoof 0.8 ^M on WEHI-3B JCS 
cells. The high potency of tryptanthrin was not surprising. As mentioned before, 
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tryptanthrin was reported to have anti-bacterial (Mitscher and Baker, 1998), 
anti-tumor (Romano and Claria, 2003; Kataoka et al., 2001), and anti-inflammatory 
(Takei et al, 2003; Hamburger, 2003) activities with an effective dosage ranging 
from nM to |aM. In addition, tryptanthrin was found to suppress the overexpression 
of M D R l as well as the P-gp in the breast cancer MCF-7 cells at 1 |aM (Yu et al.’ 
2007). In this study, another potential candidate compound derived from Banlangen, 
indirubin-3'-oxime was also tested on different myeloid cell lines. With the exception 
of K-562 cells, it was found to be less potent than tryptanthrin for all the leukemia 
cell line tested. Indirubin-3'-oxime has been found to suppress the growth of human 
breast cancer cell line MCF-7 with an IC50 value of 3.3 ^iM (Marko et al” 2001). 
Mechanistic studies showed that it inhibits Cdk-cyclin complexes, such as 
Cdkl/cyclin B, Cdk2/cyclin A and Cdk2/cyclin E by competing with ATP for binding 
to the catalytic subunit of Cdk which leads to G2/M arrest in many cell lines and Gi/S 
arrest in Jurkat cells (Hoessel et al, 1999; Marko et al., 2001). Since the mechanism 
of this drug was already well-studied, and it was found to exhibit lower potency than 
tryptanthrin in our present study, therefore, in this project, we would like to focus on 
the potential of tryptanthrin as an anti-leukemia drug and using the murine 
myelomonocytic leukemia WEHI-3B JCS as a cellular model since this well 
characterized and subcloned cell line (Mak et al,, 1993) was found to be very 
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sensitive towards tryptanthrin. 
In order to understand whether the growth inhibition exerted by tryptanthrin on 
WEHI-3B JCS cells was due to its cytotoxic effect, trypan blue exclusion assay was 
performed. The results showed that no significant cytotoxicity was observed when 
WEHI-3B JCS cells were treated with 1 nM to 5 fiM for 48 hours. A 30% of 
cytotoxicity was observed only when WEHI-3B JCS cells were treated with 5 juM 
tryptanthrin for 3 days. The observed growth-inhibitory effect of tryptanthrin on 
WEHI-3B JCS cells was unlikely due to solvent effect as WEHI-3B JCS cells treated 
with 0.05% DMSO for 72 hours demonstrated no significant anti-proliferative effect. 
In addition, when normal cells like the thioglycollate-elicited murine peritoneal 
macrophages and the human hepatocyte-like WRL 68 cells were treated with 
tryptanthrin for 48 hours, our result showed that tryptanthrin exhibited little, if any, 
cytotoxicity on these cells, demonstrating that its anti-proliferative effect on myeloid 
leukemia cells is tumor specific. 
The anti-proliferative effect of tryptanthrin was found to be dose-dependent, as 
well as time-dependent. From the kinetic study of tryptanthrin on WEHI-3B JCS 
cells, a higher anti-proliferative effect can be achieved by prolonging the incubation 
time, e.g. up to 72 hours. The reason could be explained by the result of the 
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reversibility test. The growth-inhibitory effect of tryptanthrin was found to be 
partially reversible when the time of exposure to tryptanthrin was short (8 and 18 
hours). Though it has been proven that anti-proliferative effect can be switched on 
within the first 24 hours, a longer incubation time is required for the irreversible 
changes. 
The development of cancer drug has undergone a major change these decades 
from identifying drugs that kill tumor cells to using a strategy of targeting molecules 
that underlining cell transformation. Cell cycle proteins are one of the targets. 
Recently, indirubin and its analogue 5-chloro-indirubin, indirubin-3'-oxime and 
indirubin-5-sulphonic acid were identified as potent and selective Cdk inhibitors 
(Vermeulen et al., 2003). Indirubin-3'-oxime has activity in several tumor models 
and blocks the cell cycle progression at Gi/S and G2/M (Marko et al, 2001). That is 
why we wanted to know if tryptanthrin inhibits the growth of leukemia WEHI-3B 
JCS cells also through induction of the cell cycle arrest. 
In this study, it was shown that the treatment of leukemia WEHI-3B JCS cells 
with tryptanthrin for 24 hours and 48 hours increased the percentage leukemia cells 
in Go/Gi phase and a decrease in the percentage of cells in S phase in a 
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dose-dependent but not time-dependent manner. The transition from one cell cycle 
phase to another occurs in a highly regulated system by different cellular proteins 
including cyclins and Cdk. Since tryptanthrin arrested the cell cycle of WEHI-3B 
JCS cells at Go/Gi phase, so it was of interest to examine its effects on the expression 
of cyclins and Cdk which regulate the entry of the cell to Gi phase or the transition 
from Gi to S phase. Three types of D cyclins, D l , D2 and D3 are involved in the 
entry to Gi phase. Although the cyclin protein levels rise and fall during the cell cycle 
and in this way they periodically activate Cdk (Evans et al, 1983; Pines, 1991). 
However, unlike other cyclins, cyclin D is not expressed periodically but is 
synthesized as long as growth factor stimulation persists (Assoian and Zhu, 1997). 
Cyclin D acts as a growth sensor to link between mitogenic stimuli and the cell cycle. 
Aberrant cyclin Dl expression has been reported in many human cancers. Cyclin D2 
and cyclin D3 have also been reported to be overexpressed in some tumors and cyclin 
E has been found to be amplified or overexpressed in some cases of breast and colon 
cancers and in acute lymphoblastic and acute myeloid leukemias (Leach et fl/.,1993; 
Hunter & Pines，1994; Keyomarsi et al, 1995; Scuderi et al, 1996; lida et al, 1997). 
In the present study, the mRNA levels of cyclin D2, D3 in WEHI-3B JCS cells 
were found to be down-regulated after treatment with tryptanthrin, and significant 
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decrease in cyclin D2, D3 gene expression was seen as early as 4 hours after 
tryptanthrin treatment. On the other hand, the expression of Cclk2, 4, 6 genes was 
found to decrease in a time-dependent manner after treatment with tryptanthrin. It is 
known that cyclin D1 binds to Cdk4 and Cdk6 in early G! in the progression of the 
cell cycle. With less Cdk4 and 6, less Cdk-cyclin D complexes can be formed which 
is a prerequisite for the continuity of the cell cycle phase Gi. Moreover, another Gi 
cyclin is cyclin E which works together with Cdk2 to regulate the progression of Gi 
phase to S phase (Ohashi et al., 1995). As for the S phase, cyclin A is required to 
work in association with Cdk2 (Girard et al., 1991). From the results we obtained, 
the decrease in the mRNA expression of Cdk2 might also hinder the formation of 
cyclin A-Cdk2 or cyclin E-Cdk2 complexes. Therefore, the cells were prevented to 
progress from phase Gi to S phase. This might account for the cell cycle arrest of 
WEHI-3B JCS cells at GQ/GI phase after tryptanthrin treatment. 
Apart from these Cdk and cyclins, there are cell cycle inhibitory proteins called 
Cdk inhibitors (CKI) which bind to Cdk alone or to the cdk-cyclin complexes and 
regulate Cdk activity. CKI pi5，pi6，pi8 and p l 9 which specifically inactivate Gi 
Cdk4 and Cdk 6 by forming a stable complex with them which prevent their further 
association with type D cyclins. On the other hand, CKI such as p21, p27 and p57, 
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are known to inactivate the Gi Cdk-cyclin complexes. In this study, the protein 
expressions of pi5，pi8 and p27 in WEHI-3B JCS cells were studied by Western 
blotting. Though only to a small extent, the increase in p i 8 and p27 might also play a 
role in the cell cycle arrest of WEHI-3B JCS cells at GQ/GI phase. p21 and p53 are 
two important CKI which modulate the progression from phase GQ/GI to S phase and 
they will be discussed in the future work in Chapter 6. 
Since tryptanthrin demonstrated potent activity in inhibiting the growth of 
WEHI-3B JCS cells in vitro, its influence on the tumorigenicity of the WEHI-3B JCS 
cells in syngeneic BALB/c mice was also examined. The results indicate that 
pretreatment of WEHI-3B JCS cells in vitro with tryptanthrin inhibited the growth of 
the leukemia cells in BALB/c mice. Apart from this, direct administration of 
tryptanthrin into WEHI-3B JCS-bearing BALB/c mice significantly suppressed the 
in vivo growth of the leukemia cells. These data suggest that tryptanthrin can exert its 
anti-proliferative effect both in vitro and in vivo. 
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Chapter 4 Apoptosis 
4.1 Introduction 
For a Caenorhabditis elegans to develop from a nematode to an adult worm, 
131 somatic cells out of 1090 are designated to undergo a genetically programmed 
cell death process which is then recognized as apoptosis (Horvitz, 1999). This 
discovery reveals that cell death is a crucial process in both development and 
homeostasis of organisms. To date, there are two types of cell death which are well 
studied and these include apoptosis and necrosis. These two types of cell death differ 
in both mechanism and morphology. The advantage of apoptosis over necrosis is that 
necrotic cells release their cellular contents to the surrounding, and sending out 
chemotactic signals which eventually cause inflammation while apoptotic cells do 
not release their cellular contents and no inflammation occurs. 
Cells undergoing apoptosis display profound structural changes, including 
chromatin condensation, cytoplasmic shrinkage, a rapid blebbing of the plasma 
membrane and nuclear disintegration and formation of apoptotic bodies. The nuclear 
collapse is associated with extensive damage to the chromatin, and DNA cleavage 
into oligonucleosomal-length DNA fragments after activation of a 
calcium-dependent endogenous endonuclease. A characteristic "DNA ladder" can be 
visualized by agarose gel electrophoresis with an ethidium bromide stain and 
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ultraviolet illumination (Bortner et al., 1995). Another biochemical feature is the 
external ization of the normal inward-facing phosphatidylserine of the cell's lipid 
bilayer to the outer layer of the plasma membrane for phagocytic recognition 
(Bratton et al, 1997). The detection of the cell surface phosphatidylserine with a 
recombinant phosphatidylserine-binding protein Annexin V is another way to 
demonstrate the onset of apoptosis (Arur et al., 2003). 
There are 3 pathways leading to apoptosis, the intrinsic, extrinsic and granzyme 
pathways. The intrinsic signaling pathway involves a diverse array of 
non-receptor-mediated stimuli that produce intracellular signals which act directly on 
targets within the cell and are mitochondria-initiated events. Bcl-2 family proteins 
take an important role in the intrinsic pathway which involves the activation of 
caspase-9 (Chinnaiyan, 1999; Hill et al, 2004). Extrinsic pathway involves 
transmembrane receptor-mediated interactions. These involve death receptors like 
Fas, TNF receptor and TRAIL (Brunner et al,, 2003). It involves the activation of the 
caspase-8 (Kischkel et al, 1995). Granzyme pathway involves the secretion of 
granzymes A and B which causes DNA cleavage and activates the caspase-10 
respectively. The three pathways finally merge together and activate the executioner 
caspase-3 except granzyme A which works in a caspase-independent fashion (Fan et 
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al., 2003). The execution pathway results in apoptosis. 
It is very often that malignant cells harbor mutations in critical components of 
the apoptotic pathways which may correlate to the poor prognosis (Mcgill and Ficher, 
1997). Many effective cancer chemotherapeutic methods have been reported to 
induce cancer cells to self-killing by activating apoptosis of the cancer cells (Mcgill 
and Ficher, 1997). A number of small molecules with specific drug targets such as 
death receptors and caspase cascades are under preclinical or clinical studies for the 
potential application in apoptosis-based therapy (Fischer and Schulze-Osthoff, 2005; 
Reed and Pellecchia, 2005). 
In Chapter 3, tryptanthrin, a weakly basic alkaloid which can be isolated from 
Indigo plants, was found to exhibit potent anti-proliferative activities on a murine 
myelomonocytic leukemia, the WEHI-3B JCS cells, both in vitro and in vivo. It has 
been shown that tryptanthrin might exert its growth-inhibitory effect on the myeloid 
leukemia WEHI-3B JCS cells by causing cell cycle arrest at the GQ/GI phase, 
however, whether it can trigger terminal differentiation and/or inducing apoptosis of 
the leukemia cells have not yet been investigated. In this chapter, the effect of 
tryptanthrin on inducing apoptosis in WEHI-3B JCS cells was studied by examining 
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the induction of DNA fragmentation using gel electrophoresis and Annexin V and PI 
double staining which was analyzed by flow cytometry. To further study the 
mechanisms involved, the change in mitochondrial membrane potential, the 
induction of caspase-3, -8 and -9 activities and the induction of ROS production in 
tryptanthrin-treated WEHI-3B JCS cells were measured. Finally, the expression of 
apoptosis-regulatory proteins like Bcl-2 family proteins and their gene expression in 
tryptanthrin-treated WEHI-3B JCS cells were also examined by Western blotting and 
real time PGR respectively. 
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4.2 Results 
4.2.1 Induction of D N A Fragmentation by Tryptanthrin in the Murine 
Myelomonocytic Leukemia WEHI-3B JCS Cells In Vitro 
DNA laddering was regarded as one of the hallmarks indicating the occurrence 
of apoptosis. In this study, internucleosomal DNA fragments were extracted by the 
method described in Chapter 2 after treatment of the leukemia WEHI-3B JCS cells 
by tryptanthrin. As shown in Fig. 4.1，it can be seen that tryptanthrin induced DNA 
fragmentation in WEHI-3B JCS cells in a dose-dependent and time-dependent 
manner. DNA fragmentation could be detected after 48 hours of tryptanthrin 
treatment, and more prominent DNA laddering was seen at higher concentrations 
(2.5 [iM and 5 | iM) of tryptanthrin. For WEHI-3B JCS cells which had been exposed 
to tryptanthrin treatment for 72 hours, DNA fragmentation could be clearly seen at 
all the concentrations (1-5 jiM) tested. In contrast, no DNA ladder was found in 
WEHI-3B JCS cells treated with solvent control (0.05% DMSO) and the DNA was 
found to be still intact. 
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Fig. 4.1: Induction of D N A fragmentation in tryptanthrin-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. The leukemia WEHI-3B JCS cells 
(104 cells/ml) were either incubated with solvent control (0.05% DMSO) (Lane 2) or 
treated with different concentrations of tryptanthrin at 3 7 � C for 48 and 72 hours. 
Apoptotic DNA fragments were extracted by mild detergent IGEPAL CA-630 lysis 
buffer, and were analyzed by electrophoresis on 2% agarose gel stained with 
ethidium bromide. 
Lane 1: 100 bp DNA Marker 
Lane 2 to Lane 6: 72 hour treatment Lane 7 to Lane 10: 48 hour treatment 
Lane 2: Cells treated with DMSO 
Lane 3: Cells treated with tryptanthrin Lane 7: Cells treated with tryptanthrin 
(1 _ (1¥) 
Lane 4: Cells treated with tryptanthrin Lane 8: Cells treated with tryptanthrin 
(1.5 _ (1.5 _ 
Lane 5: Cells treated with tryptanthrin Lane 9: Cells treated with tryptanthrin 
(2.5 _ (2.5 _ 
Lane 6: Cells treated with tryptanthrin Lane 10: Cells treated with tryptanthrin 
(5 _ (5 _ 
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4.2.2 Induction of Phosphatidylserine Externalization by Tryptanthrin in the 
Murine Myelomonocytic Leukemia WEHI-3B JCS Cells 
It was proven that the loss of phospholipids asymmetry which leads to an 
externalization of phosphatidylserine outside the plasma membrane is an early event 
of apoptosis. The anti-coagulant Annexin V preferentially binds to negatively 
charged phospholipids such as phosphatidylserine (Koopman et al., 1994; Martin et 
al., 1995; van Heerde et al., 1995). By conjugating green fluorescent protein (GFP) 
to Annexin V which preferentially binds to the externalized phosphatidylserine, it 
enables us to use the marker to identify apoptotic cells by flow cytometry. During the 
early phase of apoptosis the cells bind Annexin V prior to the loss of the plasma 
membrane's ability to exclude propidium iodide (PI). Therefore, one can 
simultaneously distinguish live, apoptotic and necrotic WEHI-3B JCS cells by 
combining Annexin V and PI staining together (Ricci et al.’ 2002). Results shown in 
Fig. 4.2 indicated that the portion of apoptotic cells increased in a dose-dependent 
manner after treatment with tryptanthrin. The percentage increased rather 
significantly at higher concentrations (2.5 |LIM and 5 ^iM) of tryptanthrin. 
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Fig. 4.2: Induction of phosphatidylserine externalization in tryptanthrin-treated 
murine myelomonocytic leukemia WEHI-3B JCS cells. The leukemia WEHI-3B 
JCS cells (104 cells/ml) were incubated with (A) solvent control (0.05% DMSO), or 
with (B) 1 iLiM (C) 2.5 \iM and (D) 5 |iM of tryptanthrin for 48 hours at 37�C hours 
and then stained with the GFP-conjugated Annexin V and propidium iodide (PI) dye. 
At the top right quadrant, cells with both Annexin V and PI positive signals are 
necrotic cells. At the bottom right quadrant, the number indicates the percentage of 
cells which were Annexin V positive and PI negative and represents the apoptotic 
cells. 
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4.2.3 Change of Mitochondrial Membrane Potential of Tryptanthrin-treated 
Murine Myelomonocytic Leukemia WEHI-3B JCS Cells 
To investigate if the intrinsic pathway is involved in apoptosis induced by 
tryptanthrin on WEHI-3B JCS cells, the change in the mitochondrial membrane 
potential (MMP) of tryptanthrin-treated WEHI-3B JCS cells was measured. In the 
intrinsic apoptotic pathway, apoptotic proteins are released from the intermembrane 
space of mitochondria into cytosol of the cells upon the depolarization of the MMP. 
A common dye JC-1 is often used to measure the MMP changes. The JC-1 dye 
accumulates in the mitochondria of healthy cells as a dimer, which gives red 
fluorescence. Upon the onset of apoptosis, the MMP changes and the JC-1 dye can 
no longer accumulate in the mitochondria and remain in the cytoplasm in a 
monomeric form which fluoresces green. The differential distribution of the red and 
green forms of the dye is easily analyzed and measured by flow cytometry. When an 
intrinsic pathway of apoptosis takes place, there is a shift of red to green fluorescence 
reflecting the MMP depolarization of the mitochondrial membrane. 
As shown in Fig 4 .3，a depolarization of MMP was detected in 
tryptanthrin-treated WEHI-3B JCS cells after 18 hours of incubation with 2.5 JLIM or 
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Fig. 4.3: Effect of tryptanthrin on the mitochondrial membrane depolarization 
in murine myelomonocytic leukemia WEHI-3B JCS cells. The leukemia 
WEH1-3B JCS cells (⑴彳 cells/ml) were incubated with (A) solvent control (0.05% 
DMSO), or (B) 1 (C) 2.5 |aM and (D) 5 ^iM of tryptanthrin for 18 hours at 37°C 
and then stained with the mitochondria-selective JC-1 dye. In the left quadrant, cells 
are with normal polarized mitochondrial membranes and emit red fluorescence. In 
the right quadrant the number indicates the percentage of cells which emits green 
fluorescence and represents cells with depolarized mitochondrial membrane. 
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4.2.4 Induction of Caspase Activities in Tryptanthrin-treated Murine 
Myelomonocytic Leukemia WEHI-3B JCS cells 
Apoptosis is a coordinated and often energy-dependent process that involves the 
activation of a group of cysteine proteases called "caspases" and a complex cascade 
of events that link the initiating stimuli to the final demise of the cell (Elmore, 2007). 
Caspases have proteolytic activity and are able to cleave proteins at aspartic acid 
residues. Once caspases are initially activated, an initiation of a protease cascade will 
be switched on in which one caspase can activate other caspases, thus amplifying the 
apoptotic signaling pathway and leads to an irreversible rapid commitment towards 
cell death. Until now, ten major caspases have been categorized into initiators 
(caspase-2,-8,-9,-10), effectors/executioners (caspase-3,-6,-7) and inflammatory 
caspases (caspase-1,-4,-5) (Cohen, 1997; Rai et al, 2005). There are also other 
caspases that have been identified which include caspase-11, caspase-12 caspase-13 
and caspase-14，and they are reported to carry out distinguished functions at different 
physiological states. The initiator caspase-8 from the extrinsic pathway and 
caspase-9 from the intrinsic pathway converged to trigger the cleavage of caspase-3 
and results in DNA fragmentation, degradation of cytoskeletal and nuclear proteins, 
cross-linking of proteins and resulting in apoptosis (Elmore, 2007). 
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In the present study, fluorogenic substrates specific to the caspases were used to 
investigate the activities of caspase-3, -8 and -9 in tryptanthrin-treated WEHI-3B JCS 
cells by fluorometric method. Tryptanthrin was found to be able to trigger the 
activation of caspase-3, -8 and -9 to different extent. Generally speaking, the effects 
of tryptanthrin on caspase-3, -8 and -9 activities were both time- and dose-dependent. 
The increase in caspase-3 activity was about 5 fold at 2.5 p-M and 15 fold at 5 ^iM 
(Fig. 4.4) that was much higher than that of caspase-8 (Fig. 4.5) and caspase-9 (Fig. 
4.6) which were found to be around 2 fold. Significant reduction of the fluorescence 
reading of the protein samples to background levels after addition of different 
caspase-specific inhibitors further confirmed the specificity of the corresponding 
caspase activity. 
151 
Chapter 4 Apoptosis 
^ 20 ： — 1 
•g • + inhibitor 48 hr 
S II - inhibitor 24 hr | 




j '�- 11 
• 1 
^ • i 
织 丄 • 
I 彳 J J 
Q ZZn^ H^ I ！ 
solvent control 1 2.5 5 
Tryptanthrin concentration ( | iM) 
Fig. 4.4: Effect of tryptanthrin on the induction of caspase-3 activity in murine 
myelomonocytic leukemia WEHI-3B JCS cells. The leukemia WEHI-3B JCS cells 
(104 cells/ml) were either incubated with solvent control (0.05% DMSO) or treated 
with different concentrations of tryptanthrin at 37°C for 24 and 48 hours. Protein 
samples were extracted and the specific substrate of caspase-3 (DEVD-AMC) was 
added with or without the caspase-3 specific inhibitor (DEVD-CHO). The 
fluorescence was then measured by the fluorescence plate reader (Cytofluo) using an 
excitation wavelength of 430 nm and an emission wavelength of 465 nm. The 
caspase-3 activity was proportional to the AMC released. The fluorescence units 
were quantified by comparing with the AMC standard curve. The caspase-3 activity 
of treated cells was compared to that of the solvent treated cells (control). 
(* p<0.005, ** p <0.001，significantly different from control) 
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Fig. 4.5: Effect of tryptanthrin on the induction of caspase-8 activity in murine 
myelomonocytic leukemia WEHI-3B JCS cells. The leukemia WEHI-3B JCS cells 
(104 cells/ml) were either incubated with solvent control (0.05% DMSO) or treated 
with different concentrations of tryptanthrin at 37°C for 24 and 48 hours. Protein 
samples were extracted and the specific substrate of caspase-8 ( lETD-AMC) was 
added with or without the caspase-8 specific inhibitor ( lETD-CHO). The 
fluorescence was then measured by the fluorescence plate reader (Cytofluo) using an 
excitation wavelength of 430 nm and an emission wavelength of 465 nm. The 
caspase-8 activity was proportional to the AMC released. The fluorescence units 
were quantified by comparing with the AMC standard curve. The caspase-8 activity 
of treated cells was compared to that of the solvent treated cells (control). 
(* p<0.005, ** p <0.001, significantly different from control) 
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Fig. 4.6: Effect of tryptanthrin on the induction of caspase-9 activity in murine 
myelomonocytic leukemia WEHI-3B JCS cells. The leukemia WEHI-3B JCS cells 
(104 cells/ml) were either incubated with solvent control (0.05% DMSO) or treated 
with different concentrations of tryptanthrin at 3 7 � C for 24 and 48 hours. Protein 
samples were extracted and the specific substrate of caspase-9 (LEHD-AFC) was 
added with or without caspase-9 specific inhibitor (LEHD-CHO). The fluorescence 
was then measured by the fluorescence plate reader (Cytofluo) using an excitation 
wavelength of 430 nm and an emission wavelength of 535 nm. The caspase-9 
activity was proportional to the AFC released. The fluorescence units were quantified 
by comparing with the AFC standard curve. The caspase-9 activity of treated cells 
was compared to that of the solvent treated cells (control). 
(* p<0.005, ** p <0.001，significantly different from control) 
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4.2.5 Induction of Reactive Oxygen Species in Tryptanthrin-treated Murine 
Myelomonocytic Leukemia WEHI-3B JCS cells 
The mitochondria's role in the regulation of cell death is well established. The 
generation of reactive oxygen species (ROS) and the release of proteins from the 
intermembrane space of mitochondria lead to the activation of different modes of cell 
death (Orrenius et al, 2007). 
The mitochondrial respiratory chain has long been recognized as an effective 
source of ROS, originating from the disproportionation of superoxide anions formed 
mainly at the levels of Complex I and III of the respiratory chain. The ROS formed 
causes cell death by a few possible mechanisms. The most common proposed 
mechanism is that ROS leads to lipid peroxidation of mitochondrial membrane which 
facilitates the release of cytochrome C and then in turn activates the caspase cascade 
(Simon et al, 2000; Orrenius et al, 2007). ROS might also damage the 
mitochondrial DNA resulting in the loss of electron transport, mitochondrial 
membrane potential, and ATP generation and eventually leads to cell death (Orrenius 
et al, 2007). Moreover, it was also suggested that the oxidative stress may interfere 
with the calcium ion homeostasis which contributes to mitochondrial mediated 
cellular damage and hence cell death (Haworth and Hunter, 1979). 
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The effect of the tryptanthrin on the induction of ROS in WEHI-3B JCS cells 
was investigated in this study. It was found that tryptanthrin was able to trigger the 
production of ROS in a dose-dependent manner after 48 hours of tryptanthrin 
treatment (Fig. 4.7). With the preincubation of the WEHI-3B JCS cells with an 
antioxidant enzyme, superoxide dismutase (SOD), it was found that the percentage of 
apoptotic cells induced by tryptanthrin was partially decreased (Fig. 4.8). 
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Fig. 4.7: Effect of tryptanthrin on the induction of R O S in murine 
myelomonocytic leukemia WEHI-3B JCS cells. The leukemia WEHI-3B JCS cells 
(104 cells/ml) were either incubated with solvent control (0.05% DMSO) or treated 
with different concentrations of tryptanthrin at 3 7 � C for 48 hours. The induced cells 
were then cultured with dichlorodihydrofluorescein diacetate (DCFDA) for one hour, 
and the fluorescence was measured by a spectrofluorometer. The fluorescence in the 
tryptanthrin-treated cells was compared to the solvent-treated cells (control) in each 
case. (*p<0.05, **p<0.005, significant different from control) 
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Fig 4.8: Effect of superoxide dismutase on tryptanthrin-induced apoptosis in 
murine myelomonocytic leukemia WEHI-3B JCS cells. The leukemia WEHI-3B 
JCS cells (104 cells/ml) were preincubated with 200 units/ml SOD for 6 hours (the 
right column) and then cultured with solvent control (0.05% DMSO), or with (A) 1 
laM (B) 1.5 fiM (C) 2 ^M and (D) 2.5 ^iM of tryptanthrin for 48 hours at 37�C and 
then stained with the GFP-conjugated Annexin V and propidium iodide (PI) dye. At 
the top right quadrant, cells with both Annexin V and PI positive signals are necrotic 
cells. At the bottom right quadrant, the number indicates the percentage of cells with 
Annexin V positive and PI negative signals and represents the apoptotic cells. 
I 
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4.2.6 Expression of Bcl-2 Family Proteins in Tryptanthrin-treated Murine 
Myelomonocytic Leukemia WEHI-3B JCS Cells 
Bcl-2 family proteins, which have either pro- or anti-apoptotic activities, have 
been studied intensively for the past decade owing to their importance in the 
regulation of apoptosis, tumorigenesis and cellular responses to anti-cancer therapy 
(Youle and Strasser, 2008). In mammals, there are at least 12 core Bcl-2 family 
proteins, including Bcl-2 itself and proteins that have structural similarity to Bcl-2. 
Bcl-2 family members can be characterized into 3 groups. One group inhibits 
apoptosis, they are B c l - 2 , BC1-XL, Bcl-w, Mcl-l , BC1-B (BC1-2LIO) and Al ( B C 1 - 2 A I ) , 
whereas a second group promotes apoptosis include Bax, Bak and Bok. A third 
group of BH3-only proteins (Bad, Bik, Bid, Hrk (death protein-5 (DP5)), Bim (Bod), 
Bmf, NOXA and PUMA) have a conserved BH3 domain that can bind and regulate 
the anti-apoptotic Bcl-2 proteins to promote apoptosis (Youle and Strasser, 2008). It 
appears that the pro-apoptotic family members Bax and Bak are crucial for inducing 
permeabilization of the outer mitochondrial membrane (OMM) and the subsequent 
release of apoptogenic molecules (such as cytochrome C and DIABLO (SMAC)) 
which leads to caspase activation. The anti-apoptotic family members, such as Bcl-2 
and BC1-XL，inhibit Bax and Bak by forming heterodimers which then prevent the 
release of mitochondrial proteins (Jiang and Wang, 2004). Recent evidence indicates 
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that BH3-only proteins de-repress Bax and Bak by direct binding and inhibition of 
Bcl-2 and other anti-apoptotic family members (Willis et al., 2007). By contrast, an 
opposing model postulates direct activation of Bax and Bak by some BH3-only 
proteins (specifically Bim, tBid and PUMA) (Youle, 2007). 
In this study, the expression of Bcl-2 family proteins in WEHI-3B JCS cells 
after tryptanthrin treatment was investigated. As shown in Fig 4.9, it was found that 
after 48 hours of exposure to tryptanthrin, the pro-apoptotic Bax and Bid protein 
expressions were increased by 3 to 4 folds, while there were 50% and 40% decrease 
in the expression of the anti-apoptotic proteins BC1-XL and Bcl-2 respectively. 
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Fig 4.9: Effects of tryptanthrin on the expression of Bcl-2 family proteins in the 
murine myelomonocytic leukemia WEHI-3B JCS cells after 48 hour treatment. 
The leukemia WEHI-3B JCS cells (10^ cells /ml) were either incubated with solvent 
control (0.05% DMSO), or with three different concentrations of tryptanthrin (1 \xM, 
2.5 )LIM, 5 )J,M) and at 3 7 ° C for 4 8 hours. The proteins of each sample were extracted 
and analyzed by Western blot as described in Chapter 2. The extracted protein (20 fig 
per sample) were electrophoresed on a polyacrylamide gel and then transferred onto 
PVDF membrane for probing with specific primary antibodies followed by 
horseradish peroxidase-conjugated secondary antibody. Then ECL detection assay 
was carried out in order to generate visible signals by exposing the membrane to 
X-ray films. The relative intensity of each protein band was normalized with respect 
to (3-actin and compared with the corresponding solvent control. The results shown 
are representative of three independent experiments with similar results. 
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4.2.7 Effects of Tryptanthrin on the mRNA Expression of Bcl-2 Family Proteins 
in the Murine Myelomonocytic Leukemia WEHI-3B JCS Cells 
Since we have shown that tryptanthrin was able to decrease the protein 
expression of ant-apoptotic Bcl-2 and BC1-XL and increase that of pro-apoptotic Bax 
and Bid, it would be of interest to know if their mRNA expressions were also 
modulated by tryptanthrin. The mRNA expressions of these Bcl-2 proteins were 
examined and quantified using the SYBR® Green QPCR. SYBR® Green is a DNA 
stain which emits fluorescence when it binds to DNA. There will be more bound 
SYBR® Green resulting from more DNA amplified by the PCR process which hence 
emits strong fluorescence. The intensity of the fluorescence will be then detected and 
recorded by the QPCR machine, in our case, the Applied Biosystems Fast Real Time 
PCR system was employed. In the present study, after treating the WEHI-3B JCS 
cells with different concentrations of tryptanthrin for 24 hours, the total mRNA was 
isolated and the cDNA synthesized by reverse transcription was then used as the 
template for the SYBR® Green QPCR analysis. It can be seen that, upon tryptanthrin 
treatment, the expression of Bcl-2 and BC1-XL mRNA decreased significantly 
especially at higher concentrations (2.5 |AM and 5 )liM) of tryptanthrin (Fig. 4.10). On 
the other hand, the mRNA expressions of Bax and Bid were markedly increased after 
tryptanthrin treatment at all concentrations tested (Fig. 4.11). These results are in line 
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with the corresponding findings for their protein expression. 
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Fig 4.10: Effects of tryptanthrin on the mRNA expression of anti-apoptotic 
Bcl-2 family proteins Bcl-2 and BC1-XL in the murine myelomonocytic leukemia 
WEHI-3B JCS cells after 24 hour treatment. The leukemia WEHI-3B JCS cells 
(104 cells /ml) were either incubated with solvent control (0.05% DMSO) or with 
three different concentrations of tryptanthrin (1 \xM, 2.5 ^iM, 5 |j,M) at 37°C for 24 
hours. After treatment, total mRNA was isolated by TRIZOL method, followed by 
reverse transcription to produce cDNA. Brilliant SYBR® Green QPCR analysis for 
Bcl-2 and BC1-XL was then performed according to the manufacturer's instruction. 
The data were analyzed by the method as described by Livak et al. (2001). 
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Fig 4.11: Effects of tryptanthrin on the mRNA expression of pro-apoptotic Bcl-2 
family proteins Bax and Bid in the murine myelomonocytic leukemia WEHI-3B 
JCS cells after 24 hour treatment. The leukemia WEHI-3B JCS cells (lO^ cells /ml) 
were either incubated with solvent control (0.05% DMSO) or with three different 
concentrations of tryptanthrin (1 |iM, 2.5 |j,M, 5 p-M) at 37°C for 24 hours. After 
treatment, total mRNA was isolated by TRIZOL method, followed by reverse 
transcription to produce cDNA. Brilliant SYBR® Green QPCR analysis for Bax and 
Bid was then performed according to the manufacturer's instruction. The data were 
analyzed by the method as described by Livak et al. (2001). 
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4.2.8 Expression of Fas and Fas Ligand Proteins in Tryptanthrin-treated 
Murine Myelomonocytic Leukemia WEHI-3B JCS cells 
The extrinsic signaling pathway that initiates apoptosis involves transmembrane 
receptor-mediated interactions. These involve death receptors that are members of 
the tumor necrosis factor (TNF) receptor gene superfamily (Locksley et al, 2001). 
To date, the best-characterized ligands and corresponding death receptors 
include FasL/Fas, T N F - a / T N F R l , Apo-3L/DR3, Apo-2L/DR4 and Apo-2L/DR5 
(Chicheportiche et al, 1997; Ashkenazi et al., 1998; Peter and Kramer, 1998; 
Suliman et al., 2001; Rubio-Moscardo et al., 2005). The sequences of events that 
define the extrinsic phase of apoptosis are best characterized with the FasL/Fas and 
TNF-a/TNFRl models. 
Since apoptosis is triggered by many different and complicated mechanisms, 
apart from the intrinsic pathway, it is also of great interest to know if the extrinsic 
pathway is involved. In our present study, the effects of tryptanthrin on the protein 
expressions of Fas and its ligand, FasL in WEHI-3B JCS cells were examined. As 
clearly shown in Fig 4.12, the Fas expression remained more or less the same as that 
found in WEHI-3B JCS cells treated with solvent, while there was a significant 
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dose-dependent increase in the expression of FasL. 
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Fig 4.12: Effects of tryptanthrin on the expressions of Fas and Fas ligand 
proteins in the murine myelomonocytic leukemia WEHI-3B JCS cells after 48 
hour treatment. The leukemia WEHI-3B JCS cells (10"* cells /ml) were either 
incubated with solvent control (0.05% DMSO), or with three different concentrations 
of tryptanthrin (1 |j.M, 2.5 |j,M, 5 jiM) at 37°C for 48 hours. The proteins of each 
sample were extracted and analyzed by Western blot as described in Chapter 2. The 
extracted proteins (20 |ig per sample) were electrophoresed on a polyacrylamide gel 
and then transferred onto PVDF membrane for probing with specific primary 
antibodies followed by horseradish peroxidase-conjugated secondary antibody. Then 
ECL detection assay was carried out in order to generate visible signals by exposing 
the membrane to X-ray films. The relative intensity of each protein band was 
normalized with respect to p-actin and compared with the corresponding solvent 
control. The results shown are one of the three representative results of three 
independent experiments. 
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4.2.9 Expression of Pro-Apoptotic Proteins in Tryptanthrin-treated Murine 
Myelomonocytic Leukemia WEHI-3B JCS cells 
The mitochondrial membrane depolarization and the formation of the 
mitochondrial permeability transition pore triggered by the intrinsic pathway finally 
lead to the release of two main groups of normally sequestered pro-apoptotic proteins 
from the intermembrane space into the cytosol (Saelens et al., 2004). The first group 
consists of cytochrome C, SMAC/DIABLO, and the serine protease HtrA2/0mi (Du 
et al.’ 2000; van Loo et al, 2002; Garrido et al.’ 2006). The second group of 
pro-apoptotic proteins are AIF, endonuclease G and CAD, but this is a late event that 
occurs after the cell has committed to die. AIF translocates to the nucleus and causes 
DNA fragmentation into �50—300 kb pieces and condensation of peripheral nuclear 
chromatin (Joza et al” 2001). AIF and endonuclease G both function in a 
caspase-independent manner (Elmore, 2007). 
As shown in Fig. 4.13, the expression of pro-caspase-3 in WEHI-3B JCS cells 
was found to be decreased after 48 hours of exposure to tryptanthrin in a 
dose-dependent manner. The cleavage of pro-caspase-3 could explain for the 
increase of caspase activity as shown previously. Tryptanthrin treatment of 
WEHI-3B JCS cells also resulted in an increase in the expression of cytochrome C in 
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the cytosol in a dose-dependent manner (Fig. 4.13), suggesting that cytochrome C 
might be translocated from the mitochondria to cytosol. Moreover, AIF which 
functions in a caspase-independent manner was also observed to be translocated from 
mitochondria to cytosol (Fig 4.14). 
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Fig 4.13: Effects of tryptanthrin on the expression of pro-apoptotic proteins in 
the murine myelomonocytic leukemia WEHI-3B JCS cells after 24/48 hour 
treatment. The leukemia WEHI-3B JCS cells (10"^  cells /ml) were either incubated 
with solvent control (0.05% DMSO), or with three different concentrations of 
tryptanthrin (1 \xM, 2.5 juM, 5 ^iM) at 37°C for 24 hours (cytochrome C and AIF) and 
48 hours (pro-caspase-3) respectively. The proteins of each sample were extracted 
and analyzed by Western blot as described in Chapter 2. The extracted proteins (20 
fig per sample) were electrophoresed on a polyacrylamide gel and then transferred 
onto PVDF membrane for probing with specific primary antibodies followed by 
horseradish peroxidase-conjugated secondary antibody. Then ECL detection assay 
was carried out in order to generate visible signals by exposing the membrane to 
X-ray films. The relative intensity of each protein band was normalized with respect 
to P-actin and compared with the corresponding solvent control. The results shown 
are one of representative of two independent experiments with similar results. 
172 
Chapter 4 Apoptosis 
4.3 Discussion 
Chemical-induced cell death can be mediated by either necrosis or apoptosis 
(Wyllie, 1997; Renvoize et al., 1998). Tryptanthrin was shown to induce apoptosis in 
the human myeloid leukemia U-937 and HL-60 cells by enhancing Fas-induced 
apoptosis and increasing caspase-3 activity (Kimoto et al, 2001). In this Chapter, the 
apoptosis-inducing effect of tryptanthrin on the murine myeloid leukemia WEHI-3B 
JCS cells and its underlying mechanisms were investigated. Fragmentation of DNA 
by endonuclease is an indicator of cellular apoptosis (Collins et al, 1997). Gel 
electrophoresis showed that tryptanthrin induced DNA fragmentation of WEHI-3B 
JCS cells in a time- and dose-dependent manner. The DNA laddering was first 
observed after 48 hours of treatment with tryptanthrin. After 72 hours of incubation, 
DNA fragmentation was found in all tryptanthrin-treated WEHI-3B JCS cells at all 
the concentrations tested. Annexin V, as a calcium ion dependent 
phospholipid-binding protein with high affinity for phosphatidylserine (PS), is 
frequently used for detection of the apoptotic cells with exposed PS (Vermes et al.， 
1995). After 48 hours of treatment with tryptanthrin, there was an elevated 
percentage of cells stained by Annexin V. All these data indicate that tryptanthrin can 
induce DNA fragmentation in WEHI-3B JCS cells. 
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There are many different mechanisms which eventually lead to the same way of 
death named apoptosis. The mechanisms used by tryptanthrin were hence 
investigated. Mitochondrial dynamics are important factors contributing to apoptotic 
pathway by stimulation of caspase and DNA fragmentation (Heath-Engel and Shore, 
2006; Kim et al., 2006). A correlation between the depolarization of mitochondria 
and DNA fragmentation has been reported previously (Marchetti et al., 1996; Inai et 
al., 1997). Mitochondria are also the major source to modulate cellular calcium 
homeostasis, which is critical for cellular signaling and chemical cytotoxicity (Trump 
and Beresesky, 1987; Heath-Engel and Shore, 2006; Kim et al, 2006). Exposure of 
WEHI-3B JCS cells to tryptanthrin led to mitochondrial membrane depolarization. 
Similarly, mitochondrial depolarization as well as swelling and destruction of 
mitochondria were also observed in U-937 and HL-60 cells treated with tryptanthrin 
(Kimoto et al., 2001). 
Caspases are widely expressed in an inactive pro-enzyme form in most cells and 
once activated can often activate other pro-caspases, allowing initiation of a protease 
cascade in which one caspase can activate other caspases, thus amplifying the 
apoptotic signaling pathway and leads to rapid cell death (Elmore, 2007). Caspase-3 
is considered to be the most important of the executioner caspases and is activated by 
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any of the initiator caspases (caspase-8, caspase-9, or caspase-10). In the present 
study of the caspase activities, it was shown that tryptanthrin significantly increased 
the activities of caspase-3, -8 and -9. The percentage increased in caspase-3 activity 
was much higher than that of caspase-8 and -9 due to the amplification of the enzyme 
cascade and caspase-3 being the final executioner. Since caspase-8 and -9 are 
regarded as the initiators of the intrinsic and extrinsic pathways of apoptosis 
respectively, so our results suggest that the apoptosis induced by tryptanthrin may 
involve both extrinsic and intrinsic pathways. 
The intrinsic pathway is mainly controlled and regulated by the Bcl-2 family of 
proteins (Cory and Adams, 2002). To date, a total of 25 genes have been identified in 
the Bcl-2 family. Some examples of the anti-apoptotic proteins include Bcl-2, Bcl-x, 
BC1-XL, Bcl-xs, and Bcl-w. On the other hand, some examples of the pro-apoptotic 
proteins are BCI-B, Bax, Bak, Bid, Bad, Bim and Bik. These proteins have special 
significance since they can either trigger cell apoptosis or abort the process. It is 
thought that Bcl-2 family proteins function mainly by controlling the mitochondrial 
membrane permeability and hence regulating the release of cytochrome C which 
eventually triggers the activation of a series of caspase cascade (Elmore, 2007). 
Upon activation, Bcl-2 proteins are localized at the outer mitochondrial membrane, 
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nuclear envelope and endoplasmic reticulum with their N-terminal towards the 
cytosol (Burlacu, 2003) and their C-terminal enables them to insert into the 
intracellular membrane (Nguyen et al., 1993). 
In this study, an increase in the expression of pro-apoptotic Bax and Bid 
proteins and a decrease in the expression of the anti-apoptotic proteins BC1-XL and 
Bcl-2 were observed using Western blotting. The results of Brilliant SYBR® Green 
QPCR analysis also showed a similar trend of changes in the expression of these 4 
proteins at the transcriptional level. 
Activation of the pro-apoptotic molecule Bax involves both translocation and 
dimerization. Normally Bax proteins are present in a monomeric form in the cytosol. 
Once stimulated with an apoptotic signal, the conformation of Bax proteins is altered 
which then induces the dimerization of Bax and translocation from cytosol to 
mitochondria where it inserts into the OMM as an integral membrane protein, using 
its C-terminal membrane anchor (Wolter et al, 1997) perhaps with organelle 
targeting specified by defined regions in the N terminus (Cartron et al, 2002). This 
translocation step of Bax, although reversible in certain situations, usually correlates 
closely with the irreversible commitment of cells to die and to the cytochrome C 
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release. 
Bid is a BH3-only molecule which was normally found in the cytoplasm in its 
inactive form. It is believed that upon cleavage, the original buried hydrophobic 
surface containing the amphipathic helix and two hydrophobic cores would be 
exposed outside and there will be a change in the net charge from -13 for Bid to -4 
for tBid (Darnell et al., 1990) which potentially forms a membrane channel in 
mitochondrial membrane which is negatively charged. Apart from this, it has been 
proposed that BH3 domain of Bid could bind to Bax generating a conformational 
change that enables Bax to target and integrate into mitochondrial membrane, 
causing mitochondrial dysfunction and apoptosis (Desagher et al., 1999). However, 
other models in which BH3-only proteins directly activate Bax and Bak are called 
into question owing to results from Bim/Bid double knockout mice and their cell 
lines, which show that these putative direct activators of Bax and Bak are not 
required for many apoptotic pathways (Willis et al, 2007). Thus, known BH3-only 
proteins appear to induce apoptosis primarily by inhibiting anti-apoptotic Bcl-2 
family members, thereby liberating Bax and Bak to cause MPT pore and activation 
of the caspase cascade. The precise biochemical mechanisms that lead to the 
activation of Bax and Bak remain largely unknown (Youle and Strasser, 2007). 
177 
Chapter 4 Apoptosis 
It was reported that Bcl-2 and BC1-XL inhibit apoptotic death primarily by 
controlling the activation of caspase proteases (Newmeyer et al, 2000). An 
additional protein designated "Aven" appears to bind both BC1-XL and adaptor protein 
apoptotic protease-activation factor-1 (Apaf-1), thereby preventing activation of 
pro-caspase-9 (Chau et al., 2000). It has also been shown that Bcl-2 and BC1-XL may 
bind to Bax and Bak after they are inserted into membranes, and this may prevent the 
formation of Bax or Bak oligomers and inhibit chain elongation (Ruffolo and Shore, 
2003). One report concluded that only the form of Bcl-2 that is found in the early 
stages of apoptosis could bind to Bax and Bak and thereby inhibits Bax or Bak 
oligomerization to promote cell survival (Kim et al., 2004). However, this would 
yield the counter-intuitive situation in which BH3-only proteins could inhibit 
apoptosis by promoting a change in the conformation of Bcl-2 so that it more 
actively inhibits Bax and Bak (Wilson-Annan, 2003). 
Intrinsic pathway is further subdivided into two main pathways: 
caspase-dependent and caspase-independent. The formation of MPT pore leads to the 
release of two main groups of normally sequestered pro-apoptotic proteins from the 
intermembrane space into the cytosol (Saelens et al., 2004). The first group consists 
of cytochrome C，SMAC/DIABLO, and HtrA2/0mi (Cai et al, 1998; Du et al, 2000; 
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Loo et al, 2002; Garrido et al, 2005). These proteins activate the caspase-dependent 
mitochondrial pathway. Fig 4.13 shows that there was an increase of cytochrome C 
in the cytosol in WEHI-3B JCS cells after treatment with tryptanthrin. Cytochrome C 
binds and activates Apaf-1 as well as pro-caspase-9, forming an "apoptosome" 
(Chinnaiyan, 1999; Hill et al., 2004), which in turn activates the inactive 
pro-caspase-3 into active caspase-3 and hence activates the CAD to cleave the 
chromatins (Jiang and Wang, 2004) and eventually leads to apoptosis. 
SMAC/DIABLO and HtrA2/0mi are reported to promote apoptosis by inhibiting 
lAP (inhibitors of apoptosis proteins) activity (van Loo et al, 2002; Schimmer, 
2004). 
The second group includes AIF and endonuclease G. Fig 4.13 shows a 
translocation of AIF from the mitochondria to cytosol. AIF subsequently translocates 
to the nucleus and causes DNA fragmentation and condensation of peripheral nuclear 
chromatin (Joza et al., 2001). Endonuclease G also translocates to the nucleus where 
it cleaves nuclear chromatin to produce oligonucleosomal DNA fragments (Li et al, 
2001). Both of them function in a caspase-independent manner. 
For the activation of the extrinsic pathway, the best-characterized ligands and 
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corresponding death receptors include FasL/Fas, TNF-a/TNFRl, Apo-3L/DR3, 
Apo-2L/DR4 and Apo-2L/DR5 (Chicheportiche et al, 1997; Ashkenazi et al, 1998; 
Peter and Kramer, 1998; Suliman et al, 2001; Rubio-Moscardo et al,’ 2005). In this 
study, it was shown that there was an increase in the protein expression of FasL in 
tryptanthrin-treated WEHI-3B JCS cells. Up-regulation of FasL often occurs in 
tumor cells following chemotherapy and may play a key role in immune evasion by 
eliminating infiltrating lymphocytes (Strand et al, 1996; Pinkoski et al.’ 2000). 
Trimerisation of Fas receptor happens immediately after the ligation of Fas receptor 
with FasL. These microaggregates of Fas receptor formed on the cell surface 
independent of caspase activity (Algeciras-Schimnich, et al., 2002) have been 
demonstrated to be the prerequisite for Fas-Associated Death Domain (FADD) 
recruitment and effective Death-Inducing Signaling Complex (DISC) formation 
(Schneider et aL, 1998). After FADD is recruited to and bound to the intracellular 
death domain of Fas receptor in response to receptor trimerisation, pro-caspase-8 and 
pro-caspase-10 are recruited and bound to FADD which induce autocleavage and 
activation of caspase-8 and caspase-10. Activated caspase-8 then cleaves and 
activates downstream effectors caspase-3 and caspase-7. In fact, caspase-8 also 
bridges the cross talk between the extrinsic and intrinsic pathways. Cleavage of the 
Bcl-2 family member BID by caspase-8 produces the pro-apoptotic tBID fragment 
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that induces cytochrome C release from mitochondria and caspase-9 activation 
(Wang et al, 1996; Gross et al., 1999). Expression of anti-apoptotic Bcl-2 family 
members can regulate the sensitivity of mitochondria to tBID and in turn the 
sensitivity of cells to Fas-mediated apoptosis (Scaffidi et aL, 1999). 
Apart from the above mentioned pathways, apoptosis can also be caused by the 
intrinsic oxidative stress. In our present study, the data show that exposure of 
WEHI-3B JCS cells to tryptanthrin could increase the ROS production. Addition of 
SOD to the tryptanthrin- treated WEHI-3B JCS cells partially reduced the number of 
cells undergoing apoptosis as demonstrated by Annexin-V and PI staining. SOD is 
the key enzyme required to remove O2" by converting it to H2O2, which is further 
eliminated by catalase and peroxidases (Fridovich, 1995). It is therefore suspected 
that the accumulation of tryptanthrin-induced ROS may be due to the inhibition of 
intracellular antioxidant defence system. Dissociation of cytochrome C from its 
binding to the outer surface of the inner membrane is facilitated by cardiolipin 
oxidation (caused by ROS) has received convincing support from several 
experimental studies, whereas the role of oxidized cardiolipin in outer membrane 
permeabilization and the release of pro-apoptotic proteins that are not bound to the 
inner membrane (e.g., SMAC/DIABLO) are less clear (Orrenius et al.’ 2007). 
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Nevertheless, lipid peroxidation of mitochondria and the interference of the calcium 
ion homeostasis caused by ROS could be another reason which triggers apoptosis in 
a synergistic manner with the intrinsic and extrinsic pathways of apoptosis in 
tryptanthrin-treated WEHI-3B JCS cells. To sum up, the possible mechanisms by 
which tryptanthrin can induce apoptosis in the leukemia WEHI-3B JCS cells are 
illustrated in Fig. 4.14. 
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Fig 4.14: Proposed mechanisms of apoptosis in the murine myelomonocytic 
leukemia JCS cells induced by tryptanthrin. Tryptanthrin induced apoptosis in the 
JCS cells by increasing the gene and protein expressions of apoptotic Bcl-2 family 
proteins Bax and Bid while decreasing that of Bcl-2 and BC1-XL. It also enhanced the 
protein expression of FasL (CD95L) and induced the ROS production. All these may 
cause the formation of mitochondrial permeability transition (MPT) pores which lead 
to a release of cytochrome C and AIF from the mitochondria, eventually causing the 
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Chapter 5 Differentiation 
5.1 Introduction 
Chemotherapy using cytotoxic agents has been harnessed for ages in curing 
leukemia, but other strategies have been explored. Leukemia is caused by the 
uncoupling of proliferation and differentiation in hematopoietic progenitor cells, 
resulting in neoplastic proliferation of these cells with incapability to differentiate 
(Leung et al.’ 2005). Differentiation therapy in which the immature leukemia cells 
are induced to attain a more mature phenotype in response to appropriate stimuli has 
been advocated to be a possible alternative for treatment of leukemia. The therapy 
was said to be more effective against myeloid leukemia, upon the induction of 
differentiation, the immature neoplastic cells simply loss the capacity to proliferate. 
All-trans-retinoic acid (ATRA) and arsenic trioxide (AS2O3) have been clearly shown 
to be effective in the treatment of APL which created the possibility that selective 
induction of differentiation and apoptosis is a new strategy in treating leukemia 
(Wang, 2003). Low doses of cytotoxic agents are known to be potent inducers of 
differentiation in vitro (Lin et al, 2007), that is why low closes of 6 mercaptopurine 
and methotrexate utilized in the ALL maintenance therapy are suspected to exert an 
anti-leukemic effect through induction of differentiation of ALL progenitors (Lin et 
al, 2007). 
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Tryptanthrin is a naturally occurring alkaloid found in medicinal Indigo plants 
such as Polygonum tinctorium and Isatis tinctoria. It has been reported to have 
cytocidal activity towards a variety of human leukemia cells and cancer cells in vitro 
(Kimoto et al, 2001; Koya-Miyata et al, 2001). Previous work has shown that low 
concentrations of tryptanthrin could enhance the expression of CD markers on 
human monocytic (U-397) and promyelocytic (HL-60) leukemia cells and induced 
their differentiation to monocyte/macrophage-like cells (Kimoto et aL, 2001). 
However, the detailed mechanism behind remains poorly understood. In Chapter 3 
and 4, tryptanthrin was found to exert potent anti-proliferative and 
apoptosis-inducing activities on the murine myelomonocytic leukemia WEHI-3B 
JCS cells, however, whether it can trigger myeloid leukemia cell differentiation has 
not been investigated. In this chapter, attempts had been made to study the 
differentiation-inducing effect of tryptanthrin. Morphological changes on 
tryptanthrin-treated WEHI-3B JCS cells were studied by using cytospin technique 
and Hemacolor staining. Then the changes in the cell size and the granularity were 
also analyzed by flow cytometry. Functional maturation of the leukemia cells was 
evaluated by measuring the NBT-reducing activity of the cells after tryptanthrin 
treatment. 
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5.2 Results 
5.2.1 Morphological Studies on Tryptanthrin-treated Murine 
Myelomonocytic Leukemia WEHI-3B JCS Cells 
The morphology of WEHI-3B JCS cells was examined after treatment with 
different concentrations of tryptanthrin for 48 hours. The leukemia WEHI-3B JCS 
cells were then centrifuged onto microscope slides and stained with Hemacolor 
solution. As shown in Fig. 5.1, tryptanthrin induced morphological changes in the 
WEHI-3B JCS cells in a dose-dependent manner. The higher the concentration 
used, the more obvious the changes. It was found that the cytoplasm versus nucleus 
ratio became larger and vacuolation was observed in the tryptanthrin-treated 
WEHI-3B JCS cells. These results suggest that tryptanthrin can induce 
morphological differentiation of the leukemia WEHI-3B JCS cells. The stained 
cells were further scored as the immature blast cells, intermediate stage cells or 
mature macrophage-like cells as described previously (Chan et al.’ 1997). It can be 
seen that the percentage of differentiated cells (which include the intermediate 
stage cells and mature macrophage-like cells) was significantly higher in the 
tryptanthrin-treated groups (8.97% - 19.2%) when compared to the solvent-treated 
group (2.64%) (Table 5.1). 
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Fig. 5.1 Morphology of the tryptanthrin-treated murine myelomonocytic 
leukemia WEHI-3B JCS cells. The leukemia WEHI-3B JCS cells (2500 cells/ml) 
were either incubated with (A) solvent control (0.05% DMSO) or with (B) 1 ^M (C) 
2.5 i^ M and (D) 5 f^ M of tryptanthrin for 48 hours. Treated cells (5 x lO* cells) were 
cytocentrifuged onto microscopic glass slides and stained with Hemacolor solutions. 
(Magnification: 400X; scale bars shown represent 50 |am) 
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Table 5.1: Morphological identification of tryptanthrin-treated WEHI-3B JCS 
cells at various stages of differentiation 
Treatment of cells Percentage of different cell types 
with Immature blast cells Intermediate stage Macrophage-like 
cells cells 
Solvent control 97.4 士 0.69 2.64 土 0.69 0 
(0.5%, v/v DMSO) 
Tryptanthrin 
1 |liM 78.3 士 4.4 7.9 ± 3 . 2 1.07 士 0.6 
2.5 nM 71.8 士 6.1 9.6 ± 3 . 4 3.5 ± 1 . 8 
5 |iM 64.0 土 0.6 11.9± 1.5 7.3 ± 1.9 
The leukemia WEHI-3B JCS cells (2,500 cells/ml) were treated with either solvent 
control or various concentrations of tryptanthrin. The morphology of the cells was 
identified by staining the cells with Hemacolor staining solution set. The stained cells 
were scored as the immature blast cells (myeloblasts), intermediate stage cells 
(myelocytes and promonocyte-like cells) or macrophage-like cells as described by 
Chan et al, (1997). At least 200 cells were counted for each determination and 
expressed in percentage of different cell types. 
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5.2.2 Effects of Tryptanthrin on the Cell Size and Granularity of the Murine 
Myelomonocytic Leukemia WEHI-3B JCS Cells 
After observing the morphological changes in the WEHI-3B JCS cells 
treated with tryptanthrin, analysis of the cell size and granularity was also 
performed using flow cytometry. Two parameters were measured, including the 
forward scatter (FSC) on the X-axis which represents the cell size and the side 
scatter (SSC) on the Y-axis which represents the granularity of cells. As shown in 
Fig. 5.2, there were dose-dependent increases in the size (FSC) and the internal 
complexity (SSC) of the WEHI-3B JCS cells treated with tryptanthrin. All these 
characteristics are well-known indicators of cell differentiation. The results further 
support that tryptanthrin can induce differentiation in the WEHI-3B JCS cells. 
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Fig. 5.2 Effects of tryptanthrin on the cell size and granularity of the murine 
myelomonocytic leukemia WEHI-3B JCS cells. The leukemia WEHI-3B JCS 
cells (104 cells/ml) were either incubated with (A) solvent control (0.05% DMSO), or 
(B) 0.5 |LIM (C) 1.5 |LIM and (D) 5 \ iU of tryptanthrin for 48 hours. Treated cells (10^ 
cells) were fixed with paraformaldehyde and were analyzed for FSC and SSC by 
using the FACSCanto flow cytometer. 
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5.2.3 Effect of Tryptanthrin on the Induction of NBT-reducing Activity in the 
Murine Myelomonocytic Leukemia WEHI-3B JCS Cells 
By morphological and flow cytometric analyses of the tryptanthrin-treated 
WEH1-3B JCS cells, tryptanthrin seems to be able to induce cell differentiation. 
However, it is of equal importance to test if the differentiated WEHI-3B JCS cells 
induced by tryptanthrin show any functional characteristics of normal macrophages. 
In normal phagocytes, reactive oxygen intermediates (ROI) are activated by 
phagocytosis. It is well documented that differentiated leukemia cells as well as 
normal phagocytic cells will produce superoxide anions when stimulated with the 
tumor promoter phorbol 12-myristate 13-acetate (PMA) (Newburger et al” 1979). 
Nitroblue tetrazolium (NBT) is dye that has been commonly used to detect indirectly 
the generation of superoxide anions by macrophages and granulocytes (Mollinedo et 
al.’ 1998). Superoxide anions can reduce the water soluble yellow NBT dye to 
produce the blue black cell-associated nitroblue diformazan deposits. Therefore, 
morphological assessment of drug-treated cells shows a good correlation between 
NBT reduction and the number of cells that undergo monocytic or granulocytic 
differentiation. In the present study, WEHI-3B JCS cells were treated with 
tryptanthrin for 48 hours. NBT-PMA solution was added and the mixture was 
- 1 9 1 -
Chapter 5 Differentiation 
incubated at 37°C in dark for 4 hours. Treated cells were then cytocentrifuged onto 
microscopic glass slides and then stained with safranin (Fig. 5.3) As shown in Table 
5.2, treatment of WEHI-3B JCS cells with 2.5 juM tryptanthrin significantly 
increased the percentage of cells with NBT-reducing activity from 0% in the solvent 
control to 15.3% in the tryptanthrin-treated group, indicating that tryptanthrin can 
induce WEHI-3B JCS cells to undergo differentiation. 
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Fig. 5.3 Effect of tryptanthrin on the induction of NBT-reducing activity in the 
murine myelomonocytic leukemia WEHI-3B JCS cells. The leukemia WEHI-3B 
JCS cells (2500 cells/ml) were either incubated with (A) solvent control (0.05% 
DMSO), or (B) 1 [iM, and (C) 2.5 |aM of tryptanthrin at 3 7 � C for 48 hours. Then, 100 
1^ 1 NBT-PMA solution was added and incubated at 3TC in dark for another 4 hours. 
Treated cells (5 x 10^ cells) were cytocentrifuged onto microscopic glass slides and 
stained with safranin for 30 seconds and washed with running water. (Magnification: 
400X; scale bars shown represent 50 |am) 
Cells showing positive results were pointed with arrow. 
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Table 5.2: Induction of NBT-reducing activity in the murine myelomonocytic 
leukemia WEHI-3B JCS Cells by tryptanthrin 
Treatment of WEHI-3B JCS cells with Percentage of cells which reduced NBT 
Solvent control 0% 
1 i l i M tryptanthrin 3.2% ± 0.6 
2.5 |iM tryptanthrin 15.3o/o 士 1.5 
The leukemia WEHI-3B JCS cells (2500 cells/ml) were either incubated with (A) 
solvent control (0.05% DMSO), or (B) 1 i^M and (C) 2.5 fiM of tryptanthrin at 37°C 
for 48 hours. Then 100 NBT-PMA solution was added and incubated at 37°C in 
dark for another 4 hours. Treated cells (5 x 10'^  cells) were cytocentrifuged onto 
microscopic glass slides and stained with safranin for 30 seconds and washed with 
running water. The differentiated cells, which had intracellular black-blue formazan 
deposit, were examined by counting at least 200 cells in triplicate for each 
determination. 
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5.3 Discussion 
Human bone marrow contains HSC that self-renew themselves and give rise to 
different blood cell types (Wu et al., 1967; Metcalf, 1998; Orkin, 2000). Normally, 
they are programmed to differentiate along cell lineage-restricted pathways of blood 
cell development by external growth factors that keep balancing cell growth, 
differentiation and programmed cell death in the bone marrow (Cantor and Orkin, 
2001; Fisher, 2002). A disruption of these processes of hematopoietic cell 
development causes leukemia. The leukemia cells acquire immortality and they do 
not undergo programmed cell death and fail to differentiate. The malignancy of the 
disease is inversely related to the degree of differentiation which suggested that 
differentiation is uncoupled from cell growth control in leukemia (Sachs, 1980). This 
brings out a message that the induction of differentiation should reduce or abrogate 
the malignant potential of leukemia cells (Tsiftsoglou et al., 2003). 
Dozens of differentiation-inducing agents have been studied as potential 
candidates in the differentiation therapy of acute leukemia. For instance, vitamin D 
and retinoid derivatives, cytokines like TNF-a and IFN-y, chemotherapeutic agents 
like hydroxyurea, medicinal plant-derived products like indirubin derivatives, etc. An 
earlier study had shown that tryptanthrin can induce differentiation in U-937 and 
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HL-60 cells as supported by the morphological change of the cells, increased in 
expression of cellular surface antigen specific for granulocytes (CD l ib ) and 
monocytes CD 14, as well as a remarkable increase in nitroblue tetrazolium (NBT) 
reducing and naphthyl butyrate esterase (NBE) activities (Kimoto et al., 2000). 
However, the detailed mechanisms remain obscure. 
In this study, the ability of tryptanthrin to trigger leukemic cell differentiation 
was examined using the murine myelomonocytic leukemia WEHI-3B JCS cells. This 
cell line retains the capability to undergo monocytic or granulocytic differentiation in 
the presence of an appropriate inducer, that is why it is a good model for studying 
leukemic cell differentiation (Mak et al., 1993). Our preliminary results show that 
tryptanthrin can induce differentiation of the WEHI-3B JCS cells. After tryptanthrin 
treatment for 48 hours, an increase in the cytoplasm to nucleus ratio and the presence 
of vacuolation were observed in the WEHI-3B JCS cells when compared to the 
control (solvent-treated) cells. Flow cytometric analysis on the FSC and SSC of 
WEHI-3B JCS cells indicated an obvious increase in SSC reflecting an increase in 
granularity in the tryptanthrin-treated WEHI-3B JCS cells. This further supports the 
differentiation-inducing property of tryptanthrin. In addition, tryptanthrin was found 
to increase the NBT-reducing activity in WEHI-3B JCS cells, indicating that 
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tryptanthrin can also induce functional maturation of the leukemia cells. Nevertheless, 
whether tryptanthrin would induce WEHI-3B JCS cells to differentiate into the 
macrophage or granulocyte lineage clearly requires further investigation. 
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Conclusions and Future Perspectives 
Tryptanthrin was found to possess a wide spectrum of biological and 
pharmacological activities, including anti-bacterial (Mitscher and Baker, 1998), 
anti-tumor (Romano and Claria, 2003; Kataoka et al 2001) and anti-inflammatory 
(Takei et al. 2003; Hamburger et al, 2003) activities. A previous report has shown 
that tryptanthrin is able to induce both apoptosis and differentiation in HL-60 cells 
and U-937 cells in vitro (Kimoto et al, 2001), however, the • underlying action 
mechanisms remain unclear. In this study, the effects of tryptanthrin on the murine 
myelomonocytic leukemia WEHI-3B JCS cells were investigated in three different 
aspects: anti-proliferative effect, apoptosis- and differentiation-inducing activities. 
As shown in Chapter 3, tryptanthrin inhibited the proliferation of the murine 
myelomonocytic leukemia WEHI-3B JCS cells in a dose- and time-dependent 
manner with an IC50 around 1.5 )j,M. Similar anti-proliferative effect was also 
demonstrated on other myeloid leukemia cell lines including HL-60, K-562 and 
EoL-1 which are of human origin and Ml of mouse origin. For the WEHI-3B JCS 
cells, tryptanthrin showed comparable potency with doxorubicin, a commonly used 
anti-leukemia drug, as both have similar IC50 values. However, tryptanthrin did not 
cause any significant cytotoxicity on normal cells such as the human hepatocyte-like 
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WRL 68 cells and normal murine peritoneal macrophages. The observed 
anti-proliferative effect of tryptanthrin on WEHI-3B JCS cells was most likely 
caused by its cytostatic effect, as direct cytotoxicity of tryptanthrin on WEHI-3B JCS 
cells was not observed as measured by the trypan blue exclusion assay. To achieve a 
more significant growth-inhibitory effect, a longer exposure time to tryptanthrin was 
needed. In order to elucidate the mechanisms behind this potent anti-proliferative 
effect exerted by tryptanthrin, studies on cell cycle profile, apoptosis- and 
differentiation-inducing activities of this compound were carried out. We have shown 
that tryptanthrin can cause cell cycle arrest of the WEHI-3B JCS cells at G Q / G I phase 
in a dose-dependent manner. Using the technique of real time PCR, the expression of 
the cell cycle-related genes including cyclin D2, D3, Cdk 2，4, 6 were found to be 
down-regulated, which might affect the formation of cyclin-Cdk complexes and 
therefore prevent the cell cycle progression from Gi phase into the S-phase, causing 
cell cycle arrest and resulting in inhibition of leukemic cell growth. Moreover, an 
increase in protein expression of the Cdk inhibitors like p i8 and p27 in 
tryptanthrin-treated WEHI-3B JCS cells will either prevent the binding of Cdk to 
cyclin D or inactivates cyclin-Cdk complexes and these might also contribute to cell 
cycle arrest of the WEHI-3B JCS cells. At the Gi/S checkpoint, cell cycle arrest 
induced by DNA damage is p53-dependent (Vermeulen et al., 2003). Usually, the 
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p53 levels in the cells are low, however, upon stimulation by DNA damage, there is 
an abrupt induction of p53 activity (Levine, 1997). p53 in turn stimulates the 
transcription of p21, a CKI, and results in Cdk inhibition and cell cycle arrest, 
preventing the replication of damaged DNA. In the case of severe cell damages, p53 
also induces cell death by activating genes (e.g. Bax, Fas and genes involved in 
oxidative stress pathway) that are involved in apoptotic signaling (Owen-Schaub et 
al, 1995; Polyak et al, 1997; Gottlieb and Oren, 1998). Therefore, expressions of 
p53 and p21 gene and protein in tryptanthrin-treated WEHI-3B JCS cells should also 
be studied in the future. Indirubin and its derivatives, which are indigoid alkaloids 
found in Banlangen, have been reported to exert potent growth-inhibitory effect on 
tumor cells through inhibiting the Cdk activities by direct interaction with Cdk's ATP 
binding site (Marko et al, 2001). It will be also interesting to see if this mechanism 
would also be involved in the case of tryptanthrin, a quinazolinone alkaloid derived 
also from Banlangen. 
Since tryptanthrin was effective in suppressing the growth of the leukemia 
WEHI-3B JCS cells in vitro’ its effect on the tumorigenicity of WEHI-3B JCS cells 
in syngeneic BALB/c mice was also examined. Our results show that pretreatment of 
WEHI-3B JCS cells with tryptanthrin could significantly reduce the in vivo growth 
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of the leukemia cells in a dose-dependent manner. Moreover, in vivo administration 
of tryptanthrin also inhibited the growth of leukemia WEHI-3B JCS cells in the 
tumor-bearing mice. Nevertheless, bio-distribution of tryptanthrin in mice should be 
carried out in order to study its toxicity and the chronic effect of the treatment so as 
to explore its potential for the treatment against leukemia. 
Apart from the cell cycle arrest, tryptanthrin also induced apoptosis in the 
WEHI-3B JCS cells. It triggered significant DNA fragmentation which is regarded as 
a hallmark for apoptosis, in a dose- and time-dependent manner. Apoptosis was 
further supported by the externalization of phosphatidylserine in WEHI-3B JCS cells 
triggered by tryptanthrin using Annexin V and PI staining; These results, when taken 
together, suggest that tryptanthrin can induce apoptosis in the myeloid leukemia 
WEHI-3B JCS cells. 
It was further found out that upon tryptanthrin treatment, a change in 
mitochondrial membrane potential was detected, which suggested that the 
tryptanthrin-induced apoptosis in WEHI-3B JCS cells might involve the intrinsic 
pathway. The increase in the caspase-3 and -9 activities further confirmed this 
hypothesis. After treatment with tryptanthrin, the mRNA and protein levels of the 
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pro-apoptotic Bcl-2 family genes (Bax and Bid) in WEHI-3B JCS cells increased in a 
dose-dependent manner, while there was a decrease in expression of the 
anti-apoptotic Bcl-2 family genes (Bcl-2 and BC1-XL). It was also observed that there 
was an increase in cytosolic cytochrome C after tryptanthrin treatment. The same 
happened for AIF, it was translocated from the mitochondria to cytoplasm. To 
conclude, tryptanthrin activated the production of Bax and Bid and suppressed that of 
Bcl-2 and BC1-XL which resulted in an enhanced formation of MPT pores. 
Cytochrome C was released from mitochondria to cytosol, it then bound to Apaf-1 
and activated pro-caspase-9 which in turn activated caspase-3 and CAD, finally led 
to apoptosis. When MPT pores were formed, the released AIF would be translocated 
to nucleus causing DNA fragmentation and resulted in apoptosis in a 
caspase-independent manner. 
An increase in caspase-8 activity was observed which indicated that apart from 
the intrinsic pathway and the caspase-independent pathway, tryptanthrin might exert 
its apoptotic effect through the extrinsic pathway. To address this hypothesis, the 
protein expression of Fas and Fas ligand was examined. The results show that 
tryptanthrin treatment did not induce an increase in Fas, however, a significant 
increase in Fas ligand expression was observed. This may explain why caspase-8 
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activity was enhanced. After caspase-8 activation, it further acted on Bid. The 
truncated Bid would then bind to Bax and aided it to form MPT pores, thereby 
initiating another round of caspase cascade. Therefore, the activation of Bid may 
represent a bridging of the intrinsic and extrinsic pathways. Though an increase in 
protein level of Bid was observed, it is also important to know if there is an increase 
in the cleavage of Bid after tryptanthrin treatment to further confirm the hypothesis. 
In addition to the above mentioned mechanism, the generation of reactive 
oxygen species (ROS) was also enhanced in tryptanthrin-treated WEHI-3B JCS cells 
in a dose-dependent manner. Prior incubation of WEHI-3B JCS cells with SOD 
partially reduced the proportion of cells undergoing apoptosis suggesting that 
tryptanthrin was able to trigger apoptosis by inducing ROS formation. However, 
whether ROS can cause cell death through lipid peroxidation of mitochondrial 
membrane, disturbance of calcium ion homeostasis or destruction of mitochondrial 
DNA are important aspects that are worthy of future investigations. 
It was observed that tryptanthrin induced apoptosis in JCS cells through 
different pathways, it may attributed to the crosstalk in between different signaling 
pathways and/or the multiple targeting of tryptanthrin on different receptors in JCS 
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cells. 
Attempts had been made in studying the ability of tryptanthrin in inducing 
differentiation in the WEHI-3B JCS cells. Morphologically, an increase in the 
cytoplasm to nucleus ratio and increased vacuolation were observed after 
tryptanthrin treatment which showed that tryptanthrin was able to induce 
differentiation in the WEHI-3B JCS cells. To further confirm this observation, the 
changes in SSC and FSC were measured by flow cytometry and the results showed 
that upon tryptanthrin treatment, there were significant increases in both size and 
granularity in the leukemia WEHI-3B JCS cells. The ability of the 
tryptanthrin-treated cells to reduce NBT also indicated that tryptanthrin was able to 
induce functional differentiation in the WEHI-3B JCS cells. Moreover, the study the 
surface phenotypic changes in tryptanthrin-treated WEHI-3B JCS cells were also 
examined. The expression of macrophage differentiation antigens including Mac-1 
and F4/80 surface markers was studied by flow cytometry. However, the results 
obtained are inconclusive due to the fact that tryptanthrin gives strong 
autofluorescence and this might mask the signal that is produced by the increase in 
the marker expression as a result of cell differentiation (data not shown). Therefore, 
Western blotting has to be carried out in the future to study the 
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differentiation-associated phenotypic changes in WEHI-3B JCS cells upon 
tryptanthrin treatment. Another functional assay was also performed using 
fluorescein diacetate and flow cytometry to measure the possible increase in the 
monocytic serine esterase activity in tryptanthrin-treated WEHI-3B JCS cells. 
However, due to the problem of autofluorescence, false negative results might be a 
concern (data not shown). The phagocytic activity of tryptanthrin-treated WEHI-3B 
JCS cells was also examined using Congo-red stained yeast. Interestingly, when 
compared to normal macrophages, WEHI-3B JCS cells treated with tryptanthrin did 
not show any increase in phagocytic activity of the cells (data not shown). Therefore, 
whether tryptanthrin can induce terminal differentiation or functional maturation of 
the WEHI-3B JCS cells along the monocytic or granulocytic pathway is an intriguing 
aspect that awaits future investigations. 
In conclusion, the results of this study indicate that tryptanthrin might exert its 
anti-proliferative effect on the murine myelomonocytic leukemia WEHI-3B JCS 
cells by causing cell cycle arrest, inducing apoptosis and/or differentiation of the 
cells. In the future, investigations should be focused on delineating the molecular 
events and signaling pathways underlying the anti-leukemia activities of tryptanthrin. 
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